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ABSTRACT OF DISSERTATION 
 
INVESTIGATING THE ROLE OF PRION PROTEIN POLYMORPHISMS  
ON PRION PATHOGENESIS 
Transmissible spongiform encephalopathies (TSEs), also known as prion 
diseases, are lethal and infectious neurodegenerative diseases of humans and 
animals. The misfolding of the normal, or cellular isoform of the prion protein 
(PrPC) into the abnormal disease-associated isoform of PrP (PrPSc) could change 
the properties of PrP, consequently, PrPSc has lethal infectivity to transmit 
diseases. The proteinaceous infectious particle consisting mainly of PrPSc is 
called prion. Transmissibility of prions is strongly influenced by multiple factors 
including PrP polymorphisms, species barriers (PrP sequence specificity) and 
prion strains (conformational specificity) by unknown mechanisms. Even though 
the ability of prions to cross a species barrier has been recognized, the precise 
mechanisms of interspecies prion transmission remain unclear.  
 
This dissertation research was conducted in order to learn more about the 
molecular mechanisms of conversion, propagation and transmission of PrPSc; 
about determinants of genetic susceptibility to infection in prion diseases; and 
about understanding those mechanisms, which might govern the zoonotic 
potential of prion diseases.  
 
First, we investigated the transmissibility risk of multiple strains of Chronic 
Wasting Disease, which is a cervid TSE, with humanized transgenic mice and 
showed that the transmission barriers between cervid and the humanized mice 
are high. Next, the structural factors underlying the species barrier of prion 
diseases were studied using cell culture systems by systematically introducing 
amino acid substitutions in the regions of PrP, where the most divergences of 
different PrP species are recognized. Thirdly, we investigated the effects of the 
genetic susceptibility to prions as well as conversion kinetics and properties of 
PrPSc using Tg mice expressing ovine PrP polymorphism (OvPrP) at codon 136 
either alanine (A) or valine (V). The templating characteristics of OvPrPSc-V136 
were dominant over OvPrPSc-A136 under co-expressions of OvPrPC-A136 and 
OvPrPC-V136. Finally, the function of PrP was studied in relation to the 
pathogenesis of Alzheimer’s disease.  
 
These studies demonstrated that the conformational compatibility between 
PrPC and PrPSc contributed to the conversion kinetics and species barrier. We 
concluded that the conformational compatibility of PrPC to PrPSc is controlled not 
only by the PrP sequence specificity but also by the tertiary structure of PrPC.    
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Chapter 1 
Introduction to prion biology 
 
Transmissible spongiform encephalopathies (TSEs), or prion diseases, are a 
group of fatal and transmissible neurodegenerative diseases affecting the central 
nervous system (CNS) of humans and animals (Prusiner, 1998). Currently, no 
cure is known for any prion disease. A typical clinical sign of patients with prion 
disease is a progressive dementia, while sheep, cattle and cervid generally 
present ataxic illness (Parry, 1962; Wells et al., 1987; Williams & Young, 1980). 
In about the last decade, the view has acquired wide acceptance that TSEs are 
caused by the misfolding of the normal, or cellular, form of the prion protein 
(commonly designated PrPC) into infectious disease-causing PrP (PrPSc) in the 
brain (Prusiner, 1998). Prions are infectious protein consisting of pathogenic 
PrPSc and defined as a “proteinaceous infectious particle that lacks nucleic acid” 
(Prusiner, 1982). The underlying mechanisms of conversion and propagation of 
PrPSc as well as transmission of prions are still under investigation.  
 
TSEs in humans 
Human prion diseases occur in various forms, including genetic, sporadic and 
infectious disorders. Inherited forms of human prion diseases are Gerstmann-
Sträussler-Scheinker (GSS), Fatal Familial Insomnia (FFI) and familial 
Creutzfeldt-Jakob disease (CJD). Germ-line mutations in the PrP gene (PRNP) 
are the cause of all of the inheritable prion diseases (Colby & Prusiner, 2011). In 
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contrast, somatic mutations in PRNP, or spontaneous conformation conversion 
of PrPC to PrPSc, are the most likely cause of such prion diseases as, sporadic 
CJD and sporadic Fatal Insomnia (Colby & Prusiner, 2011). Sporadic CJD is the 
most common form of human prion diseases accounting for approximately 85% 
of prion disease patients (Colby & Prusiner, 2011). Infectious prion disease forms 
include Kuru and variant or iatrogenic CJDs. Kuru was found in a Fore linguistic 
group residing in the highlands of Papua, New Guinea, and person-to-person 
transmission occurred through the tribe practice of ritual cannibalism (Klitzman et 
al., 1984). Variant CJD (vCJD) is that form of human prion disease best known 
among the general public. Epidemiological and experimental studies have 
provided good evidence that vCJD might be caused by the consumption of 
bovine spongiform encephalopathy (BSE)-contaminated products (Asante et al., 
2002; Bruce et al., 1997; Collinge et al., 1996; Scott et al., 1999; Will et al., 
1996). Iatrogenic CJD is most likely induced by the accidental use of prion-
contaminated surgical tools (Davanipour et al., 1984; Kondo & Kuroiwa, 1982; 
Masters & Richardson, 1978; Will & Matthews, 1982), as well as by transmission 
from human growth hormone and gonadotropin, dura matter grafts, and 
transplants of corneas harvested from individuals who died from CJD (Duffy et 
al., 1974; Koch et al., 1985).  
 
TSEs in animals 
TSEs in animals include chronic wasting disease (CWD) of deer, elk and moose, 
scrapie of sheep, goat and moufflon, transmissible mink encephalopathy, BSE, 
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feline spongiform encephalopathy (FSE) and exotic ungulate encephalopathy 
(EUE). FSEs affect domestic cats (Leggett et al., 1990; Wyatt et al., 1991) and 
captive wild members of the cat family (Eiden et al., 2010; Lezmi et al., 2003).  
EUEs are found in exotic zoo ruminants of the cattle family (Kirkwood & 
Cunningham, 1994). CWD, scrapie, TME and BSE are described below in more 
detail. 
 
Chronic wasting disease (CWD), a TSE of free-ranging and captive deer, elk 
and moose, is highly contagious (Baeten et al., 2007; Miller et al., 2000; Williams, 
2005; Williams & Young, 1980, 1982, 1992). Since it was first recognized in a 
wildlife facility in Northern Colorado in 1967 (Williams & Young, 1980), cases of 
CWD have increasingly been reported from this and additional states, while other 
cases have shown up abroad. As of 2012, CWD has been identified in 18 states: 
Colorado, Wyoming, South Dakota, Nebraska, Wisconsin, New Mexico, 
Minnesota, Oklahoma, Illinois, Utah, New York State, West Virginia, Kansas, 
Michigan, Virginia, Missouri, North Dakota and Maryland (Chronic Wasting 
Disease Alliance, 2012). It has also appeared in two provinces (Alberta and 
Saskatchewan) in Canada (Chronic Wasting Disease Alliance, 2012). In South 
Korea, deer imported from Canada are found to be CWD positive in 2005 (Kim et 
al., 2005). Since then, CWD has been recognized in South Korea (Sohn, 2011). 
It is difficult to determine how CWD has spread throughout North America, 
inasmuch as CWD is not always found in states adjoining the affected states. 
Plausible explanations include the simple fact of increased awareness of CWD, 
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inadvertent interstate transfer of asymptomatic infected animals, or the possibility 
that CWD is a sporadic disease. Thus, CWD’s origins in North America are 
unclear. 
 It has been debated whether endemic levels of CWD are maintained due 
to high efficiency of horizontal transmission of CWD in North America. One 
possible explanation is that decomposing carcasses of CWD-affected animals, 
feces, urine or saliva remain as highly contagious prion sources in an 
environment to continue spreading disease in animals. Some studies report that 
prions could bind to metal and mineral deposits in the soil and be maintained in 
the soil over decades (Johnson et al., 2006; Miller et al., 2004; Seidel et al., 
2007). Prions have been identified in bedding, food and water shared by CWD-
affected animals (Mathiason et al., 2009), in saliva (Haley et al., 2009; Mathiason 
et al., 2006), in urine (Haley et al., 2009), in feces (Tamguney et al., 2009b) and 
in antler velvet (Angers et al., 2009), all of which are potential sources for 
infectious transmission. When prions are shed to the environment, whether soil 
or aquatic, prions remain in the environment over period of time. When animals 
have any contacts with prions remained in the environment, prions could invade 
the animals. Even though the levels of prions might be low in the environment, 
animals could develop disease by repeated exposures.  
 Could new CWD strains arise and acquire new host-range properties 
during horizontal transmission? It has been questioned whether intraspecies 
transmission of CWD increase chances of propagating new strains, which might 
have lower cervid to human species barriers (Barria et al., 2011). There is so far 
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strong evidence that at least two distinct strains of CWD propagate in deer and 
elk (Angers et al., 2010). Since efficient horizontal transmission of CWD has 
been evidenced, natural CWD agents are most likely going through serial 
passages among cervid in wild or captive environments. Intraspecies 
transmissions in vivo and in vitro increased the propagation of human PrPSc in 
vitro (Barria et al., 2011), suggesting that there is potential for the spread of CWD 
to humans by intraspecies transmissions. In addition, it has been reported that 
other forms of prions are able to change transmission properties during 
interspecies passages, with resultant change of the host range (Bartz et al., 
1998) and the production of multiple strains (Bessen & Marsh, 1992b). There 
thus remains a meaningful potential for the adaptation of CWD prions, so that 
they acquire the property of infecting multiple new species, including humans. It 
would therefore be important to understand how strains arise in the environment 
that CWD is constantly disposed.   
 
Scrapie is a TSE of sheep, goats and moufflon (Dickinson, 1976; Wood et al., 
1992). The first recognized cases of scrapie were documented in England in 
1732, with further cases in Germany in 1759 (reviewed in (Prusiner, 2004)). 
Thus, scrapie has been recognized for around 300 years and has been spread 
across the world, especially in the northern hemisphere, by importing and 
exporting domestic sheep. Curiously, Australia and New Zealand are recognized 
as scrapie free countries (Hunter & Cairns, 1998). When scrapie turned up in 
those countries, entire flocks were terminated to prevent its spread to other 
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flocks. Moreover, Australia and New Zealand use more stringent surveillance 
systems to maintain a scrapie-free environment.     
 The transmissibility of TSEs was first demonstrated in sheep using brain 
homogenates from scrapie-affected sheep (Cuillé & Chelle, 1936, 1938). 
Subsequent sheep studies reported that different scrapie sources produced 
different transmission characteristics. In early studies of sheep scrapie, classical 
scrapie sheep brain pool number 1 (SSBP/1)-inoculated sheep was classified 
positive or negative, developing upon the incubation time after inoculation 
(Dickinson, 1976). The gene involved in the incubation period was called Sip (for 
scrapie incubation period) and later identified as a PrP gene (Basler et al., 1986) 
and two alleles were indicated as sA and pA (partially dominant) (Dickinson & 
Outram, 1988). The negative group of sheep survived from subcutaneous (s.c.) 
inoculation of scrapie, and the associated gene was characterized as SippApA 
(Foster & Hunter, 1991). In contrast, sheep from the positive group developed 
disease within 150-400 days after inoculation; here, the genes were identified as 
either SipsAsA or SipsApA (Foster & Hunter, 1991). The results indicated that sheep 
carrying SipsA developed disease with a shorter incubation time than sheep with 
SippApA. Interestingly, the negative group sheep developed diseases with a 
shorter incubation time with a different classical scrapie isolate, referred to as 
CH1641, and BSE prions than the positive group sheep (Foster & Dickinson, 
1988b; Foster et al., 1993), indicating that the gene SippApA, which is associated 
with a long incubation time with SSBP/1 prion, behaves differently with other 
prion isolates. These studies presented indications that interactions between 
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genetic variations in the ovine PrP gene and prion strains were not 
straightforward, and that disease outcomes/incubation times depended upon the 
combinations between genetic variations of PrPC and strain variations of PrPSc.  
 The genetic susceptibility of sheep to scrapie has been studied using 
mouse models after the discovery of the PrP gene (Prnp in mice or PRNP in 
higher eukaryotes). Since then, the genetic linkage between Prnp and the length 
of scrapie incubation time was established in mice (Carlson et al., 1986). 
Furthermore, two distinct alleles in Prnp were identified, and the biological 
property of short or long scrapie prion incubation times was associated with 
these two alleles (Westaway et al., 1987). Later studies demonstrated that one 
allele was converted to PrPSc more efficiently over the other; in addition, the copy 
number of Prnp in Tg mice controlled the incubation time (Carlson et al., 1994; 
Westaway et al., 1987). Interestingly, these findings do not apply for some prion 
strains. 
 Three major scrapie susceptibility-linked polymorphisms were identified in 
the ovine PrP gene including amino acid residues at 136 (alanine [A] or valine 
[V]), 154 (arginine [R] or histidine [H]) and 171 (glutamine [Q], R or H) (Goldmann 
et al., 1991; Goldmann et al., 1994). Transmission studies in Cheviot sheep 
showed that homozygosity for V at codon 136 was associated with short 
incubation times after inoculation with SSBP/1, while heterozygosity was linked 
to longer incubation times (Goldmann et al., 1994).  Sheep homozygous for A at 
codon 136 were resistant to SSBP/1 inoculation (Goldmann et al., 1994). The 
same findings were also reported in studies with US sheep (Maciulis et al., 
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1992), suggesting that the scrapie susceptibility-linked polymorphism at codon 
136 was not limited to Cheviot sheep. It has been reported that the polymorphism 
of Q or R at residue 171 is also correlated with susceptibility to scrapie 
(Goldmann et al., 1994; Westaway et al., 1994a). Q171 is linked to susceptibility 
to scrapie, while R171 is correlated with resistant to scrapie. Sheep homozygous 
for R at codon 171 did not develop disease upon inoculation of SSBP/1, and 
sheep heterozygous for Q/R at codon 171 were relatively resistant. Limited 
studies in Cheviot and Icelandic sheep showed that H at residue 154 conferred 
resistance to scrapie (Baylis et al., 2004; Hunter et al., 1996; Laplanche et al., 
1993; Thorgeirsdottir et al., 1999). Thus, the H154Q polymorphism is linked to a 
small extent to a sheep’s susceptibility. 
 In contrast, CH1641 isolate has a completely different propensity for those 
three polymorphisms. Unlike SSBP/1, A136 and V136 are most susceptible and 
resistant to CH1641, respectively (Goldmann et al., 1994). In addition, it has 
been reported that homozygosity for Q at codon 171 was linked to short 
incubation times, and sheep heterozygous for Q/R at codon 171 presented much 
longer incubation time with CH1641 (Goldmann et al., 1994). In conclusion, the 
combined effects of genetic polymorphism of the ovine PrP gene and agent 
strain variation act to present a complex picture of scrapie susceptibility in sheep. 
Taken together, three major sheep PrP polymorphisms participate in 
determining susceptibility and resistance to scrapie; however, the participation of 
each polymorphism in susceptibility involves in different levels. Since two 
dimorphisms and one trimorphism play roles here, 12 combinations of these 
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polymorphisms are possible. Nonetheless, only 5 out of 12 combinations have 
been reported from the sheep flocks, the frequency of appearance of any of the 
other combinations is extremely low (Belt et al., 1995; Ikeda et al., 1995). The 
five combinations are A at codon 136, R at codon 154 and R at codon 171 
(ARR), ARQ, AHQ, ARH and VRQ, and homozygous for ARR and VRQ are most 
resistant and susceptible to scrapie, respectively. Even though two additional 
combinations of AHR and VRR were later reported (Kutzer et al., 2002), the five 
genotypes appear with higher frequencies. Subsequent studies by multiple 
investigators have reported the same polymorphic effects on the susceptibility of 
scrapie in vivo and in vitro studies. However, the underlying mechanisms of how 
the polymorphisms regulate the susceptibility and resistance to scrapie are still 
not clear.   
 
Transmissible mink encephalopathy (TME) is a sporadic form of TSEs found 
in farmed mink (Hartsough & Burger, 1965). TME was first reported in 1947 in a 
farm in Brown County, Wisconsin, then again later in 1961 in several farms in 
Sheboygan, Calumet and Manitowoc Counties, Wisconsin, with a third outbreak 
in 1963 in Sawyer County, Wisconsin. The affected farms in Wisconsin all fed 
mink with a ready-mix feed supplied and manufactured by the same feed plant, 
which suggests that the disease was caused by the consumption of prion-
contaminated food (Liberski et al., 2009). The last outbreak was found in 1985 in 
Stetsonville, Wisconsin, where it was later found that TME-affected mink had 
been fed contaminated cattle meat from downer dairy cows. In order to examine 
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whether the contaminated cattle were the cause of TME, infected cattle tissue 
was experimentally inoculated into groups of mink, resulting in the development 
of fatal diseases (Marsh & Bessen, 1993). Additional TME cases were reported 
in Idaho (Hartsough & Burger, 1965), Canada (Hadlow & Karstad, 1968), Finland 
and the former East Germany (Hartung et al., 1970; Johannsen & Hartung, 1970) 
and the former Soviet Union (Danilov et al., 1974; Dukur et al., 1986).  
The interspecies transmission studies of TME-affected mink agents from 
the last outbreak in Stetsonville were performed using Syrian golden hamsters, 
and TME-infected hamsters showed two distinct clinical presentations including 
hyper (HY) and drowsy (DY) after third passages (Bessen & Marsh, 1992b). The 
characteristics of the HY and DY differed in incubation time, brain titer, lesion 
profiles in the brain, pathogenicity as well as biochemical properties (Bessen & 
Marsh, 1992a, b). The HY has a shorter incubation time and high brain titer, 
whereas the DY has a longer incubation time and low brain titer. Interestingly, 
when the HY and DY agents were inoculated back to mink, only the DY agent 
could produce disease in mink (Bessen & Marsh, 1992b). The DY agent was 
able to produce disease in hamsters after long incubation time thus still retained 
the transmissibility property. These studies suggested that TME from the 
Stetsonville contained the mixed strains of both HY and DY, moreover, the DY 
was the major pathogen. The studies in TME were the first study to identify the 
different biochemical properties of multiple strains present in prions.  
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Bovine spongiform encephalopathy (BSE) is a TSE of cattle, and first found in 
1986, in Weybridge, United Kingdom (Wells et al., 1987). Since 1986, the 
numbers of BSE cases in United Kingdom rapidly increased in the following six 
years, and the peak of BSE cases was reported during 1992 and 1993. 
Subsequently, the numbers of BSE were gradually declined over the next 
decade. BSE incidence was found to coincide with feeding of meat and bone 
meal (MBM) as a dietary protein supplement in dairy herds (Wilesmith et al., 
1991). MBM was produced from rendered animal parts, and was generally fed to 
cattle from one-week-old of age until the time of slaughter. The identification of 
the source of outbreak and vigorous actions were able to control the epidemic of 
BSE in Great Britain by 2002. In the course of the epidemiological studies, one 
hypothesis was raised that sheep scrapie-contaminated materials were mixed 
into the MBM at the slaughterhouse plants and fed to cattle, which developed 
disease because scrapie materials were present all the time at the 
slaughterhouse (Taylor, 1989; Taylor, 1996; Wilesmith et al., 1991; Wilesmith et 
al., 1988).  In addition, scrapie is endemic in sheep populations in Great Britain. 
However, the hypothesis BSE was derived form a scrapie strain has not been 
established.         
 In 1994, few years after the peak of BSE, the first cases of vCJD were 
diagnosed in teenagers and young adults in Great Britain (Will et al., 1996). In 
the following years, more vCJD cases were reported in Great Britain as well as in 
other countries, and more than 200 individuals with vCJD have been reported 
(World Health Organization, 2012). The epidemiological studies of vCJD 
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concluded that those individuals with vCJD developed disease because of the 
consumption of BSE-contaminated cattle products (Prusiner, 2004). BSE is the 
first established case of interspecies transmission of TSE to humans. Since then, 
the zoonotic potential of TSEs became more concerns when we thought about 
the animals in TSEs.     
 
Prion protein and its isoforms 
The PrP gene is well-conserved protein among mammalian species and is 
ubiquitously expressed, particularly in the CNS, and especially in neurons, in 
both diseased and non-diseased brains (Prusiner, 1998). PrP is a glycoprotein 
that is attached to the cell membrane through a glycosylphosphatidylinositol 
(GPI) anchor (Stahl et al., 1990; Stahl et al., 1987). PrP transits in the secretory 
pathway of endoplasmic reticulum (ER). Posttranslational modification of PrP 
starts after entering the ER, which is mediated by an amino (N)-terminal signal 
peptide of 22 amino acids (Hope et al., 1986; Turk et al., 1988) and carboxyl (C)-
terminal signal peptide of 23 amino acids (Heske et al., 2004; Stahl et al., 1990) 
(Figure 1.1.) (Holscher et al., 2001). When entered ER, the N-terminal signal 
peptide is cleaved by a signal peptidase. During passage through ER, two N-
linked carbohydrate chains are attached to asparagines at residues 180 and 196 
(mouse numbers) (Haraguchi et al., 1989), and a disulfide bond is formed 
between residues 178 and 213 (mouse numbers) (Turk et al., 1988). Finally, in 
order to bring about attachment to the cell membrane, a GPI-anchor is added 
following cleavage of the C-terminal signal peptide (Endo et al., 1989; Oesch et 
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al., 1985). During the secretory pathway, an ER-based quality control removes 
misfolded PrP to the cytosol for proteasomal degradation (Drisaldi et al., 2003). 
The whole process of maturation to transportation is accomplished within one 
hour (Borchelt et al., 1990; Caughey et al., 1989). The half-life PrPC in chronically 
infected cells was found to be approximately 5 hours, while that of PrPSc was 
approximately 15 hours (Table 1.1.) (Borchelt et al., 1990).  
 The ‘natural’ or ‘normal’ functions of PrP have not been clearly identified, 
although PrP appears to be involved in signal transduction (reviewed in (Taylor & 
Hooper, 2006; Tsui-Pierchala et al., 2002)), synaptic transmission (Collinge et al., 
1994), neuroprotection (reviewed in (Roucou & LeBlanc, 2005; Roucou et al., 
2004)), immunoregulation (reviewed in (Isaacs et al., 2006)), copper binding 
(reviewed in (Millhauser, 2007; Vassallo & Herms, 2003), induction of apoptosis 
(Kim et al., 2004; Kuwahara et al., 1999), circadian rhythm and sleep (Medori et 
al., 1992), adaptation to stress (Nico et al., 2005), and memory processing 
(Coitinho et al., 2007; Coitinho et al., 2006). Even though PrP is ubiquitously 
expressed in the adult brain, the expression of PrP during early stages of 
development is tightly regulated (Mobley et al., 1988), suggesting a possible 
important function of PrP during development. However, Prnp deficient (Prnp0/0) 
mice develop normally and have a normal lifespan (Bueler et al., 1992), raising 
the possibility that loss of PrP might be compensated by unknown functionally 
related proteins.  
 Both PrPC and PrPSc consist of the same primary structure and appear to 
possess invariant posttranslational modifications (Stahl et al., 1993). However, 
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Fourier-transform infrared (FTIR) and circular dichroism (CD) studies showed 
that PrPC consisted mainly of α-helices (40%) and small percent of β-sheets, 
while PrPSc contained more β-sheets (45%) and a lesser quantity of α-helices 
(30%) (Pan et al., 1993; Pergami et al., 1996). Further, structural studies of 
recombinant PrP using solution phase nuclear magnetic resonance (NMR 
spectroscopy) identified three α-helices and two regions of β-sheet structures 
(Riek et al., 1996; Zahn et al., 2000).  
The differing biochemical properties of PrPC and PrPSc are summarized in 
Table 1.1. Sensitivity to protease digestion has been used to distinguish PrPC 
and some forms of PrPSc (Prusiner, 2004). After protease digestion of PrPSc, it 
produces protease-resistant molecules of approximately 142 amino acids with a 
molecular mass of 27-30 kDa, referred to as PrP 27-30 (Figure 1.1.) (Bolton et 
al., 1982; Prusiner et al., 1982). However, PrPC and some other forms of PrPSc, 
referred to as protease-sensitive PrPSc (Gambetti et al., 2008) are completely 
digested under the same conditions of protease digestion. It is important to note 
the existence of protease-sensitive PrPSc, which has been reported to be 
involved in specific types of human prion diseases (Colucci et al., 2006; Gambetti 
et al., 2011; Gambetti et al., 2008). Furthermore, PrPSc tends to form oligomers 
and/or aggregates including amyloid plaques and fibrils. In contrast, PrPC 
remains monomeric. The solubilities of the two isoforms are different: PrPC is 
soluble, PrPSc is not. Therefore, after ultracentrifugation at 100,000 x g, PrPSc 
can be collected into pellets. As mentioned above, the half-life of PrPC is known 
to be approximately 5 hours, whereupon PrPC will be recycled by cells. However, 
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PrPSc is known to not merely to survive for long periods, but also to accumulate 
to the point of causing disease. PrPC is not infectious. However, when PrPC 
undergoes the conformational changes to unfold α-helices and refold into β-
sheets to convert into PrPSc, it gains a lethal infectivity (Prusiner, 1998). 
Furthermore, prions consisting of solely PrPSc are resistant to heat, harsh 
chemicals and denaturants (Gordon, 1946) as well as UV irradiation (Alper et al., 
1967). 
 
PrPC → PrPSc conversion models  
It is widely accepted that PrPC undergoes a profound conformational structural 
change to become the pathogenic PrPSc isoform, and the conformational change 
requires PrPC and PrPSc (Prusiner, 1998). The conversion of PrPSc does not 
require nucleic acids; however, RNA facilitates conformational conversion in vitro 
conversion assays (Deleault et al., 2003; Wang et al., 2010). This “protein only 
hypothesis” has been supported by extensive prion researches, even though the 
exact PrPC to PrPSc conversion mechanisms have not been yet established. 
However, the two important models of PrPSc conversion and propagation have 
been proposed: namely the heterodimer template-associated and nucleated-
polymerization models. The template-associated model was proposed to explain 
the replication of PrPSc (Cohen et al., 1994). Although the nucleated-
polymerization model was originally offered to explain polymerization of proteins 
(Oosawa & Asakura, 1975), it has been employed to explain the amyloid 
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formation in the protein misfolding diseases including prion diseases (Gajdusek, 
1994a, b; Harper & Lansbury, 1997).  
The heterodimer template-associated model suggests that monomeric 
PrPSc becomes a template to convert PrPC to PrPSc (Figure 1.2.A) (Cohen et al., 
1994). In this model, PrPC is in equilibrium with an intermediate form, referred to 
as PrP*, and PrP* can form a heterodimer complex with PrPSc, which becomes a 
template to alter the conformation of PrP* into infectious isoform PrPSc, resulting 
in the formation of a homodimer complex. The homodimer complex can 
dissociate into two monomers, which can become additional templates to 
produce more PrPSc. A hypothetical protein X is thought to play roles in the 
conversion of PrPC to PrPSc and also catalyze the PrPSc conversion (Kaneko et 
al., 1997; Telling et al., 1995; Telling et al., 1994). In this model, PrPSc is 
thermodynamically stable compared to PrPC; furthermore, the conversion of 
PrPSc from PrP* is less likely to happen without a catalyst.  
 Several series of experiments demonstrated the exponential growth of 
PrPSc (Kocisko et al., 1995; Kocisko et al., 1994); however, the template-
associated model alone does not accommodate the explanation of rapid 
formation of PrPSc fibrils or aggregates. To yield a plausible explanation of this 
exponential polymerization event and subsequent rapid accumulation of PrPSc, 
two hypotheses were proposed based on the nucleated-polymerization theory 
(Masel et al., 1999). One theory is called the autocatalytic nucleated-
polymerization model (Figure 1.2.B.) (Cohen et al., 1994). In this model, PrPC 
directly interacts with PrPSc seed in fibril or aggregate forms, and the conversion 
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reaction is the rate-limiting step. The PrPSc conversion step might be catalyzed 
by protein X. Another scenario is the non-catalytic nucleated-polymerization 
model (Figure 1.2.C.) (Caughey et al., 1995). Unlike the autocatalytic model, 
PrP* rather than PrPC interacts with the seed to form stable polymers, and the 
PrPSc conversion step occurs “non-catalytically”. The rate-limiting step is the 
reversible reaction between PrPC and PrP*, and the reaction might be facilitated 
by protein X.  The rest of the steps to form PrPSc fibrils and aggregates are 
irreversible. In the nucleation-associated models, the initial formation of PrPSc 
seeds might require a longer time. However, once stable PrPSc seeds are 
assembled, the addition of PrPSc to the seeds can be accelerated. In addition, 
fragmentation of the fibrils can fabricate more seeds for more nucleation 
reactions.  
 Even though there are three kinetic models of the PrPSc conversion to help 
clarify matters, no one model alone can explain every case of the PrPSc 
propagation. The heterodimer template-associated model explains an initial 
formation of PrPSc. When the accumulation of PrPSc reaches a threshold that 
cells cannot clear, PrPSc might form oligomeric fibrils, following which nucleated-
polymerization would ensue to propagate additional PrPSc. Therefore, it might be 
more practical to imagine that combinations of these models provide better 
insight into the precise mechanisms of the PrPSc conversion. 
  
In vitro conversion of PrPSc: cell-free conversion vs. protein misfolding 
cyclic amplification (PMCA)  
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The molecular mechanisms underlying the conversion of PrPC to PrPSc have long 
been of concern in prion research. One investigative approach was developed 
using an in vitro system called cell-fee conversion, which involves mixing labeled 
recombinant PrP with a 50-fold molar excess semi-purified PrPSc and incubating 
for 2-45 hours at 37°C (Caughey et al., 1995; Kocisko et al., 1994). PrPSc 
conversion can be monitored and quantified by monitoring accumulation of newly 
converted labeled protease-resistant PrPSc, and it was reported that 
approximately 20% of PrPC was converted to PrPSc in this cell-free conversion 
system (Caughey et al., 1995; Horiuchi & Caughey, 1999). The conversion 
process involves two kinetic steps of interaction and conformational change 
(DebBurman et al., 1997; Horiuchi & Caughey, 1999). The first step is for PrPC to 
interact with PrPSc, where the interaction depends on the compatibility of their 
primary structures. The second step is the conversion of PrPC to PrPSc by 
undergoing structural change to become a protease-resistant PrPSc (Callahan et 
al., 2001; DebBurman et al., 1997; Horiuchi & Caughey, 1999; Rigter & Bossers, 
2005).   
 Soto and his colleagues developed another in vitro system to propagate 
PrPSc called protein misfolding cyclic amplification (PMCA), which is 
accomplished by mixing approximately 30-fold molar excess of either 
recombinant PrP or brain homogenates as PrPC source into PrPSc as a template, 
then incubating in repeated cycles of sonication and incubation at 37°C (Saborio 
et al., 2001). PMCA involves two alternative steps of sonication and incubation. 
The first step, sonication, breaks PrPSc fibrils or aggregates into fragments, which 
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allows them to become a template or to grow into larger fibrils or aggregates 
again, by adding newly synthesized PrPSc onto the nucleation sites. During the 
second step, incubation, PrPC is recruited by the PrPSc templates and undergoes 
structural change to become PrPSc, whereby it can become a new template or be 
added onto the existing PrPSc.  
 The cell-free conversion system has provided strong evidences, in 
addition to numerous animal studies, that PrPSc contains all information 
necessary to convert PrPC into PrPSc, and that the conversion process is 
independent of nucleic acids. Moreover, the above two in vitro systems gave 
proof that PrPSc becomes a template to convert PrPC into PrPSc. More efficient 
conversion of PrPSc in PMCA using brain homogenates suggests that other 
molecules also facilitate the PrPSc conversion, and it supports the speculation 
that conversion of PrPSc requires the presence of protein X. Together, the in vitro 
conversion systems can be a powerful tool to understand the kinetics of 
conversion of PrPSc.       
 
Zoonotic potential of TSEs from species barriers to prion strains 
TSEs are diseases of animals and humans. Transmissions of TSEs are 
constrained by a species barrier, which can be described in difficulty or 
impossibility of prion propagation from one species to another (Wickner et al., 
2009). The higher the species barrier between a host and donor is, the longer the 
incubation time requires. The species barrier is generally difficult to overcome in 
the transmission of prions. However, the diseases are unique in a way that the 
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pathogen prions, which consist with only proteins, could overcome the species 
barrier by propagating new prion strains.  
The presence of different strains in scrapie has been recognized since 
1960s (Pattison & Millson, 1961). The classical definition of prion strains is 
defined by incubation time and neuronal vacuolation profiling (Dickinson et al., 
1968; Fraser & Dickinson, 1973), moreover, the biochemical properties including 
PrPSc profiling, deposition, glycosylation and migration patterns are taken into 
account for additional characterization of prion strains (Prusiner, 2004). The 
unique properties of prion strains can be maintained during propagation and 
subsequently passaged onto next hosts. Although the primary structure of PrP is 
an important determinant of prion species barriers (Telling et al., 1995; Telling et 
al., 1994), prion strains are also involve in the susceptibility to infection of prions 
between species. Since prion strains are subject to apparent mutations and 
selective amplification (Li et al., 2010), the selection process of prion strains 
might allow adapting a new host range and overcoming a species barrier. 
Therefore, understanding the molecular mechanisms responsible for interspecies 
transmission of prions are essential for controlling the transmissions of prions 
horizontally as well as vertically.  
 
Transgenics in prion research 
Prion research has benefited from the development of Tg mice, which are 
produced by integrating a target gene at random sites using homologous 
recombination. The use of Tg mice makes it possible to control the genetic 
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background compared to other animal studies, such as, sheep, cervid and 
bovine. Tg mouse models not only are cost-effective but also accelerate 
understanding of prion diseases and development of new therapeutic 
approaches.      
The first PrP gene knockout (Prnp0/0) mouse was generated in 1992 
(Bueler et al., 1992). Importantly, the Prnp0/0 mice were resistant to prions 
(Bueler et al., 1993). The Prnp0/0 mice did not have any developmental issues 
and have a normal lifespan (Bueler et al., 1992) even though some studies 
showed that altered synaptic behavior, such as, synaptic inhibition in the 
hippocampal brain slices of the Prnp0/0 mice (Collinge et al., 1994; Whittington et 
al., 1995). However, other groups reported the absence of the synaptic inhibition 
in the brains of the Prnp0/0 mice (Herms et al., 1995; Lledo et al., 1996). Other 
line of Prnp0/0 mice generated by other group showed ataxia around 70 weeks of 
age, and the loss of Purkinje cells were observed in the brain (Sakaguchi et al., 
1996). However, the ataxia and loss of Purkinje cells were rescued by crossing to 
Tg mice overexpressing mouse PrP (Nishida et al., 1999), suggesting that PrP 
might play roles in the Purkinje cells mediated atrophy, which presents in ataxia.   
 Mice expressing different expression levels of PrP revealed that the 
incubation time after inoculation was inversely proportional to the expression 
levels of PrP in Tg mice (Prusiner et al., 1990). In addition, Tg mice 
overexpressing Syrian hamster or sheep PrP spontaneously developed disease 
at older age (Westaway et al., 1994b). However, overexpression of PrP does not 
always produce spontaneous disease. For example, Tg mice expressing human 
 
 
22 
PrP with a mutation from glutamic acid (E) to lysine (K) at codon 200, which are 
found in FFI patients, did not develop spontaneous disease (Asante et al., 2009). 
Gene-targeted knockin (targeted gene insertion to a Prnp specific locus) mice 
expressing human PrP encoding a mutation from aspartic acid to asparagine at 
codon 177 developed spontaneous disease at older age (Jackson et al., 2009). 
Even though locations of the mutations involved in FFI were not exactly same 
between the overexpressed (Asante et al., 2009) and knockin (Jackson et al., 
2009) mice, these results suggest that a knockin mouse model is the better 
system to study FFI. The knockin mouse model allows determining the functions 
of PrP under the endogenous environment since a mouse PrP gene is replaced 
with a target gene at the specific locus.  
 Another advantage of Tg mice is to be able to study the functions of PrP 
using chimeric proteins. Tg mice expressing a chimeric PrP between mouse and 
human was generated previously, and the study showed that the specific part of 
mouse PrP was required for the efficient propagation of PrPSc (Telling et al., 
1995; Telling et al., 1996), suggesting a hypothesis that PrPSc conversion 
requires interactions between PrP at the mouse specific site and mouse specific 
cofactors or chaperons.  
 
Roles of PrP concerning the pathogenesis of Alzheimer’s disease 
Alzheimer’s disease (AD) is a progressive neurologic disease resulting in 
dementia and loss of cognitive function (Reitz et al., 2012). Oligomeric and 
fibrillar forms of the amyloid β (Aβ) peptide, derived from the amyloid precursor 
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protein (APP), are thought to drive the pathogenesis of AD. The formation of 
oligomeric Aβ or amyloid fibrils results in reduced neuronal activity and synaptic 
plasticity, leading to neuronal cell death in the CNS by unclear mechanisms. 
There are similarities between the pathologies of AD and prion diseases.   
Both AD and prion disease share common features, such as, amyloid 
plaques, significant neuronal loss, abnormal activities of synapses and gliosis 
around amyloid plaques (Garcao et al., 2006; Hardy & Gwinn-Hardy, 1998). The 
main components of amyloid plaques in AD are Aβ42 and 40 peptides (Debatin 
et al., 2008). Interestingly, it has been reported that punctate PrPC was 
immunohistochemically detected in Aβ plaques in AD brains (Ferrer et al., 2001). 
In prion diseases, the amyloid plaques mainly consist of PrPSc (Garcao et al., 
2006). In both diseases, the mechanisms of neuronal cell death caused by Aβ42 
and PrPSc are still unclear. 
Recent studies indicated a direct link between prion and AD, and 
suggested that PrPC is a receptor for mediating the toxic effects of oligomeric Aβ 
(Gimbel et al., 2010; Lauren et al., 2009). Strittmatter and his colleagues 
demonstrated that oligomeric Aβ42, but not the monomer, bound to PrPC with 
nanomolar affinity and disrupted synaptic plasticity in hippocampal slices from 
PrP wild-type mice (Lauren et al., 2009). They further showed that the disruption 
by oligomeric Aβ42 was prevented in the absence of PrPC and was blocked by 
anti-PrP antibody treatments. They suggested that the binding of oligomeric 
Aβ42 to PrPC caused synaptic dysfunction. However, other groups failed to 
replicate the same effects of PrPC using the Prnp knockout or mouse PrP 
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overexpressing Tg mice (Balducci et al., 2010; Calella et al., 2010). Strittmatter 
group demonstrated in the subsequent study that PrPC required for axonal 
degradation, loss of synaptic markers, early death and learning and memory 
deficits in AD Tg mice (Gimbel et al., 2010).  
  It has been considered that prion diseases are caused by not only a gain 
of neurotoxic function by converting to PrPSc from PrPC but also a loss of 
protective function of PrPC (Winklhofer et al., 2008). As explained in the earlier 
section, PrPC is involved in signal transduction, synaptic transmission, 
neuroprotection and many others; however, a clear picture of the physiological 
function of PrPC is still under investigation. Thus, understanding the roles of PrPC 
in the pathogenesis of AD will greatly help to identify the function of PrPC.  
   
Dissertation research 
This dissertation consists of 6 chapters. In this dissertation, I am addressing the 
fundamental question: what are the molecular mechanisms of PrPSc conversion 
and genetic susceptibility to infection in prion diseases? I will address the 
underlying mechanisms of the transmission/species barrier of prion infection by 
investigating the transmission of prions between different species and within the 
same species. I will utilize Tg mouse and in vitro PrPSc conversion models to 
answer the above question. I will examine the transmission/species barrier of 
prions by directly testing the transmission risks of CWD into humans using Tg 
mouse models in Chapter 2. Next, I will examine the structural factors underlying 
the species barrier and susceptibility to prion infection using cell culture models 
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in Chapter 3. I will also discuss the transmission barriers within the same species 
in Chapter 4. Finally, I will investigate the function of PrPC in the pathogenesis of 
AD in Chapter 5.  
Chapter 2 will explore the transmission risks of CWD into humans using 
Tg mice expressing human PrP. I will address the impacts of the human PrP 
polymorphism at codon 129 coding either methionine or valine on the 
interspecies transmission of multiple strains of CWD.  
Chapter 3 will discuss the structural factors involve in susceptibility to 
prion infection. I will utilize cell culture models to test the hypothesis that the loop 
region between the β2-sheet and α2-helix and its interaction site at the C-
terminal region of PrP determines the susceptibility to prions. First, I will explain 
whether the structural definitions of the β2-α2 loop would change susceptibility to 
prions. Then, I will explain whether interrupting the interaction between the β2-α2 
loop and C-terminal of PrP would alter susceptibility to prion infection. Finally, I 
will explain whether introducing the substitutions of horse specific amino acid 
residues in the β2-α2 loop and its interaction region at the C-terminal of mouse 
PrP would change susceptibility to prions. The series of cell culture studies were 
aimed to understand the roles of the PrP structures in the susceptibility to 
infection in prion pathogenesis by systematically introducing substitutions of 
amino acids in specific regions of PrP.  
Chapter 4 will discuss how the transmission barrier of prions within the 
same species is determined by a PrP polymorphism. I will address how the ovine 
polymorphism at codon 136 expressing either alanine or valine determines 
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susceptibility to infection of classical sheep scrapie isolates using Tg mouse 
models and a unique antibody to distinguish the ovine 136 polymorphism. I will 
ask the following three questions regarding the effects of co-expressing A136 
and V136 alleles on the replication of scrapie. 
(1) Are OvPrP-A136 and OvPrP-V136 independently converted to PrPSc, and 
their properties also independently maintained? 
(2) Does conversion of OvPrPC-V136 dominate that of OvPrPC-A136? 
(3) Does expression of either allele inhibit conversion of the other? 
In addition, I will apply computational modeling approaches to explain potential 
structural differences between the ovine PrP polymorphisms at codon 136, which 
might elucidate the effects of genetic susceptibility on prion pathogenesis.     
Chapter 5 will explore the role of PrP in the pathogenesis of Alzheimer’s 
disease by quantifying the expressed levels of PrP in the brains from individuals 
with different stages of AD. I will detail unaltered PrP expression in the 
rostrocaudal regions of individuals with different stages of AD. I will also address 
whether there is a correlation between the human PrP polymorphism and the 
levels of PrP expression, and whether there is a correlation between the human 
PrP polymorphism at codon 129 and onset of AD.  
 In Chapter 6, I will discuss how the findings in the previous chapters are 
tied together into the conformational selection model, which explains the 
selective conformations between PrPC and PrPSc are determined for conversion 
of PrPC to occur. Furthermore, I will propose future studies to further expand the 
understanding of the molecular mechanisms of conversion of PrPSc. 
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Table 1.1. Biochemical properties of PrP. The cellular isoform of prion protein 
(PrPC) retains normal structural conformation and is expressed in healthy and 
diseased individuals. The disease-associated pathogenic isoform PrPSc is a 
misfolded form of PrP and can polymerize into fibrils and/or aggregates resulting 
in highly infectious PK-resistant protein. 
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Figure 1.1. Structural features of mouse PrP that encodes a protein of 254 
amino acids. The top bar diagram indicates that PrP contains five octarepeats 
(PHGGGWGQ), three α-helices and two β-sheets. Two secretory signal peptides 
reside at the amino (N)-terminal (residues 1-22) and carboxyl (C)-terminal 
(residues 232-254) of PrP. Both of the signal peptides mediate to enter the 
secretory pathway of endoplasmic reticulum (ER). Posttranslational modification 
of PrP starts after entering the ER. The N-terminal signal peptide is cleaved by a 
signal peptidase when entered ER. Then, two N-linked carbohydrate chains 
(CHO) are attached to asparagines at codon 180 and 196, and a disulfide bond 
(S-S) is formed between codons 178 and 213. Finally, in order to bring about 
attachment to the cell membrane, a glycosylphosphatidylinositol (GPI)-anchor is 
attached to the C-terminal of PrP at residue 231 following cleavage of the C-
terminal signal peptide. The mature PrPC (the second bar diagram) is 209 amino 
acids in length (residues 23-231). In the secretory pathway, an ER-based quality 
control removes misfolded PrP to the cytosol for proteasomal degradation. The 
whole process of maturation to transportation is accomplished within one hour. 
The third bar diagram indicates PrPSc has the octarepeats, one disulfide bond 
and two glycosylations; however, the secondary structure of PrPSc has not been 
well characterized except a β-sheet rich structure. After limited protease 
digestion of PrPSc, the C-terminal of PrPSc is remained to form a protease-
resistant molecule of approximately 142 amino acids with a molecular mass of 
27-30 kDa, referred to as PrP 27-30 (the bottom diagram).   
  
        
N C 
β-1 H1 H2 H3 β-2 Octarepeats 
       
S S 
Signal 
  
 
PrP
C
 
PrP
Sc
 
PrP
 
27-30 
Signal 
CHO 
N-181 
CHO 
N-197 GPI 
 
 
30 
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
S
c
 PrP
Sc
 
A. Heterodimer template-associated 
model
 PrP
Sc
 
 PrP
C
  PrP
Sc
 
Heterodimer 
 PrP
S
c
 PrP
Sc
 
Homodimer 
Catalyzed by 
protein X 
 X 
B. Autocatalytic nucleated-polymerization 
model
 PrP
Sc
  PrP
Sc
 + 
 PrP
C
 + 
Catalyzed by 
protein X 
C. Non-catalytic nucleated-polymerization 
model
 PrP
C
  PrP* 
+ 
 PrP* 
 PrP
Sc
 
 PrP*  PrP* 
 X  
 PrP
Sc
 
 PrP
Sc
 
 PrP
S
c
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
C
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
S
c
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
S
c
 PrP
Sc
 
 PrP
S
c
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
 
 PrP
Sc
  X 
 X 
Seed 
Seed 
Formation of 
fibrils and/or 
aggregates 
Fragmentation 
fabricates 
seeds 
 
 
31 
 
Figure 1.2. Template-associated and nucleated-polymerization models of 
prion conversion. A. PrPC is in equilibrium with an intermediate form, referred to 
as PrP*, and PrP* can form a heterodimer complex with PrPSc, which becomes a 
template to alter the conformation of PrP* into infectious isoform PrPSc, resulting 
in the formation of a homodimer complex. The homodimer complex can 
dissociate into two monomers, which can become additional templates to 
produce more PrPSc. A hypothetical protein X is thought to play roles in the 
conversion of PrPC to PrPSc and also catalyze the PrPSc conversion. PrPSc is 
thermodynamically stable compared to PrPC; furthermore, the conversion of 
PrPSc from PrP* is less likely to happen without a catalyst. B. The autocatalytic 
nucleated-polymerization model offers an additional explanation of the 
exponential growth of PrPSc. In this model, PrPC directly interacts with PrPSc seed 
in fibril or aggregate forms, and the conversion reaction is the rate-limiting step. 
The PrPSc conversion step might be catalyzed by protein X. Since the seed is 
thermodynamically stable, the addition of new PrPSc can accelerate the formation 
of longer fibrils or larger aggregates. C. The non-catalytic nucleated-
polymerization model explains that PrP* rather than PrPC interacts with the seed 
to form stable polymers, and the PrPSc  conversion step occurs non-catalytically. 
The rate-limiting step is the reversible reaction between PrPC and PrP*, and the 
reaction might be facilitated by protein X.  The rest of the steps to form PrPSc 
fibrils and aggregates are irreversible.  
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Chapter 2 
Transgenetic modeling of the CWD species barrier to humans 
 
Introduction 
Chronic wasting disease (CWD) is a transmissible spongiform encephalopathy 
(TSE) affecting free-ranging and captive deer, elk, and moose, and is highly 
contagious (Baeten et al., 2007; Miller et al., 2000; Williams, 2005; Williams & 
Young, 1980, 1982, 1992). Since 1967, when the first case of CWD was reported 
in Colorado, the endemic area in North America has steadily spread, with other 
cases reported abroad (Williams & Young, 1980). In fact, by 2005, CWD was 
reported from 12 states in the United States and 2 provinces in Canada with an 
additional case in South Korea (Chronic Wasting Disease Alliance, 2012; Kim et 
al., 2005; Prusiner, 2004). Moreover, by 2012, new CWD cases had been 
identified in those 12 states and in 7 other states as well as in South Korea 
(Chronic Wasting Disease Alliance, 2012; Sohn, 2011). The increasing incidence 
of CWD in wild and captive-farm animals in North America raises doubts about 
the safety of consuming potentially CWD-contaminated cervid meat or products. 
The transmissibility risk of CWD into humans remains unclear at the present 
time.  
The transmission of bovine spongiform encephalopathy (BSE) into 
humans has been reported worldwide, and more than 200 people have 
developed and died from variant Creutzfeldt-Jakob disease (vCJD) through 
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exposure to BSE-contaminated products (Prusiner, 2004; World Health 
Organization, 2012). Given that wild game animals, especially deer and elk, are 
extensively hunted and consumed throughout North America, and the zoonotic 
potential of BSE is now recognized (Bruce et al., 1997; Scott et al., 1999), these 
facts arouse related epidemiological concerns as to whether CWD from deer and 
elk is transmissible to humans, likewise whether a CWD epidemic in deer and elk 
populations might increase transmission risks for humans.  
In recent years, numerous approaches have been employed to address 
these issues. In one approach, transmissibility of CWD has been tested through 
the use of transgenic (Tg) mouse models. To date, studies of this nature report 
no evidence of the transmission of CWD into the transgenic mice expressing 
human PrP (Kong et al., 2005; Sandberg et al., 2010; Tamguney et al., 2006; 
Wilson et al., 2012). Another approach used two nonhuman primate species, 
squirrel monkeys and cynomolgus macaques, as a model of CWD transmission 
to humans. Two studies reported that squirrel monkeys inoculated orally and 
intracerebrally with CWD from deer and elk developed disease, and the 
accumulation of PrPSc was detected in their brains (Marsh et al., 2005; Race et 
al., 2009b). However, cynomolgus macaques, which are evolutionally closer to 
humans (Hayasaka et al., 1988), did not develop any signs of disease following 
either oral or intracerebral transmission of deer and elk CWD isolates (Marsh et 
al., 2005; Race et al., 2009b). A third approach involves possible links between 
the high prevalence of CWD in deer and elk and the incidence of CJD in 
Colorado, where CWD is endemic. In this approach, epidemiological surveillance 
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studies were conducted. Thus far, no positive associations have been found 
(Belay et al., 2004; Mawhinney et al., 2006). Other studies, focusing on the 
conversion of human PrPSc, used an in vitro model. These likewise reported that 
CWD PrPSc failed to convert human PrPC into PrPSc (Barria et al., 2011; Kurt et 
al., 2009). In addition, the extremely inefficient conversion of recombinant human 
PrPSc using CWD PrPSc in comparison with the species matched (cervid) 
recombinant PrPSc conversion was reported (Raymond et al., 2000). Together, 
the above-mentioned studies suggest that there is a high species barrier 
between cervid and human.  
Although the previously mentioned studies suggest that CWD presents a 
low risk of the zoonotic potential, other recent studies remind us that there still 
are significant questions about the transmissibility of CWD into humans. One of 
those concerns the tissues consumed by humans which are derived from deer or 
elk with CWD, including skeletal muscle (Angers et al., 2006), antler velvet 
(Angers et al., 2009), blood (Mathiason et al., 2006) and fat (Race et al., 2009a), 
particularly when such tissues harbor infectious prions. Another study found that 
at least two distinct strains of CWD (referred to as CWD1 and CWD2) propagate 
in deer and elk (Angers et al., 2010); however, the host-range properties of 
CWD1 and CWD2 are still unknown. A further complication is the fact that prion 
strains can mutate to adapt not only within the same species with different 
genetic backgrounds, such as animals of same species expressing Prnp 
polymorphisms, but also following transmission to a new host (Asante et al., 
2002; Lloyd et al., 2004; Mead et al., 2009; Wadsworth et al., 2004). Such 
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mutational events can result in the formation of new prion strains with 
unpredictable biological properties, including the acquisition of a new host-range. 
Consequently, it is difficult to predict the number of CWD strains that may exist 
and propagate in a given population of animals. In this connection, it is extremely 
important to assess the transmissibility of new CWD strains into humans when 
such strains are identified.  
Codon 129, and the corresponding 132 residue in elk, significantly 
influenced the transmission of BSE and CWD prions respectively in Tg mouse 
models (Green et al., 2008). It would follow from this that, the genetic 
susceptibility of humans to CWD should also be determined. Moreover, cervid 
PrPSc converted human PrPC after CWD prions were stabilized by successive 
passages in vivo and in vitro (Barria et al., 2011), suggesting the potential 
adaptation of cervid PrPSc in humans to develop disease. In spite of all these 
many and varied concerns, it does seem that the species barrier of prion 
transmission species barrier between human and cervid is certainly not easy to 
overcome. There remains significant potential that new CWD strains can arise 
and acquire new host-range during horizontal transmission.  
The studies detailed below aim to test whether CWD1 and CWD2 strains 
are transmissible to Tg(HuPrP) mice, and to address the impact of the human 
PrP methionine (M) or valine (V) residue 129 polymorphism on the CWD-to-
human species barrier. To address the hypotheses, Tg(HuPrP) mice encoding 
either M or V129 human PrP polymorphism referred to as Tg(HuPrP-M129) and 
Tg(HuPrP-V129) mice were intracerebrally inoculated with previously 
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characterized CWD1 and CWD2 strains. The Soto group demonstrated the 
amplification of human PrPSc with the successive stabilized CWD in vitro, 
Tg(HuPrP) mice were intracerebrally inoculated with CWD prions that had been 
passaged multiple times in Tg mice expressing deer PrP to determine whether 
the propagation of human PrPSc could occur with the stabilized CWD isolate in 
the animal system. 
 
Materials and Methods 
Transgenic mice expressing human PrP. Hemizygous Tg mice expressing 
human PrP encoding either M or V at residue 129 (referred to as Tg(HuPrP-
M129)6816+/- and Tg(HuPrP-V129)7826+/-, respectively) were previously 
generated (Kurt et al., 2009). Tg mouse lines were maintained by breeding with 
Prnp knockout (Prnp0/0) FVB mice on an FVB background, referred to as 
FVB/Prnp0/0 mice. Tg offspring were identified by tail biopsy and extraction of 
genomic DNA followed by polymerase chain reaction (PCR) screening for the 
presence of the transgene using a standard protocol. Briefly, approximately 1 cm 
of tail tissue was digested overnight at 55°C with proteinase K (PK) at a final 
concentration of 0.5 mg/ml in 50 mM Tris pH 8.0, 100 mM 
ethylenediaminetetraacetic acid (EDTA), 0.5% sodium dodecyl sulfate (SDS), the 
DNA extracted with phenol and chloroform and concentrated by ethanol 
precipitation. Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- were used in 
the following studies. The expression levels of PrP in the brains of Tg(HuPrP-
M129)6816+/- and Tg(HuPrP-V129)7826+/- mice are 16-fold and 2-fold 
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overexpressed comparing to PrP expressed in the brains of wild-type FVB mice, 
respectively (Figure 2.1.).  
 
Transmission studies and CWD inocula. Pertinent information on the CWD 
inocula used in the following studies is summarized in Tables 2.1. and 2.3. Elk 
CWD isolate (99W12389) was obtained from a CWD affected elk from the 
Wyoming State Veterinary Laboratory. Elk Bala05 CWD isolate was obtained 
from an elk, which was naturally affected with CWD, from the Canadian Food 
Inspection Agency, Ottawa, Ontario Canada. Deer CWD isolate (9179) was 
obtained from a deer, which was naturally affected with CWD, from Wyoming 
(Angers et al., 2010). Deer H92 CWD isolate was obtained from a mule deer, 
which was naturally affected with CWD, from Colorado State University, Fort 
Collins, Colorado. The CWD isolates 99W12389, Bala05 and 9179 previously 
produced disease in Tg(Deer PrP)1536+/- mice expressing deer PrP, previously 
referred to as Tg(CerPrP)1536+/- mice. These isolates were selected because 
their biological properties upon transmission reflected phenotypes that were 
consistent with CWD1, CWD2 and mixtures of the two CWD types (CWD mix) 
(Angers et al., 2010).  
In separate studies, H92 isolate was serially passaged three times in 
Tg(Deer PrP)1536+/- mice and characterized as CWD mix (Angers et al., 2010). 
In the tertiary passage, one Tg(Deer PrP)1536+/- mouse inoculated with the 
serially passaged H92 CWD developed disease at 193 days post inoculation 
(dpi), which will be referred as a short incubation time; and another Tg(Deer 
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PrP)1536+/- mouse with the serially passaged H92 CWD developed disease at 
299 dpi, referred as a long incubation time. In this study, two diseased Tg(Deer 
PrP)1536+/- mouse brains from the short and long incubation time groups were 
used to inoculate Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/-  mice 
(Table 2.4.). 
Blocks of the CWD-positive brains were prepared as 10% (w/v) in sterile 
phosphate buffered saline (PBS) lacking Ca2+ and Mg2+ ions by repeated 
extrusion through a series of needles of decreasing diameter from 18 gauge to 
22 gauge. Ten-percent brain homogenate was diluted to 1% (v/v) in PBS and 
thoroughly homogenized using a 26 gauge needle syringe. Groups of 5-week-old 
Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice were anesthetized 
with halothane and injected with 30 µl of 1 % (w/v) brain homogenate 
intracerebrally into the right parietal lobe using a 26 gauge needle syringe.   
 
Determination of incubation time. Animals were monitored for general health 
on a daily basis as well as for manifestations of progressive neurological 
dysfunction normally associated with prion diseases. The clinical manifestation of 
disease was determined by the presence of at least three of the following clinical 
signs: truncal ataxia, kyphotic posture, hind-limb paresis, loss of extensor reflex, 
difficulty righting from a supine position, flattened gait and tail stiffening. Animals 
were diagnosed when at least two investigators agree with the clinical 
manifestation of disease. Severity of clinical signs were scored for 13 clinical 
signs using 0 = absence, 1 = mild, 2 = moderate and 3= severe. In addition, all 
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animals were recorded on video at the time of diagnosis and/or right before 
termination. The incubation time was defined as a period of the time between the 
day the prion was inoculated and the first day the diagnosis was given; therefore, 
the incubation time was indicated in ‘days post inoculation’ (dpi). 
 
Detection of PrPSc by western blotting analysis. The right hemisphere of each 
brain was collected for western blot analysis. Ten-percent (w/v) brain 
homogenates were prepared in sterile PBS by repeated extrusions through a 
series of needles of decreasing diameter from 18 to 22 gauge.  
The concentration of total protein in each sample was determined by 
bicinchoninic acid assay and standardized for each lane (40 µg per lane). 
Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis and transferred to polyvinylidene difluoride Immobilon-FL (PVDF) 
membranes (Millipore). The transferred membrane was blocked with 5% (w/v) 
non-fat milk in 0.5% (v/v) Tween-20 in Tris-buffered saline (TBST) and 
immunoprobed with mouse monoclonal antibody anti-PrP PRC5 followed by 
horseradish peroxidase-conjugated anti-mouse secondary antibody. Proteins 
were visualized using ECL Plus (GE Healthcare) in an FLA-5000 scanner 
(Fujifilm Life Science). The expression levels of PrPC in Tg(HuPrP) mice were 
determined by reading each histogram of PrPC signals on the western blot using 
MultiGauge (Fujifilm Life Science). 
All brain samples from the CWD-inoculated Tg(HuPrP-M129)6816+/- and 
Tg(HuPrP-V129)7826+/- mice with and without manifestation of neurological 
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dysfunction were analyzed for the presence of PrPSc by western blotting. Four µl 
of 10% brain homogenate mixed in PBS with 2% sarkosyl was treated with PK 
with a final concentration of 100 µg/ml for 1 hour at 37°C and ultracentrifuged at 
100,000 × g for 1 hour at 4°C to concentrate PrPSc. Digested and undigested 
samples were assessed by western blotting with appropriate controls. An 
FVB/Prnp0/0 (KO) was used as a negative control for the anti-PrP antibody. An 
uninfected Tg(HuPrP) was used as a negative control for the presence of PK 
resistant PrPSc. The deer CWD (99W12389) was used as a positive control for 
the presence of PK resistant PrPSc. Electrophoresis, transfer of proteins to a 
PVDF membrane and western blotting using PRC5 were performed as described 
above.  
 
Evaluation of spongiform degeneration. Spongiosis development is a 
neuropathological feature of prion diseases including CWD, and representative 
animals displaying signs of neurological dysfunction were determined for 
vacuolation (spongiform change) in the brain. The left hemisphere of each brain 
was collected for neuropathological analyses. The half-brains were fixed in 4% 
formaldehyde for 24 hours, transferred to sterile PBS and paraffin wax 
embedded. Brain sections of 8 µm thickness were coronally cut to areas 
corresponding to the four levels of the brain containing the nine brain regions 
including the medulla, cerebellum, midbrain, hypothalamus, thalamus, 
hippocampus, paraterminal body and cerebral cortex at the levels of the septum 
and hippocampus (Figure 2.4.). The brain sections were collected on positively 
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charged slides. Harris haematoxylin and eosin (H & E) staining was performed by 
a standard method at the Veterinary Diagnosis Laboratory Colorado State 
University. Appropriate positive (RML diseased wild-type FVB mouse brains) and 
negative controls (uninfected Tg(HuPrP-M129)6816+/- and Tg(HuPrP-
V129)7826+/- mouse brains) were also performed with experiments. The H & E 
staining provides nuclear staining and counterstaining to provide guidance to 
observe the vacuolation development on brain sections. The criteria for 
spongiosis development in prion diseases are: (1) region specific (Figure 2.4.), 
(2) appearing between nerve cell bodies and (3) the formation of vacuolation, 
which can be diffuse but intensive or appearing in the groups which often look to 
be a floral form (Figure 2.5.10.) (Prusiner, 2004). In addition to the positive 
control explained above, another positive control, CWD-inoculated Tg(Deer 
PrP)1536+/- mouse brain, on which the H & E staining was performed previously, 
was used (Figure 2.5.10.). The images were taken on a BX60 microscope 
equipped with a DP-71 charge-coupled diode (CCD) camera (Olympus) and 
composed with Adobe Photoshop.  
 
Statistical analysis. Statistical analysis of impacts of the human PrP 
polymorphism at codon 129 on the manifestation of clinical signs in CWD-
inoculated Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice was 
performed using a Fisher’s exact test for each CWD prion strain separately. 
Statistical analysis of the severity of clinical signs was determined using a 
Kruskal-Wallis one-way analysis of variance (ANOVA) to compare six groups 
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(CWD1, CWD2 or CWD mix inoculated Tg(HuPrP-M129)6816+/- and Tg(HuPrP-
V129)7826+/- mice) for each clinical sign. All data were analyzed with GraphPad 
Prism 5. Differences with p < 0.05 was considered to be a significant. 
 
Results 
Manifestation of clinical signs in CWD-inoculated Tg(HuPrP) mice. 
Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice expressing PrP in the 
central nervous system (CNS) at levels 16-fold and 2-fold higher than an FVB 
mouse were used in the following studies, respectively (Figure 2.1.) Three of 
eight Tg(HuPrP-M129)6816+/- mice inoculated with CWD1 (99W12389 elk isolate 
from Wyoming) developed truncal ataxia, hind-limb paresis and difficulty righting 
from a supine posture. The mean incubation time for mice to manifest clinical 
signs was 442 ± 90 dpi (± standard error of the mean, SEM) (range, 263–532 
dpi) (Table 2.1. Table 2.2. and Figure 2.2.). Additional neurological dysfunctions 
including kyphotic posture, tail stiffening, loss of extensor reflex, flattened gait, 
head bobbing, aggressive behavior, slowed movement and rough coat, were also 
observed in three of the CWD1-inoculated Tg(HuPrP-M129)6816+/- mice. Four of 
eight Tg(HuPrP-M129)6816+/- mice inoculated with CWD2 (Bala05 elk-isolate 
from Ontario Canada) developed tail stiffening, hind-lib paresis and loss of weight 
or condition after an average of 425 ± 60 dpi (range, 284–551 dpi) (Table 2.1. 
Table 2.2. and Figure 2.2.). These mice also exhibited some of the following 
neurological dysfunctions: truncal ataxia, kyphotic posture, loss of extensor 
reflex, difficulty righting, flattened gait, head bobbing, aggressive behavior, 
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slowed movement and rough coat. Two of eight Tg(HuPrP-M129)6816+/- mice 
inoculated with CWD mix (9179 deer isolate from Wyoming) developed kyphotic 
posture, tail stiffening, slowed movement and rough coat after an average of 354 
± 70 dpi (range, 315–393 dpi) (Table 2.1. Table 2.2. and Figure 2.2.). These two 
mice also exhibited some of the following neurological dysfunctions: truncal 
ataxia, loss of extensor reflex, circling and loss of weight or condition.   
One of eight Tg(HuPrP-V129)7826+/- mice inoculated with CWD1 
developed tail stiffening, head bobbing and rough coat after 543 dpi (Table 2.1. 
Table 2.2. and Figure 2.2.). None of eight Tg(HuPrP-V129)7826+/- mice 
inoculated with CWD2 presented clinical signs after 657 dpi (Table 2.1. Table 
2.2. and Figure 2.2.). One of seven Tg(HuPrP-V129)7826+/- mice inoculated with 
CWD mix developed truncal ataxia, kyphotic posture, tail stiffening, loss of 
extensor reflex, flattened gait, slowed movement, dull or rough coat and loss of 
weight or condition after 488 dpi (Table 2.1. Table 2.2. and Figure 2.2.). Other 
study animals did not present with clinical signs associated with prion disease 
and died from unrelated medical issues, such as, skin irritation, development of 
abdominal mass or pulmonary issues  (open circles in Figure 2.2.). The 
remaining animals in these studies were terminated at 657 dpi due to aging 
(triangles in Figure 2.2.).  
Severity of clinical signs manifested by CWD-inoculated Tg(HuPrP-
M129)6816+/- and Tg(HuPrP-V129)7826+/- mice was scored and summarized in 
Table 2.2. Scores were determined by each clinical sign in each animal, and a 
sum of scores given for each animal was indicated under each clinical sign 
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(Table 2.2). A total score of severity of clinical signs in CWD1-inouclated 
Tg(HuPrP-M129)6816+/- mice was 42 consisting of scores of 11 clinical signs: 
truncal ataxia (a score was 6, scores will be indicated in parenthesis for the 
following clinical signs), kyphotic posture (1), tail stiffening (5), hind-limb paresis 
(6), loss of extensor reflex (4), difficulty righting from a supine position (5), 
flattened gait (4), head bobbing (2), aggressive behavior (1), slowed movement 
(3) and dull or rough coat (5) (Table 2.2.). A total score of severity of clinical 
signs in CWD2-inouclated Tg(HuPrP-M129)6816+/- mice was 56 consisting of 
scores of 12 clinical signs: truncal ataxia (2), kyphotic posture (4), tail stiffening 
(8), hind-limb paresis (4), loss of extensor reflex (4), difficulty righting from a 
supine position (4), flattened gait (6), head bobbing (1), aggressive behavior (6), 
slowed movement (4), dull or rough coat (6) and loss of weight or condition (7) 
(Table 2.2.). A total score of severity of clinical signs in CWD mix-inoculated 
Tg(HuPrP-M129)6816+/- mice was 14 consisting of scores of 8 clinical signs: 
truncal ataxia (1), kyphotic posture (2), tail stiffening (2), loss of extensor reflex 
(1), slowed movement (2), circling (1), dull or rough coat (4) and loss of weight or 
condition (1) (Table 2.2.). A total score of severity of clinical signs in CWD1-
inouclated Tg(HuPrP-V129)7826+/- mice was 3 consisting of scores of 3 clinical 
signs: tail stiffening (1), head bobbing (1), and dull or rough coat (1) (Table 2.2.). 
A total score of severity of clinical signs in CWD mix-inoculated Tg(HuPrP-
V129)7826+/- mice was 11 consisting of scores of 8 clinical signs: truncal ataxia 
(1), kyphotic posture (2), tail stiffening (1), loss of extensor reflex (1), flattened 
gait (1), slowed movement (1), dull or rough coat (2) and loss of weight or 
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condition (2) (Table 2.2.). Statistical analysis of the severity of the clinical signs 
was performed using a Kruskal-Wallis one-way ANOVA between groups. The 
total scores of severity of clinical signs between different CWD prions and 
between  Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice were not 
statistically significant; however, one clinical sign, difficulty righting from a supine 
position was turned out to be statistically significant (p<0.043) (Table 2.2.). Two 
other clinical signs including hind-limb paresis and loss of weight or condition 
were borderline significant (p<0.055 and p<0.061, respectively) (Table 2.2.). 
CWD1 and CWD2 inoculated Tg(HuPrP-M129)6816+/- mice exhibited 
multiple clinical signs, which were rapidly progressed. On the other hand, CWD 
mix inoculated Tg(HuPrP-M129)6816+/- mice developed fewer neurological signs 
compared to CWD1 and CWD2 inoculated Tg(HuPrP-M129)6816+/- mice. CWD1 
and CWD mix inoculated Tg(HuPrP-V129)7826+/- mice also exhibited fewer 
neurological signs than CWD-inoculated Tg(HuPrP-M129)6816+/- mice. A 
Fisher’s exact test was performed to determine whether the human PrP 129 
polymorphism impacted on the manifestation of clinical signs in CWD-inoculated 
Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice; however, no 
statistically significant difference (p<0.05) between M and V at the 129 
polymorphism was found in each CWD-inoculated animal group. The p-value of a 
Fisher’s exact test in CWD2-inoculated Tg(HuPrP-M129)6816+/- and Tg(HuPrP-
V129)7826+/- mice turned out to be a borderline significance (p>0.077) (Table 
2.1.). Overall, Tg mice expressing the HuPrP polymorphism M129 mice tended to 
develop more overt clinical signs compared to Tg(HuPrP-V129)7826+/- mice. 
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No evidence of PrPSc in the CWD inoculated Tg mouse brains. The right half-
brains of all the animals in the studies were analyzed for the presence of PK 
resistant PrPSc in western blotting analyses. Even though the samples were 
enriched for the presence of aggregated PrP, by ultracentrifugation in the 
presence of non-denaturing detergents, which is a property of disease-
associated PrP, PrPSc was not detected by western blotting in any of the study 
animals. Two representative samples from each group of the CWD1, CWD2 and 
CWD mix inoculated Tg(HuPrP) mice are shown along with PK-digested and -
undigested samples, as well as with appropriate positive and negative controls, 
in Figure 2.3. As negative control, uninfected Tg(HuPrP) mouse brains were 
used and showed the presence of PrPC but not PrPSc. As positive control, deer 
CWD (99W12389) isolate was used and revealed PrPSc in the sample, 
demonstrating our ability to distinguish disease-associated PrP in this assay. 
  
Absence of spongiform degeneration in the brains of clinically affected 
CWD inoculated Tg(HuPrP) mice. Selected brains from animals manifesting 
clinical signs were further analyzed for the development of spongiosis. Nine brain 
regions, including the medulla, cerebellum, midbrain, hypothalamus, thalamus, 
hippocampus, paraterminal body, cerebral cortex at the levels of the septum and 
hippocampus, were assessed for the development of disease-related vacuolation 
in CWD inoculated Tg(HuPrP) mice, which manifested clinical signs (Table 2.4.). 
Even though the CWD inoculated Tg(HuPrP) mice presented prion disease-
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associated clinical signs, disease-associated spongiosis was not observed in any 
of the analyzed mice (Figure 2.5.). Some spongiosis observed in the brains was 
not region specific and did not appear to be the result of neuronal vacuolation 
those observations were inconsistent with the types of prion disease-associated 
spongiosis (Figure 2.5.10.). Since many of the study animals were aged (some 
were close to 600 days old), the spongiosis observed in those animal brains were 
more likely associated with aging.  
 
No signs of disease in Tg(HuPrP) mice inoculated with CWD prions 
passaged multiple times in Tg(Deer PrP)1536+/- mice. In separate studies, 
Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice were intracerebrally 
inoculated with CWD isolates that had been passaged multiple times in Tg(Deer 
PrP)1536+/- mice (Table 2.4.). None of the mice developed neurological 
dysfunctions, and all died from unrelated medical issues (range, 162-646 dpi) 
(Table 2.4. and Figure 2.6.). Ten Tg(HuPrP-V129)7826+/- mice, which did not 
develop any clinical signs, were terminated at 560 dpi, while eight Tg(HuPrP-
M129)6816+/- mice, which did exhibit clinical signs, were further observed for the 
progression of neurological dysfunction. Four Tg(HuPrP-M129)6816+/- mice 
inoculated with serially passaged CWD from a short incubation time group, and 
another four Tg(HuPrP-M129)6816+/- mice inoculated with serially passaged 
CWD from a long incubation time group, did not progress the clinical signs in the 
next 100 days. Thus, all remaining mice were terminated at 646 dpi.    
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Discussion 
To model the species barrier between humans and CWD prions, Tg(HuPrP-
M129)6816+/- and Tg(HuPrP-V129)7826+/- mice were tested for their 
susceptibility to CWD1 and CWD2 strains as well as isolates containing a mixture 
of both. A subset of CWD-inoculated animals developed the progressive clinical 
signs; however, the examination of brain material from these diseased mice 
failed to confirm the presence of protease-resistant human PrPSc or 
neuropathological signs associated with prion disease (Table 2.2. and Figure 
2.3.). These results are consistent with a significant species barrier in humans to 
these CWD strains. The additional assessment of the susceptibility to the serially 
passaged CWD isolates was also performed using Tg(HuPrP-M129)6816+/- and 
Tg(HuPrP-V129)7826+/- mice. None of the serially passaged CWD inoculated 
animals developed disease with the absence of clinical signs and PrPSc in the 
brains. Because of the lack of disease, the impact of human PrP 129 
polymorphism on the susceptibility of CWD was inconclusive in the above 
studies.  
In these studies, the species barrier between the CWDs and Tg(HuPrP) 
mice was not overcome in the primary transmission. PrPSc deposition and 
spongiform development were not identified in the 16-fold and 2-fold 
overexpressing Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mouse 
brains, respectively. However, the presence of progressive signs of neurological 
dysfunction in the CWD-inoculated Tg(HuPrP) mice cannot be ignored. This 
suggests that the conversion of human PrPSc might occur, but slowly, when 
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cervid PrPSc is intracerebrally inoculated into Tg(HuPrP) mice. Race and 
colleagues demonstrated that gradual adaptation of hamster PrPSc to mouse 
PrPC occurred slowly in two distinct phases, including an abnormal protease-
resistant PrP (PrP-res)-negative phase followed by a replication phase during 
serial passages (Race et al., 2002). In addition, protease-resistant PrPSc was not 
always detectable in both of the phases (Race et al., 2002). In the present study, 
the PK-resistant PrPSc and spongiform change were undetectable in the brains 
from the CWD-inoculated Tg(HuPrP) mice; however, the propagation of PK-
sensitive PrPSc might occur in the brains causing the clinical signs. Moreover, the 
formations of PK-sensitive PrPSc plaques and spongiform degenerative have 
been identified in diseased human brains (Gambetti et al., 2008; Zou et al., 
2010b). Another group also reported that sheep scrapie diseased brains in some 
cases contained far more PK-sensitive PrPSc than PK-resistant PrPSc, and the 
PK-sensitive PrPSc had an ability to produce PK-resistant PrPSc in vitro (Thackray 
et al., 2007; Tzaban et al., 2002). These studies raise a question whether PK-
sensitive PrPSc is present in the CWD-inoculated Tg(HuPrP) mice. If so, the 
manifestation of clinical signs in those Tg(HuPrP) mice might be a result of 
accumulation of PK-sensitive PrPSc in the brain.  
If true prion transmission has occurred, the CWD-inoculated Tg(HuPrP) 
mice in the studies might be in either PrP-res-negative or replication phases. 
Therefore, a subset of the CWD-inoculated Tg(HuPrP) mice manifested the 
neurological dysfunction, which might be caused by the accumulation of human 
PrPSc, in the absence of a detectable amount of proteinase-resistant PrPSc in the 
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brains. To fully address this issue in the near future, one might find it useful to 
serially passage the brain materials from the CWD-inoculated Tg(HuPrP) mice 
displaying clinical signs into the genotype matched Tg(HuPrP) mice.  
Prion disease incubation times in humans are known to extend for 
decades. In fact, Kuru, a human prion disease found in Papua New Guinea, has 
a report incubation time of over 50 years (Collinge et al., 2006; Collinge et al., 
2008). This shows that quite lengthy periods are required for replication of PrPSc 
in humans, before disease development without a species barrier. In the present 
study, most of the CWD inoculated Tg(HuPrP) mice remained without signs of 
prion disease for >600 dpi even though a subset of the animals are clinical 
(Figure 2.2.). Four other studies also reported the negative transmissions of 
CWD into Tg mice expressing human PrP encoding either M or V at residue 129 
(Kong et al., 2005; Sandberg et al., 2010; Tamguney et al., 2006; Wilson et al., 
2012). The Gambetti group reported that three out of 29 CWD-inoculated Tg 
mice expressing human PrP M 129 polymorphism (Tg40) presented mild ataxia 
without accumulation of either PK-resistant and PK-sensitive PrPSc after >756 
dpi, and another group of CWD-inoculated humanized mice expressing the M 
129 polymorphism (Tg1) did not present any clinical signs after >657 dpi. Based 
on the absence of PrPSc and lack of such key neuropathological features as, 
spongiform change, gliosis and PrPSc plaques in the brain, it was concluded that 
the mild ataxia in three Tg40 mice was not associated with prion disease. The 
Prusiner group inoculated 8 different CWD isolates from elk and deer into 
Tg(HuPrP-M129)440 hemizygous mice and reported no clinical signs in CWD-
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inoculated Tg440 mice after >500 dpi. The Collinge group also reported no 
clinical signs in CWD-inoculated Tg(HuPrP-M129)45, Tg(HuPrP-M129)35 and 
Tg(HuPrP-V129)152 homozygous mice after >700 dpi. The histology of CWD-
inoculated Tg(HuPrP) mouse brains was not different from age-matched non-
inoculated Tg(HuPrP) mouse brains. The Barron’s group reported no clinical 
signs in CWD-inoculated Tg(HuPrP-M129) and Tg(HuPrP-V129) homozygous 
mice, or in Tg(HuPrP-M/V129) hemizygous mice after >680 dpi, >722 dpi, >730 
dpi, respectively. Considering the long incubation times in human for prion 
diseases, one has reason to think the incubation time of 500-700 days might be 
insufficient for accumulation of detectable amounts of PrPSc in the brain, or to 
cause CWD disease in Tg(HuPrP) mice.  
Furthermore, the hamster-to-mouse species barrier of prion was 
overcome after three serial passages of a total of 1200 to >1550 days (Race et 
al., 2002). PK-resistant PrPSc started appearing in the brains of asymptomatic 
mice inoculated with brain homogenates from the mouse passaged hamster 
prions from the secondary transmission; and in the next transmission with brain 
homogenates from the secondary transmission, disease was produced in mice. 
The study demonstrated that the gradual adaptation of hamster prion required a 
substantial amount of time even between the rodents. Therefore, serial passages 
of the materials from the CWD-inoculated Tg(HuPrP) mice need to be evaluated 
for clearly establishing lack of transmission of CWD into humans.     
It was essential to further analyze the CWD-inoculated Tg(HuPrP) mice 
with clinical signs for the development of prion diseases due to the inconclusive 
 
 
52 
results of the presence of the clinical signs without PrPSc deposition in the Tg 
mice. Spongiosis development, which is a neuropathological feature of prion 
diseases including CWD, was also examined in the clinical Tg(HuPrP) mice with 
CWD. The features for spongiosis development in prion diseases are: (1) region 
specific (Figure 2.4.), (2) appearing between nerve cell bodies and (3) the 
formation of vacuolation, which can be diffuse but intensive or appearing in the 
groups which often look to be a floral form (Figure 2.5.) (Prusiner, 2004). The 
analyzed CWD-infected Tg(HuPrP) mouse brains with clinical signs presented 
fewer vacuolations between or on cells; in those which did show, vacuoles 
appeared only randomly in their brains. Therefore, vacuolation found in these 
animals was not associated with prion diseases. More precise evaluation of the 
disease associated spongiosis development in the CWD inoculated Tg(HuPrP) 
mouse brains could be done if a PBS inoculated age matched Tg(HuPrP) mouse 
brain was available for a prion disease negative control. The age matched control 
from the genotype matched Tg mice would be a great help in evaluating whether 
vacuolation in the brain is due to aging or to prion diseases. As an additional 
positive control, Tg(HuPrP) mice with human prion diseases would be useful. 
Other groups have been utilizing the Tg(HuPrP) mouse model to study the 
interspecies transmission of prions as well as the biochemical properties of PrPSc 
(Asante et al., 2002; Wadsworth et al., 2004). Information based on the Tg 
mouse model has advanced our understanding of the species barrier of prions to 
humans including BSE (Asante et al., 2002; Wadsworth et al., 2004). In future 
studies, the named positive and negative controls would be extremely helpful in 
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assessing any associations among the intensity of vacuolation in specific 
regions, clinical signs and presence or absence of PrPSc deposition or plaques in 
CWD-inoculated Tg(HuPrP) mice.  
Codon 129 polymorphism of the human PrP has an impact on the 
susceptibility to prion diseases including BSE, and the M 129 polymorphism was 
reported to be more susceptible to BSE and variant CJD (Lloyd et al., 2004; 
Wadsworth et al., 2004). In the present studies, we expected that the CWD-
inoculated Tg(HuPrP-M129)6816+/- mice were more likely to develop multiple 
clinical signs than were Tg(HuPrP-V129)7826+/- mice (Table 2.2.). However, it 
was not clear whether the PrP 129 polymorphism impacted on the development 
of the multiple clinical sings in Tg(HuPrP-M129)6816+/- mice. The higher number 
of Tg(HuPrP-M129)6816+/- mice which manifested the multiple clinical signs 
might be due to the overexpression of PrP because Tg(HuPrP-M129)6816+/- 
mice express 8-fold higher levels of PrP than do Tg(HuPrP-V129)7826+/- mice. It 
has been reported that there is a reciprocal relationship between the expression 
level of PrP and onset of disease (Prusiner et al., 1990). The higher the level of 
PrP expressed in Tg mice, the shorter the incubation time after inoculation with 
prions. Since protease-resistant PrPSc could not be detected in either the CWD-
inoculated Tg(HuPrP-M129)6816+/- or the Tg(HuPrP-V129)7826+/- mice, there is 
perhaps reason to support that the human 129 polymorphism might not have an 
impact on the conversion efficiency of PK-resistant PrPSc during the primary 
transmission.    
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The present study showed that a significantly high species barrier 
between cervid and humans exists. CWD transmission studies in Tg(HuPrP) 
mice were performed by the intracerebral inoculation, which is considerably more 
efficient in transmitting prions than oral consumption (Prusiner et al., 1985; Race 
et al., 2009b). If CWD is transmitted to humans, consumption of CWD-
contaminated products is the most likely route into humans. The present studies 
and others show that none of the CWD-inoculated Tg(HuPrP) mice accumulated 
PK-resistant PrPSc in their brains, suggesting a lower risk of transmission of CWD 
into humans. In view of the substantial incubation times for humans prion 
diseases, as well as the remarkable persistence of prions in adapting within both 
the same and in different species, it is important to continue evaluating the 
transmission of CWD in serial passages, as well as to test new strains of CWD 
as identified for verifying the transmission of CWD into humans.    
Mindful of existing data on the successful amplification of human PrPSc 
with serially stabilized CWD isolates in vivo and in vitro, Tg(HuPrP) mice were 
also inoculated with the CWD isolates which had been passaged multiple times 
in Tg(Deer PrP)1536+/- mice. The intent was to test whether the selected CWD 
PrPSc increased its pathogenicity to humans during adaptation through the 
multiple passages in Tg(Deer PrP)1536+/- mice. Unlike in the in vitro study, 
evidence of PrPSc propagation was not observed in the CWD-inoculated 
Tg(HuPrP) mice; none of the mice developed any clinical signs after >646 dpi. 
The different results might be due to the use of two different systems. The 
present study used an animal model, and the previous study used a cell free 
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amplification system in vitro. In addition, as discussed above, the length of the 
incubation time even up to 646 dpi might not be long enough to see disease 
development in those study animals.  
Even though the present studies did not prove the CWD transmission into 
Tg(HuPrP) during the primary passage, the zoonotic potential of CWD has not 
been eliminated. As there is always the possibility of preclinical and subclinical 
carriers of BSE in humans, it is important to take into consideration that a similar 
situation might occur with CWD. The modified hypothesis is that PK-sensitive 
PrPSc is first propagated in CWD-inoculated Tg(HuPrP) mouse brain with or 
without the presentation of clinical signs; later PK-resistant PrPSc becomes 
detectable. To address this hypothesis, brain materials from the CWD-inoculated 
Tg(HuPrP) mice with clinical signs in these studies will be passaged to genotype 
matched Tg(HuPrP) mice. When the mice manifest clinical signs, the presence of 
both PK-sensitive and resistant PrPSc needs to be determined in addition to the 
neuropathological features.  
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Table 2.1. Transmission of CWD isolates into Tg(HuPrP-M129)6816+/-  and 
Tg(HuPrP-V129)7826+/- mice. Incubation time indicates days post inoculation 
(dpi) in mean ± SEM (standard error of the mean). The PrP expression was 
determined by comparing to a wild-type FVB mouse. A Fisher’s exact test was 
performed to determine whether the human PrP 129 polymorphism impacted on 
the manifestation of clinical signs in CWD-inoculated Tg(HuPrP-M129)6816+/- 
and Tg(HuPrP-V129)7826+/- mice; however, no statistically significant difference 
(p<0.05) between M and V at the 129 polymorphism was found in each CWD-
inoculated animal group. The p-value of a Fisher’s exact test in CWD2-inoculated 
Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice turned out to be a 
borderline significance (p>0.077). 
 
Prion CWD1 CWD2 CWD mix 
Isolate 99W12389 Bala05 9179 
Location Wyoming Ontario Canada Wyoming 
Origin Elk Elk Deer 
Recipient Tg HuPrP M129 
HuPrP 
V129 
HuPrP 
M129 
HuPrP 
V129 
HuPrP 
M129 
HuPrP 
V129 
PrP expression  
(n-fold) 16 2 16 2 16 2 
Incubation time 
(dpi) 442 ± 90 543 425 ± 60 - 354 ± 70 488 
No. of animals 
with clinical 
signs/ a total 
No. of animals 
inoculated  
3/8 1/8 4/8 0/8 2/8 1/7 
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Table 2.2. Summary of neurological dysfunctions manifested in the CWD 
inoculated Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice. The 
number of CWD-inoculated Tg(HuPrP) mice with clinical signs is indicated in 
parentheses in each section of clinical signs. Severity of clinical signs were 
scored for 13 clinical signs using 0 = absence, 1 = mild, 2 = moderate and 3= 
severe. A total score of clinical signs manifested in animals were indicated in 
each section of clinical signs. A total score of all clinical signs were shown in the 
last row under each CWD-inoculated animal group. Statistical analysis of severity 
of clinical signs was determined using a Kruskal-Wallis one-way analysis of 
variance. A p-value is reported only when the value is significant (p<0.05) or 
borderline significant. ‘No’ indicates p>0.1. 
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Recipient Tg p<0.1 HuPrP-M129 HuPrP-V129 
Inoculum  CWD1 CWD2 
CWD 
mix CWD1 
CWD 
mix 
No. of animals with 
clinical signs/ a 
total No. of animals 
inoculated  
 3/8 4/8 2/8 1/8 1/7 
Truncal ataxia No 6 (3) 2 (2) 1 (1)  1 (1) 
Kyphotic posture No 1 (1) 4 (3) 2 (2)  2 (1) 
Tail stiffening  No 5 (2) 8 (4) 2 (2) 1 (1) 1 (1) 
Hind-limb paresis  0.055 6 (3) 4 (3)    
Loss of extensor 
reflex No 4 (2) 4 (3) 1 (1)  1 (1) 
Difficulty righting 
from a supine 
position  
0.043 5 (3) 4 (2)    
Flattened gait  No 4 (2) 6 (3)   1 (1) 
Head bobbing No 2 (1) 1 (1)  1 (1)  
Aggressive behavior No 1 (1) 6 (2)    
Slowed movement No 3 (2) 4 (3) 2 (2)  1 (1) 
Circling No   1 (1)   
Dull or rough coat No 5 (3) 6 (3) 4 (2) 1 (1) 2 (1) 
Loss of weight or 
condition 0.061  7 (4) 1 (1)  2 (1) 
Total score No 42 56 14 3 11 
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Table 2.3. Origin of CWD isolate used in serial transmission studies.  
 
 
Prion CWD mix 
Original isolate H92 
Location Colorado 
Origin Mule deer 
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Table 2.4. Transmission of serially passaged CWD isolates into Tg(HuPrP-
M129)6816+/- and Tg(HuPrP-V129)7826+/- mice. Elk CWD H92 isolate was 
passaged three times in Tg(Deer PrP)1536+/- mice prior to testing the 
transmission of CWD in Tg(HuPrP) mice in this study. Two individual samples 
were chosen from a pool of short incubation time group (200 dpi) and a pool of 
long incubation time group (300 dpi) to inoculate groups of Tg(HuPrP-
M129)6816+/- and Tg(HuPrP-V129)7826+/- mice. Incubation time or time of death 
indicates days post inoculation (dpi). Time of death shows a period of time from 
the day that a first animal was terminated to the day that a last animal was 
terminated. The PrP expression was determined by comparing to a wild-type 
FVB mouse.  
 
Inoculum 
H92 CWD passaged multiple times in Tg(Deer PrP) mice 
Short incubation time 
(193 dpi) 
Long incubation time 
(299 dpi) 
Recipient Tg HuPrP M129 
HuPrP 
V129 
HuPrP 
M129 
HuPrP 
V129 
PrP expression  
(n-fold) 16 2 16 2 
Time of death (dpi) 543 – 646 171 – 560 162 – 646 451 - 560 
No. of animals ill/ No. 
of animals inoculated  0/6 0/7 0/6 0/7 
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Figure 2.1. The expression levels of PrP in the transgenic mouse brains 
compared to a wild-type FVB mouse brain. The PrPC expression levels in 
Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mouse brains were 
determined by comparing to a wild-type FVB mouse brain in western blot using 
anti-PrP PRC5 monoclonal antibody. The PrPC levels in Tg(HuPrP-M129)6816+/-  
and Tg(HuPrP-V129)7826+/- overexpressed 16-fold and 2-fold more than the 
FVB, respectively. A total amount of protein was standardized to 40µg per lane. 
An FVB/Prnp0/0 (KO) is used as a negative control. Molecular markers indicate 
50, 40, 30 and 20 kDa from top to bottom. Two cropped images are from the 
same exposure of the same blot.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20k 
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50k 
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Incubation time, days ± SEM  
(manifestation of clinical signs, n/n0) 
Recipient CWD 1 CWD 2 CWD mix 
Tg (HuPrP-M129) 442 ± 90 (3/8) 425 ± 60 (4/8) 354 ± 70 (2/7) 
Tg (HuPrP-V129) 543 (1/8) (0/8) 488 (1/7) 
 
 
Figure 2.2. Summary of incubation times of CWD-inoculated Tg(HuPrP) 
mice. Some inoculated animals manifested clinical signs associated with prion 
disease that were rapidly progressive (filled circles). Atypical death indicates that 
animals die from unrelated causes (open circles). Animals not developing prion 
disease were sacrificed 650 days after inoculation (triangles). The incubation 
times of CWD-inoculated Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- 
mice with clinical signs were summarized in the table. Incubation time indicates 
days post inoculation (dpi) in mean ± SEM (standard error of the mean). 
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Figure 2.3. Western blot analysis showed that there is no evidence of 
protease-resistant PrPSc deposition in the brains from CWD-inoculated 
Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice. Representative 
samples from each group of the CWD1, CWD2 and CWD mix inoculated 
Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice were shown in A and 
B, respectively. Blots were probed with anti-PrP PRC5 monoclonal antibody. An 
FVB/Prnp0/0 (KO) is used as a negative control for the anti-PrP antibody. An 
uninfected Tg(HuPrP) was used as a negative control for the presence of 
proteinase K (PK) resistant PrPSc. The deer CWD (99W12389) was used as a 
positive control for the presence of PK resistant PrPSc. Samples, which were 
treated with PK, indicate (+). Samples without PK digestion indicate (-). Molecular 
markers indicate 53, 36, 28 and 19 kDa from top to bottom.  
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Figure 2.4. Evaluation of spongiosis degeneration in the mouse brain with 
prion disease. Nine brain regions were assessed for the development of 
spongiosis in diseased animals. A. paraterminal body (7) and cerebral cortex (9) 
at the level of the septum. B. hypothalamus (4), thalamus (5), hippocampus (6) 
and cerebral cortex (8). C. midbrain (3). D. medulla (1) and cerebellum (2).  
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2. Cerebellum 3. Midbrain 1. Medulla 
4. Hypothalamus 6. Hippocampus 5. Thalamus 
8. Cerebral 
cortex
7. Paraterminal body 9. Cerebral cortex 
10. Positive control 
Hippocampus 
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Figure 2.5. No spongiosis degeneration in the brains of CWD-inoculated 
Tg(HuPrP) mice was observed. Nine brain regions were assessed for the 
development of disease related vacuolations in CWD-inoculated Tg(HuPrP) 
mice, which manifested clinical signs. Nine brain regions are (1) medulla, (2) 
cerebellum, (3) midbrain, (4) hypothalamus, (5) thalamus, (6) hippocampus, (7) 
paraterminal body, (8 and 9) cerebral cortex. A positive control of spongiosis 
degeneration from a CWD1-inoculated Tg(Deer PrP)1536+/- mouse brain 
(hippocampus) (10). Two enlarged image of the positive control (10) are shown in 
10-A and 10-B. The circle in 10-A indicates a size of vacuoles varies in the brain, 
and vacuoles appear between dark purple spots (cell nuclei), showing that 
spongiform changes appear between cells. Arrows in 10-B indicates vacuolations 
are diffuse but intensive in the specific brain regions and appear in the groups. 
The magnification of the images (1-10) is 100X. 
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Figure 2.6. No Tg(HuPrP) mice developed prion disease after 500 days post 
inoculation of serially passaged deer CWD isolates. Tg(HuPrP-M129)6816+/- 
and Tg(HuPrP-V129)7826+/- mice inoculated with the mule deer CWD H92 
isolates that had been passaged multiple times in Tg(Deer PrP)1536+/- mice, did 
not develop signs of prion disease. Filled circles indicate CWD inoculated 
Tg(HuPrP-M129)6816+/-  mice. Open circles indicate CWD inoculated Tg(HuPrP-
V129)7826+/-  mice.  
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Chapter 3 
Investigating the role of the β2-α2 loop and its interaction site of the C-
terminal region of mouse prion protein in prion propagation using cell 
culture models 
 
Introduction 
Transmissibility of prion diseases within the same species is highly efficient; 
however, prions are not always transmittable from one species to another. This 
phenomenon is referred to as a species barrier or transmission barrier. The 
ability of prions to cross a species barrier has been recognized, for example, the 
interspecies transmission of bovine spongiform encephalopathy (BSE) into 
humans (Bruce et al., 1997; Scott et al., 1999). Since then, the zoonotic potential 
of prions is particularly important in understanding the interspecies transmission 
of prions.  
The primary structure of prion protein (PrP) is well conserved among 
mammalian species (Prusiner, 1998). A small difference in the primary structures 
of mammalian PrPs is concentrated in the loop region between the β2-sheet and 
α2-helix, therefore, it has been proposed that the β2-α2 loop of PrP governs a 
species barrier (Billeter et al., 1997; Schatzl et al., 1995). Further, mouse-human 
chimeric transgenic (Tg) studies suggest that the species barrier between human 
and mouse is mediated by a hypothetical ‘protein X’ (Telling et al., 1995), while 
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an NMR structural study postulated that a potential binding site of protein X in 
PrP is located within the loop region between the β2-sheet and α2-helix (Billeter 
et al., 1997). Since the C-terminal domain of PrP with residue 121-231 among 
mammalian species has a 90% identity, the three-dimensional structure of 
PrP(121-231) was anticipated to be identical among species (Billeter et al., 
1997). However, numerous NMR studies revealed fine differences in the tertiary 
structures of mammalian PrPs, especially in the β2-α2 loop region, suggesting 
that the subtle differences in the tertiary structure of PrP plays a role in a species 
barrier (Christen et al., 2008; Christen et al., 2009; Fernandez-Funez et al., 2011; 
Gossert et al., 2005; Perez et al., 2010; Zhang, 2011). Sigurdson and her 
colleagues generated Tg mice expressing the altered β2-α2 loop and challenged 
the Tg mice with prions, resulting in changes in incubation times (Sigurdson et 
al., 2010; Sigurdson et al., 2011).  
 The loop linking the β2-sheet and α2-helix in PrP resides in amino acid 
residues between 164 and 174 (mouse numbers), and its structure in mammals 
is highly diverged among mammals (Gossert et al., 2005). NMR structural 
studies reported that, in mice, humans and bovines, the β2-α2 loop of PrP was 
highly disordered, meaning that the loop was flexible (Gossert et al., 2005), 
whereas in elk, bank voles, wallabies, horses, dogs, cats, pigs, rabbits and sheep 
carrying a polymorphism at residue 168 expressing either histidine or arginine, 
PrP have distinctly well-defined structure, meaning that the loop is rigid (Christen 
et al., 2009; Gossert et al., 2005; Lysek et al., 2005; Perez et al., 2010; Zhang, 
2011). The Prusiner and Wüthrich groups resolved the structure of Syrian 
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hamster PrP, and later the Wüthrich group reported that the structure of the β2-
α2 loop in Syrian hamster PrP was partially defined and shown to be similar to 
elk PrP (Gossert et al., 2005). A comparison of primary structures of mouse PrP 
with a flexible loop, and elk PrP with a rigid loop reveals that two amino acid 
residues are different at 169 and 173. Focusing on those two residues, the 
Wüthrich group performed a NMR structural study and showed that the double 
substitutions S169N and N173T in recombinant mouse PrP could produce a rigid 
loop, while the single substitution N173T was not sufficient to produce a rigid 
loop (Gossert et al., 2005). The following molecular dynamics simulation study 
demonstrated that amino acid at residue 169 in the β2-α2 loop of PrP controlled 
the structure of the loop (Gorfe & Caflisch, 2007). The single substitution S169N 
in mouse PrP changed the β2-α2 loop to rigid, therefore, it would seem that 
residue 169 has more impact on conferring rigidity on the loop structure than 
does residue 173 (Gorfe & Caflisch, 2007).    
Intrigued by the afore-mentioned series of NMR structural studies, the 
Aguzzi group generated Tg mice overexpressing mouse PrP with the double 
substitutions S169N and N173T in the β2-α2 loop on a Prnp knockout 
background, referred to as tg1020 mice, and reported that tg1020 mice 
spontaneously developed disease at 145 to 637 days of age (Sigurdson et al., 
2009). The brains of diseased mice accumulated PK-resistant PrPSc, and disease 
was shown to be transmissible (Sigurdson et al., 2009). Subsequently, Tg mice 
expressing mouse PrP with the single substitution D166S in the β2-α2 loop on a 
Prnp knockout background (TgMoPrP166) were generated, and these mice 
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spontaneously developed disease around 500 days of age (Sigurdson et al., 
2011). In contrast to tg1020, these diseased mice accumulated PK-sensitive 
PrPSc in the brain (Sigurdson et al., 2011). Moreover, mouse-adapted RML 
scrapie prions and CWD prions produced disease in tg1020 mice at 323 ± 92 
days post inoculation (dpi) and 279 ± 48 dpi, respectively, demonstrating that, in 
comparison with wild-type mice, disease onset with RML is delayed, but with 
CWD is accelerated (Sigurdson et al., 2010). Interestingly, both tg1020 and 
TgMoPrP166 mice had the rigid β2-α2 loop based on the previous NMR structural 
studies (Gossert et al., 2005; Perez et al., 2010), respectively. 
The Sigurdson group further demonstrated that the species barrier could 
be lowered by presenting the identical amino acid residue at 169 between donor 
and host PrP (Bett et al., 2012). Similarly, when TgMoPrP166 mice were 
inoculated with RML and CWD, only RML-infected TgMoPrP166 mice developed 
disease, indicating the substitution D166S had little impact on the susceptibility of 
these mice to mouse prions (Bett et al., 2012). Additionally, the single 
substitutions D166A, D166G, D166S and D166E were introduced in mouse PrP 
and generated in a catecholaminergic differentiated (CAD) neuronal cell culture 
system, and all of the variant mouse PrPs were susceptible to RML infection 
(Bett et al., 2012). These findings resulted in the hypothesis that the primary 
structural elements within the β2-α2 loop of PrP are what determine the species 
barrier, rather than the structure of the loop, whether flexible or rigid.  
However, there could be additional regions determining the susceptibility 
to prions. The C-terminal region of PrP cannot be ignored since codon 225 
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polymorphism of cervid PrP either serine (S) or phenylalanine (F), strongly 
influences susceptibility to CWD (Jewell et al., 2005). The frequency of SF 
(heterozygous) or FF (homozygous) genotypes in CWD-positive free-ranging 
deer was significantly lower than cervid homozygous for SS, suggesting that deer 
PrP with either genotype heterozygous for SF or homozygous for FF is less likely 
to develop CWD prion disease (Jewell et al., 2005). Another finding of the NMR 
structural study is that a long-range interaction between the β2-α2 loop and C-
terminal region of PrP in tammar wallaby exists (Christen et al., 2009). It was 
reported that residue 165 (mouse number) in the β2-α2 loop and residue 224 
(mouse number) interacted closely, suggesting that the interaction of two regions 
rather than the β2-α2 loop alone determines susceptibility to prions (Christen et 
al., 2009). Therefore, it becomes essential to study whether long-range 
interaction between the β2-α2 loop and C-terminal region of PrP does indeed 
control the susceptibility of prions.   
 Which residues in the β2-α2 loop and C-terminal region of PrP do in fact 
control the susceptibility of prions? In attempt to answer this question, the 
primary structures of horse and mouse PrP were aligned. As a result, three 
amino acid residues in the β2-α2 loop and two amino acid residues in the C-
terminal region were mismatched. Interestingly, no TSEs have thus far been 
reported in horses. Studying the effects of introducing horse-specific substitutions 
into mouse PrP could help to clarify more precisely which specific amino acid 
residues determine the transmission efficiency.  
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In the present study, it is hypothesized that the β2-α2 loop and C-terminal 
region as a whole determines the susceptibility of prions. To study the 
hypothesis, various substitutions were introduced to mouse and horse PrP to see 
whether the substitutions altered the susceptibility to RML, CWD or horse prions 
in cell culture. The study consists of three parts; the susceptibility of prions was 
determined in association with 1) the structural definition of the β2-α2 loop of PrP 
with either flexible or rigid, 2) the interaction between the β2-α2 loop and C-
terminal region of PrP, and 3) unique amino acid residues in the β2-α2 loop and 
C-terminal region of horse PrP.   
 
Materials and Methods 
Cell cultures. Rabbit epithelial kidney (RK13) cells (ATCC, CCL-37, Manassas, 
VA) were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma, 
St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin (Pen/Strep) at 37°C in a humidified 5% CO2 incubator. 
RK13 cells were observed daily and split at 1:10 dilution every 5 days. 
 
Plasmid constructions. The mouse PrP encoding sequence with a point or 
double mutation(s) were designed between two restriction endonuclease enzyme 
sites AflII at the 5’ and EcoRI at the 3’ end. Mutated expression cassettes were 
synthesized and cloned into pUC57 by GenScript (Piscataway, NJ). Digested 
expression cassettes were cloned into the AflII and EcoRI restriction sites of the 
mammalian expression vector pIRESpuro3 (Clontech, Mountain View, CA). The 
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presence of the inserts was verified by colony polymerase chain reaction (PCR). 
Table 3.1. summarizes the information about the 15 constructs generated in the 
study. Six expression vectors carrying a point mutation in the β2-α2 loop of 
mouse PrP are referred to in the following way: mouse PrP with the substitution 
of serine (S) with asparagine (N) at codon 169 (mPrP[S169N] for short), mouse 
PrP with the substitution of N with threonine (T) at codon 173 (mPrP[N173T]), 
mouse PrP with the substitution of valine (V) with alanine (A) at codon 165 
(mPrP[V165A]), mouse PrP with the substitution aspartic acid (D) with S at codon 
166 (mPrP[D166S]), mouse PrP with the substitution of glutamine (Q) with 
glutamic acid (E) at codon 167 (mPrP[Q167E]) and mouse PrP with the 
substitution of N with lysine (K) at codon 173 (mPrP[N173K]). Three expression 
vectors containing double mutations in the β2-α2 loop of mouse PrP are referred 
to as mPrP[S169N, N173T], mPrP[D166S, Q167E] and mPrP[D166S, N172K]. 
Four expression vectors carrying a point mutation in the C-terminal interaction 
site of mouse PrP with the substitution of tyrosine (Y) with A at codon 224 
(mPrP[Y224A]), the substitution of Y with A at codon 225 (mPrP[Y225A]), the 
substitution of Y with phenylalanine (F) at codon 224 (mPrP[Y224F]) and the 
substitution of Y with Q at codon 225 (mPrP[Y225Q]). One expression vector 
carrying a double mutation in the C-terminal interaction site of mouse PrP is 
referred to as mPrP[Y224A, Y225A]. One expression vector harboring a point 
mutation in the β2-α2 loop of horse PrP is referred to as HorsePrP[S167D]. 
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Generation of stably transfected RK13 cells expressing mutant mouse or 
horse PrP. RK13 cells were plated in 6-well plates with DMEM/FBS lacking 
antibiotics one day prior to transfection. Transfection was performed using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). DNA-Lipofectamine complexes 
were prepared by mixing 4 µg of DNA with 10 µl of lipofectamine in Opti-MEM I 
Reduced Serum Medium (Invitrogen, Carlsbad, CA) without serum. RK13 cells 
were rinsed with Opti-MEM to remove residual serum, then 200 µl of the DNA-
Lipofectamine complexes were gently added onto the monolayer of cells. After 5 
hours incubation, the complexes were removed from cell cultures, and DMEM 
with FBS and Pen/Strep was added onto the transfected RK13 cells. After 48 
hours, the medium was replaced with DMEM/10% containing 1 µg/ml of 
puromycin. Selective medium was changed every 3 days until resistant cells 
were obtained. Expression levels of PrP were determined by western blotting 
comparing expression levels to that of RK13 cells expressing a wild-type mouse 
PrP (RKM). RK13 cells were also transfected with empty pIRESpuro3 vectors. As 
negative controls for transfection, additional RK13 cells were transfected with 
DNA alone without lipofectamine and with lipofectamine alone without DNA. 
 
Prion inocula. A pool of wild-type FVB mouse brains, which died following 
infection with mouse-adapted Rocky Mountain Laboratories (RML) scrapie 
prions, was used as mouse prion inoculum. A brain from a transgenic (Tg) 
mouse expressing elk PrP, referred to as Tg(ElkPrP)5037, which had succumbed 
to disease following infection with a pool of CWD-affected elk brains, referred to 
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05-0306 obtained from our collaborators at the Canadian Food Inspection 
Agency, Ottawa, Ontario Canada was used as the CWD inoculum. These prion-
infected brains were prepared at 10% (w/v) in Opti-MEM by repeated extraction 
through successively decreasing needle diameter from 18 to 22 gauge. Further, 
10% brain homogenates from RML and CWD prions were diluted, respectively, 
to 0.2 and 1% (w/v) in Opti-MEM and thoroughly homogenized using a 26 gauge 
needle syringe.  
 Hemizygous Tg mice expressing horse PrP encoding K at residue 175 
were previously generated on a Prnp knockout FVB background, and referred to 
as Tg(EqPrP)5525+/-. Groups of Tg(EqPrP)5525+/- mice were infected with sheep 
scrapie SSBP/1 prions, as a result, 2 out of 6 Tg(EqPrP)5525+/- mice developed 
disease (unpublished data). It is important to note that the brain materials from 
two diseased Tg(EqPrP)5525+/- mice were inoculated into another groups of 
Tg(EqPrP)5525+/- mice; however, none of the mice developed disease 
(unpublished data). A brain homogenate from a diseased Tg(EqPrP)5525+/- 
mouse, referred to as horse prion, was used for cell infections in this study. The 
brain homogenate was diluted to 0.8% (w/v) in Opti-MEM as described above.   
 
Cell infections. For cell infection, 106 cells/ml were plated in 6-well plates one 
day prior to infection. Cells were rinsed with cold PBS twice, then either RML or 
CWD prions in a total volume of 1 ml per well was added to cell monolayers.  
After 5 hours, 2 ml of Opti-MEM medium containing 10% FBS was added. Next 
day, cells were transferred at 1:1 dilution to 10 cm plates and split at 1:10 dilution 
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every 5 days up to 5 passages. Cells were lysed in cold lysis buffer (0.5% 
sodium deoxycholate, 0.5% Igepal CA-630, 150 mM NaCl, and 50 mM Tris, pH 
7.5) for 5 minutes in ice. Cell lysates were analyzed for PrPC or PrPSc in western 
blotting. 
 
Analysis of PrPC and PrPSc. Cell lysates from each cell line including both 
infected and uninfected samples were collected at passage 3 and 5 after 
infection. The concentration of total protein in each sample was determined by 
bicinchoninic acid assay. For undigested samples, the total amount of proteins 
was standardized at 30 µg per lane when anti-PrP 6H4 or PRC5 antibodies were 
used for analysis. The total amount of proteins was standardized at 90 µg per 
lane when anti-PrP PRC9 antibody was used for analysis. For proteinase K (PK) 
digestion, total protein in cell lysates was normalized to 2 mg/ml in cold lysis 
buffer with PK added at a final concentration of 50 µg/ml. PK-digested cell 
lysates were ultracentrifuged at 100,000 x g for 1 hour at 4°C. The pellet was 
resuspended in sodium dodecyl sulfate-polyacrylamide (SDS)-page loading 
buffer, boiled at 100°C for 5 minutes and examined by western blotting. Proteins 
were resolved by SDS gel electrophoresis and transferred to polyvinylidene 
difluoride Immobilon-FL (PVDF-FL) membranes (Millipore). The membrane was 
blocked with 5% non-fat milk in 0.5% Tween-20 in Tris-buffered saline (TBST) 
and immunoprobed with anti-PrP mouse monoclonal antibody (mAb) 6H4 
(Prionics AG, Schlieren-Zurich), PRC5, or PRC9 followed by horseradish 
peroxidase-conjugated anti-mouse secondary antibody. Proteins were visualized 
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using ECL Plus (GE Healthcare) using an FLA-5000 scanner (Fujifilm Life 
Science). The expression levels of PrPC in cell lines were determined by 
densitometric analysis of PrPC signals on the western blot using MultiGauge 
(Fujifilm Life Science).  
   
Cell blotting. Cells were plated onto plastic coverslips in 12-well plates five 
passages after infection. Cells were grown to confluence, medium removed and 
washed twice with cold PBS. The side of the coverslips on which cells were 
grown was placed face down onto a PVDF membrane pre-soaked with cold lysis 
buffer and pressed firmly for 1 minute to transfer all cells onto the membrane. 
Coverslips were carefully removed. Membranes were air-dried for 2 hours and 
stored at -20°C. Membranes were re-wetted with cold lysis buffer and treated 
with PK at a final concentration of 5 µg/ml in cold lysis buffer for 90 minutes at 
37°C with constant shaking. Protease digestion was terminated by the addition of 
phenylmethylsulfonyl fluoride (PMSF) at a final concentration of 2 mM for 20 min. 
Membranes were rinsed four times with distilled water and immersed in 3 M 
guanidine isothiocyanate/10 mM Tris-HCl, pH 8.0 for 10 minutes then rinsed four 
times with distilled water. Membranes were immunoprobed with 6H4 in the same 
way as with western blots described above.  
 
Results 
In this study, rabbit epithelial kidney (RK13) cells were used to assess the 
correlations between the β2-α2 loop and prion susceptibility. RK13 cells have 
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been used to study the propagation of PrPSc in vitro since the Vilette group 
established that RK13 cells expressing rodent, ovine and cattle PrP were 
permissive to multiple prion infections (Courageot et al., 2008; Vilette et al., 
2001). The use of a RK13 cell culture model accelerates studies in the 
pathogenesis of prions by as a quicker and cost-effective model in addition to 
animal models. No detectable amount of endogenous PrP is expressed in RK13 
cells, even though RK13 cells have a Prnp gene. Thus, RK13 cells are effectively 
natural PrP knockout cells. In contrast to animal models, the use of cell culture 
systems in general allow us to control more variables in experiments, making 
them an ideal in vitro cell model to study the propagation of prions.  
 
Levels of PrP in RK13 cells expressing mutant PrP. All of the newly 
generated 15 cell lines showed detectable levels of PrP on western blots using 
6H4 or PRC5 (Figure 3.1. and 3.2.). Most of the mutant cell lines expressed 1.6-
fold to 1.9-fold higher PrP levels than RKM on the western blot probed with 6H4 
except for 1.2-fold in RKM[V165A], 3.5-fold in RKM[Y225A], 2.2-fold in 
RKM[Q167E] and 2.5-fold in RKM[D166S, Q167E] (Figure 3.2.). The blot probed 
with PRC5 showed 1.2-fold to 1.6-fold higher PrP levels compared to RML in 
most of the cell lines except 0.8-fold in RKM[V165A] and 2-fold in RKM[Y225A] 
(Figure 3.2.). Both results showed that RKM[V165A] expressed relatively lower 
levels of PrP and RKM[Y225A] expressed relatively higher levels of PrP 
compared to RKM. The rest of the cell lines expressed a similar range of PrP 
levels. In addition, it is important to point out that PrP was not detected in RK13 
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cells with an empty pIRESpuro3 vector (RKV), confirming that RK13 cells did not 
express detectable levels of PrP (Figure 3.1.).    
 Both 6H4 and PRC5 antibodies equally recognized the mutant mouse PrP 
in cell culture; however, reactivity with PRC9 antibody was dependent on 
mutations within PrP. PRC9 could not recognize the mutant mouse PrP when 
amino acid residue at 224 was mutated from tyrosine (Y) to either alanine (A) or 
phenylalanine (F) (Table 3.2. and Figure 3.2.). Moreover, PRC9 lost reactivity 
when Y at residue 225 in mouse PrP was mutated to glutamine (Q) but not F 
(Table 3.2.). In addition, mouse PrP with the substitution V165A was not 
recognized by PRC9. For this reason, in the following experiments, only 6H4 and 
PRC5 were used for immunoblotting since PRC9 varies in reactivity with the 
mutant mouse PrP’s. 
  
Changing the β2-α2 loop structure of mouse PrP altered susceptibility to 
RML but not CWD. Two amino acids are different between mouse and elk PrP 
within the β2-α2 loop. Mouse PrP contains serine (S) at residue 169 and 
asparagine (N) at residue 173 and keeps the β2-α2 loop flexible, while elk PrP 
contains N at residue 169 (mouse number) and threonine (T) at residue 173 
(mouse number) and has a rigid loop (Gossert et al., 2005).  
In the first experiment, the flexible β2-α2 loop of mouse PrP was changed 
to the rigid loop by introducing the double mutation at residue 169 from S to N 
and at residue 173 N to T. The western blot showed that PrPSc did not 
accumulate in RML-infected RKM[S169N, N173T] cells at passage 3 (Figure 
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3.3.A). Next, the single substitution S169N was introduced in to mouse PrP, and 
this substitution was sufficient to change the flexible β2-α2 loop of mouse PrP to 
the rigid loop (Sigurdson et al., 2011). RKM[S169N] cells also lost the 
susceptibility to RML at passage 3 (Figure 3.3.B). RML-infected RKM[S169N] 
cells were maintained for up to five passages after infection to see if delayed 
propagation of PrPSc occurred. However, PrPSc was absent in the RML-infected 
cells at passage 5 on western blot, suggesting that RKM[S169N] cells were 
resistant to RML (Figure 3.3.C). This result indicates that changing the loop 
structure in mouse PrP led to loss of susceptibility to RML. In contrast, the lack of 
PrPSc in CWD-infected RKM[S169N, N173T] and RKM[S169N] cells showed that 
introducing the rigid loop in mouse PrP was not sufficient to confer susceptibility 
to CWD (Figure 3.4.A and B, respectively). 
Subsequently, the substitution N173T was introduced into mouse PrP. 
Even though this single substitution was sufficient to maintain a flexible β2-α2 
loop (Gossert et al., 2005), the point mutation resulted in inhibition of PrPSc 
formation following infection with RML (Figure 3.3.D).  
PrPSc was not identified in CWD-infected RKM[N173T] cells at passage 3, 
showing that the substitution were not sufficient to confer susceptibility to an 
otherwise mouse PrP primary structure to CWD prions  (Figure 3.4.C). 
For RML infection, both RML/FVB and RML/RKM presented PK-resistant 
PrPSc in each blot, indicating our ability to detect RML PrPSc on western blots 
(Figure 3.3.). The presence of PrPC and absence of PrPSc in the uninfected cell 
lines were confirmed, showing that the positive signal of PrPSc was valid. Every 
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blot showed the absence of signals in uninfected RKV samples indicating that the 
antibody recognition on western blots was specific to PrP. In addition, the 
absence of signals in infected RKV controls indicates that no residual PrPSc from 
the inoculum remained at passage 3 or 5. The presence of PK-resistant PrPSc in 
RML-infected RKM indicated the cell infection was successful.  
Likewise, for CWD infection, both CWD/Tg(ElkPrP) and CWD/RKE 
presented PK-resistant PrPSc in each blot, indicating our ability to detect CWD 
PrPSc on western blots (Figure 3.4.). The presence of PrPC and absence of PrPSc 
in the uninfected cell lines were confirmed showing that the positive signal of 
PrPSc is valid. The absence of signals in CWD-infected RKM indicating that no 
residual PrPSc from the inoculum remained at passage 3. The presence of PK-
resistant PrPSc in CWD-infected RKE indicates the cell infection was successful. 
Those positive and negative controls demonstrated that it was possible to infect 
cells and detect newly generated PrPSc in this assay. 
The antibody specificity and absence of residual inocula was verified by 
examining the absence of PrPC and PrPSc in RKV on western blots. The ability to 
detect RML PrPSc on western blots was verified by presenting the PK-resistant 
PrPSc from brain homogenates from RML-infected wild-type FVB mice 
(RML/FVB) and/or cell lysates from RML-infected RKM cells (RML/RKM). The 
presence of PrPC and absence of PrPSc in the uninfected cell lines were 
confirmed, thus the accumulation of PrPSc was due to prion infection. The 
presence of PK-resistant PrPSc in RML-infected RKM indicated that the cell 
infection was successful.  
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In addition to the above controls, the detectability of CWD PrPSc on 
western blots was verified by presenting the PK-resistant PrPSc from brain 
homogenates from Bala05 CWD-infected Tg(ElkPrP) mice (CWD/Tg(ElkPrP)) 
and cell lysates from CWD-infected RKE cells (CWD/RKE). Successful CWD 
infection was demonstrated by presenting the presence of PK-resistant PrPSc in 
CWD-infected RKE. RKM was used as a negative control for the infection of 
CWD prion because mouse PrP is resistant to PrPSc propagation. The absence 
of signals in CWD-infected RKM indicates that no residual PrPSc from the 
inoculum remained at passage 3. Those positive and negative controls 
demonstrated that the ability to infect cells and detect newly generated PrPSc in 
this assay. 
For dot blotting, infected and uninfected samples were determined for the 
accumulation of PrPSc. As negative control, uninfected samples were used for the 
absence of PrPSc. As positive control, cell lysates from RK13 cells expressing elk 
PrP (RKE) chronically infected with sheep scrapie SSBP/1 or 48x35 isolates 
were used. The absence and presence of PrPSc in the negative and positive 
controls demonstrated this technique’s ability to detect PrPSc. 
 
Interrupting the interaction between the β2-α2 loop and C-terminal region in 
mouse PrP changed the susceptibility to RML. Inspired by the NMR study of 
tammar wallaby PrP (Christen et al., 2009), alanine substitutions were introduced 
to mouse PrP at residues 165, 224 and 225, in order to establish whether 
interrupting the interaction between the β2-α2 loop and C-terminal regions 
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altered susceptibility to RML. The alanine substitution at residue 165 in the β2-α2 
loop of mouse PrP has been previously shown to make the flexible loop of 
mouse PrP into the rigid loop (Christen et al., 2009). The western blot showed 
ambiguous signals of PrPSc from RML-infected RKM[V165A] cells; however, 
these were most likely due to leaked signals from neighboring samples (Figure 
3.5.A.). In the following experiment, the dot blot confirmed that RML failed to 
propagate PrPSc in RKM[V165A] cells (Figure 3.7.). The absence of PrPSc 
accumulation in RML-infected RKM[Y224A] and RKM[Y225A] cells was verified 
by western and dot blotting, indicating that two residues in the C-terminal 
interaction site are important determinants for the susceptibility to RML (Figure 
3.5.B. and 3.7.). Although RKM[Y224A] and RKM[Y225A] cells was flexible and 
rigid loops between the β2-sheet and α2-helix, respectively (Christen et al., 
2009), both of the cell lines lost susceptibility to RML, indicating that the 
structural definition of the β2-α2 loop did not correlate with the susceptibility of 
RML. In addition, the double mutation at residue 224 and 225 failed to propagate 
PrPSc upon RML infection (Figure 3.5.A.). Some signals were shown in PK-
digested uninfected RKM[Y224A] and RKM[Y225A] cells (Figure 3.5.A). These 
were most likely due to either undigested PrP or leaked samples from the 
neighboring lanes since PK-resistant core of PrPSc at 27-30 kDa was not present 
in those lanes. Moreover, the dot blot, which is a sensitive assay for PrPSc 
detection (Scott et al., 1993), confirmed RML-infected RKM[Y224A], 
RKM[Y225A] and RKM[Y224A, Y225A] cells could not produce PrPSc at passage 
3 (Figure 3.7.). The above results indicate that secondary structural constrains, 
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producing rigidity or flexibility within the β2-α2 loop, do not determine 
susceptibility to RML prions. Rather, the results suggest that specific primary 
determinants at key residues within the β2-α2 loop and C-terminal regions 
determine susceptibility to RML.  
 
Horse-specific substitutions within the β2-α2 loop and its interaction site of 
mouse PrP resulted in loss of susceptibility to RML. In order to study unique 
amino acid residues in the β2-α2 loop and C-terminal regions of horse PrP, horse 
specific substitutions at residues 166, 167,172, 224 and 225 were introduced into 
the mouse PrP primary structure. RK13 cells expressing those mutant mouse 
PrP constructs were tested for susceptibility to RML prions. It should be noted 
that previous work showed substitution of D166S in the β2-α2 loop of mouse PrP 
changed the loop from flexible to rigid, whereas other single or double 
substitutions except the double substitution of D166S and Q167E did not alter 
the structure of the β2-α2 loop (Perez et al., 2010). Our western blot data 
showed that a weak signal of PK-resistant PrPSc around 19 and 27-25 kDa in the 
sample from RML-infected RKM[D166S] cells at passage 3 (Figure 3.6.A.). 
Moreover, the dot blot showed no accumulation of PrPSc in RML-infected 
RKM[D166S] cells at passage 5 (Figure 3.7.). The results of the western and dot 
blotting indicate that conversion of PrPSc was inefficient and unstable in RML-
infected RKM[D166S] cells. Accumulation of PrPSc was not detected in RML-
infected RK13 cells expressing horse PrP with a substitution of S to D at codon 
167 (HorsePrP[S167D]) by both western and dot blotting. In conclusion, 
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changing a single residue in horse PrP at residue 167 to corresponding residue 
in mouse PrP was insufficient to induce susceptibility to RML prions (Figure 
3.6.A. and Figure 3.7.).  
Although the apparent signal in the PK-digested sample from RML-
infected RKM[Q167E] cells was present, the signal was most likely due to the 
undigested PrP or leaked sample from the neighboring lanes (Figure 3.6.B.). 
Moreover, the dot blot showed no accumulation of PrPSc in RML-infected 
RKM[Q167E] cells (Figure 3.7.). The absence of PrPSc was shown in 
RKM[D166S, Q167E] cells by both western and dot blotting (Figure 3.6.B.). 
RKM[N172K] and RKM[D166S, N172K] cells failed to accumulate PrPSc upon 
RML infection (Figure 3.6.C. and Figure 3.7). Therefore, the substitutions Q167E 
and N172K with or without D166S in mouse PrP resulted in the loss of 
susceptibility to RML. Both western and dot blotting failed to detect PrPSc in RML-
infected RKM[Y224A] and RKM[Y225A] cells (Figure 3.6.D. and Figure 3.7). The 
substitutions Y224A and Y225A in the C-terminal region, which is the interaction 
site of the β2-α2 loop, of mouse PrP kept the loop flexible but resulted in the loss 
of the susceptibility to RML. 
 
Horse-specific substitutions in mouse PrP were not sufficient to stimulate 
susceptibility to horse prion. RK13 cells expressing selected mutant mouse 
PrP including RKM[D166S], RKM[D166S, Q167E], RKM[D166S, N172K], 
RKM[Y224F], RKM[Y225Q] and RK13HorsePrP[S167D] were infected with horse 
prions generated in Tg mice expressing horse PrP (unpublished data). The dot 
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blot showed that none of above horse-prion infected cells accumulated PrPSc at 
passage 5 (Figure 3.7.). In addition, horse prion infected RKM cells also failed to 
produce PrPSc, indicating the presence of species barrier between mouse and 
horse PrP (Figure 3.7.). 
 
Discussion 
NMR structural studies have shown that specific residues within the β2-α2 loop 
and the C-terminal region interact in the tertiary structure of PrP (Christen et al., 
2009). In order to test the hypothesis that these residues play a role in 
determining susceptibility to prion infection, various mutations were introduced in 
the β2-α2 loop and/or the C-terminal region. RK13 cells expressing those variant 
mouse PrP were infected with RML or CWD to determine whether these 
mutations altered the ability of the expressed PrP to be converted to PrPSc (Table 
3.1.). Substitutions in the β2-α2 loop and C-terminal region of mouse PrP were 
sufficient to prevent PrPSc conversion upon RML prion infection (Figure 3.3., 3.5., 
3.6. and 3.7.). Introducing the rigid loop in mouse PrP created the transmission 
barrier to RML (Figure 3.3.) but did not lower the transmission barrier of CWD 
(Figure 3.4.). Disrupting the interaction between the β2-α2 loop and C-terminal 
region of mouse PrP also offered protection from the RML transmission (Figure 
3.3. and 3.4.). The results of detailed examination of diverged amino acid 
residues in the β2-α2 loop and C-terminal region of mouse PrP identified more 
precisely the specific amino acid residues playing critical roles in prion 
transmission. In other words, changing the primary structure of the β2-α2 loop 
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and C-terminal region modifies susceptibility to prions, suggesting that the 
distinctive amino acid residues in those critical regions of PrP make a significant 
contribution to constructing a species barrier.  
The diverged primary structures of PrP in the β2-α2 loop region among 
mammals guided us to this investigation of the role of the loop in a species 
barrier. NMR structural and animal studies suggested that the structural definition 
of the β2-α2 loop decides the susceptibility of RML and CWD (Gorfe & Caflisch, 
2007; Gossert et al., 2005; Sigurdson et al., 2010). In addition, the most recent 
study from the Sigurdson group suggested that the narrowed area of the primary 
structure of the β2-α2 loop determined the interspecies prion conversion (Bett et 
al., 2012). In the present study, the series of experiments with RML transmission 
demonstrated that the point mutations in the β2-α2 loop and C-terminal 
interaction region were sufficient to create a transmission barrier in cell cultures, 
although some substitutions maintained the flexible loop. Even though the β2-α2 
loop of PrP is involved in determining a species barrier, choosing either flexible 
or rigid loop between β2-sheet and α2-helix in PrP does not regulate the 
susceptibility to prions. Consistent with the recent report from the Sigurdson 
group (Bett et al., 2012), the structural definition of the β2-α2 loop of PrP has little 
involvement in prion transmission. 
To investigate whether the interaction between the β2-α2 loop and C-
terminal region plays a role in prion transmission, single or double substitutions 
were introduced in mouse PrP at residues 165, 224 and 225. Long-range 
interactions were reported between residue 165 in the β2-α2 loop and residue 
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224 in the C-terminal region of tammar wallaby PrP (Christen et al., 2009).  Since 
the previous NMR study showed that alanine substitutions at residue 165, 224 
and 225 interrupted the interaction between the loop and C-terminal region of 
PrP (Christen et al., 2009), in the present study, it was anticipated that 
interrupting the interaction could change the prion transmission. To directly 
address this question, we infected RK13 cells expressing the variant mouse PrP 
lacking the interaction with RML prions. As a result, all of the variant PrP lost the 
susceptibility to RML, suggesting that the interaction between the β2-α2 loop and 
C-terminal region of PrP has a great impact on a species barrier.    
The β2-α2 loop of PrP consists of eleven amino acids, and four out of 
eleven are conserved among mammalian species. Two amino acid residues at 
166 and 172 (mouse number) are conserved among the mammalian species 
except horses. One amino acid at residue 170 is conserved among species but 
unique in tammar wallaby PrP. Another four amino acid residues at 165, 167, 
169 and 173 are divergent among the species. The studies in vivo and vitro 
demonstrated that the amino acid residue 169 played significant roles in the 
conversion of PrPSc (Avbelj et al., 2011; Kurt et al., 2009; Sigurdson et al., 2010), 
suggesting the residue has an important role in the prion transmission. In 
addition, horse-specific amino acid residue 166 had been reported to have a little 
influence on the prion transmission (Bett et al., 2012). However, roles of the five 
other diverged amino acid residues have not been studied in relation to prion 
transmission. In order to study the roles of each amino acid in the β2-α2 loop and 
C-terminal region of PrP in the prion transmission, the above diverged seven 
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amino acid residues in the loop and its interaction site were mutated in mouse 
PrP. As anticipated, the substitution S169N in mouse PrP altered susceptibility to 
RML in cell culture consistent with the result of Tg mouse expressing mouse PrP 
with the S169N substitution (Sigurdson et al., 2010). Even though the conversion 
of PrPSc was not efficient in RK13 cells expressing mouse PrP[D166S], the 
substitution did not completely prevent the PrPSc propagation.  
The present study also supports the data that the Tg mice expressing 
MoPrP166 maintained susceptibility to RML and produced PK-resistant PrPSc 
(Sigurdson et al., 2011). An additional study might explain the reason why the 
substitution of D166S in mouse PrP is susceptible to RML. TgF35 mice 
expressing deletion mutant mouse PrP (Δ32-134) spontaneously developed 
disease; however, TgF35 mice were rescued by either coexpressing wild-type 
mouse PrP or mouse PrP[D166S], suggesting that mouse PrP[D166S] could 
serve similar functions to wild-type PrP (Sigurdson et al., 2010).  
In the present study, substitutions of other five residues at 165, 167, 170, 
172 and 173 were also examined as to whether susceptibility to RML was altered 
in cell culture. As a result, the conversion of PrPSc prevented in the RML-infected 
RK13 cells expressing those five variant mouse PrP, suggesting those five 
residues have significant effects on the prion transmission. The present study 
evinces the specific six amino acid residues in the β2-α2 loop of mouse PrP that 
play significant roles in deciding the susceptibility of RML.   
  The present study showed that introducing elk PrP residues in mouse PrP 
(S169N and N173T) was not sufficient to lower the transmission barrier of CWD 
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in cell culture. Additionally, RML failed to propagate in RK13 cells expressing 
most of the variant mouse PrP except D166S. The results suggest that lowering 
the existing species barrier is challenging; however, a single amino acid 
substitution of mouse PrP is sufficient to inhibit the propagation of PrPSc with 
RML. In order to further test the transmission barrier, RK13 cells expressing 
variant mouse PrP with horse specific substitutions were infected with horse 
prion. The horse specific substitutions of D166S, Q167E, N172K, Y224F and 
Y225Q in mouse PrP were unable to convert PrPSc responding to horse prion 
infection, indicating that the single substitutions were not able to lower the 
transmission barrier of horse prion. Nonetheless, the limitations to the 
experiments with horse prion infection in cell culture need to be discussed. The 
horse prion has not yet proven to be transmissible because the secondary 
passage of the material could not produce disease in Tg(EqPrP)+/- mice. 
Because the transmissibility properties of horse prion remain unclear, a positive 
control for the infection assay with horse prion was unavailable. RK13 cells 
expressing a wild-type horse PrP (RK13HorsePrP) were not included, although 
the transmissibility of horse prion was uncertain in cell culture. In the present 
study, horse prion infection was performed along with RML infection, and the cell 
infection procedure was verified by presenting successful RML infection results. 
In future studies, it will be interesting to examine whether the same amino acid 
residues required for RML transmission in mouse PrP also determines the 
susceptibility of horse prion. 
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The primary structure of PrP is not the only critical determinant for the 
transmission barrier of prions. The primary structures of human and cattle PrP 
are not identical; however, BSE prions have an ability to produce disease-related 
PrPSc in Tg mice expressing human PrP (Lloyd et al., 2004; Wadsworth et al., 
2004). This suggests that there are additional requirements for the transmission 
of prions. Another possible requirement for prion transmission is a three-
dimensional compatibility between host PrPC and donor PrPSc. The 
conformational compatibility can be obtained even when there are variations in 
the primary structures of host and donor PrP. In any study of the effects of 
compatibility between donor PrPSc and host PrPC on the transmission barrier of 
prions, it will be extremely challenging to directly obtain the structural information 
of native PrPC and especially PrPSc because there are still limitations to the 
resolution of current technologies. Instead, by way of an extension to the present 
study, systematic studies of introducing multiple substitutions in mammalian PrP 
may well be useful in gaining more insight into the transmission of prions.        
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Table 3.1. Summary of expression vectors for point or double mutation(s) 
to alter the structure of the β2-α2 loop in mouse PrP. The mammalian 
expression plasmid pIRESpuro3 carrying 15 different mutant PrP were 
constructed. Three mutants followed by an elk PrP include elk specific 
substitutions at residues 169 and/or 173 in mouse PrP. Four mutants followed by 
a wallaby PrP include alanine substitutions at residues 165, 224 and/or 225 in 
mouse PrP. Seven mutants followed by a horse PrP include horse specific 
substitutions at residues 166, 167, 172, 224 and/or 225 in mouse PrP. The last 
mutant in the table is a horse PrP variant with a point mutation at residue 167 
(horse number which is equivalent to 166 in mouse). Bold letters indicate 
mutated amino acid residues in the constructs. N/D indicates that the loop 
structure has not been determined by NMR.   
 
PrP 
Amino acid residue (mouse number) Structure of 
β2-α2 loop 
based on 
NMR 
β2-α2 loop C-terminal 
165 166 167 169 172 173 224 225 
Mouse PrP (mPrP) V D Q S N N Y Y Flexible 
Elk PrP V D Q N N T Y Y Rigid 
mPrP[S169N] V D Q N N N Y Y Rigid 
mPrP[N173T] V D Q S N T Y Y Flexible 
mPrP[S169N, N173T] V D Q N N T Y Y Rigid 
Wallaby PrP I D Q G N S A Q Rigid 
 mPrP[V165A] A D Q S N N Y Y Rigid 
 mPrP[Y224A] V D Q S N N A Y Flexible 
 mPrP[Y225A] V D Q S N N Y A Rigid 
 mPrP[Y224A, Y225A] V D Q S N N A A Rigid 
Horse PrP V S E S K N F Q Rigid 
 mPrP[D166S] V S Q S N N Y Y Rigid 
 mPrP[Q167E] V D E S N N Y Y Flexible 
 mPrP[N172K] V D Q S K N Y Y Flexible 
 mPrP[D166S, Q167E] V S E S N N Y Y N/D 
 mPrP[D166S, N172K] V S Q S K N Y Y Rigid 
 mPrP[Y224F] V D Q S N N F Y Flexible 
 mPrP[Y225Q] V D Q S N N Y Q Flexible 
 HorsePrP[S167D]  V D E S K N F Q N/D 
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Table 3.2. Reactivities of anti-PrP mAbs with the PrP variants carrying the 
altered β2-α2 loop and its interaction at the C-terminal of PrP. The 
expression levels of PrP in RK13 cells expressing variant mouse or horse PrP 
were determined using three different anti-PrP mAbs including 6H4, PRC5 and 
PRC9. A positive (+) indicates a mAb could recognize a variant PrP, whereas a 
negative (−) indicates a mAb did not recognize a variant PrP. N/D indicates the 
β2-α2 loop structure has not been determined by NMR or the reactivity of an 
antibody has not been determined.  
 
RK13 cells expressing 
mutant or wild-type PrP  
Structure of  
β2-α2 loop 
based on NMR 
mAb 
PRC9 6H4 PRC5 
Mouse PrP (RKM) Flexible + + + 
RKM[S169N] Rigid + + N/D 
RKM[N173T] Flexible + + N/D 
RKM[S169N, N173T] Rigid + + N/D 
 RKM[V165A] Rigid − + + 
 RKM[Y224A] Flexible − + + 
 RKM[Y225A] Rigid + + + 
 RKM[Y224A, Y225A] Rigid − + + 
 RKM[D166S] Rigid + + + 
 RKM[Q167E] Flexible + + + 
 RKM[N172K] Flexible + + + 
 RKM[D166S, Q167E] N/D + + + 
 RKM[D166S, N172K] Rigid + + + 
 RKM[Y224F] Flexible − + + 
 RKM[Y225Q] Flexible − + + 
 RK13HorsePrP[S167D]  N/D − + + 
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Figure 3.1. Expression of PrP in RK13 cells expressing variant mouse PrP. 
The expression of PrP was determined in RKM[S169N], RKM[N173T] and 
RKM[S169N, N173T] on western blots using mAb 6H4 (A) and PRC9 (B). The 
above western blots showed all of three cell lines expressed the sufficient levels 
of PrP. RK13 cells with an empty vector (RKV) were used as a negative control. 
RK13 cells expressing a wild-type mouse PrP (RKM) were used as a positive 
control. Molecular markers indicate 53, 36, 28 and 19 kDa from top to bottom. 
Cropped images are from the same exposure of the same blot.   
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Figure 3.2. PrP expression levels in RK13 cells expressing variant mouse 
PrP carrying the altered β2-α2 loop. The western blots with anti-PrP mAb 6H4 
(A) and PRC5 (B) showed that all of the cell lines expressed sufficient levels of 
PrP. The last western blot was probed with anti-PrP mAb PRC9, which is a 
mouse specific antibody (C). PRC9 recognizes some of the mutant cell lines but 
not all of the lines. Lanes 1. RK13 cells with an empty pIRESpuro vector (RKV); 
2. RK13 cells expressing a wild-type mouse PrP (RKM); 3. RKM[V165A]; 4. 
RKM[Y224A]; 5. RKM[Y225A]; 6. RKM[Y224A, Y225A]; 7. RKM[D166S]; 8. 
RKM[Q167E]; 9. RKM[N172K]; 10. RKM[D166S, Q167E]; 11. RKM[D166S, 
N172K]; 12. RKM[Y224F]; 13. HorsePrP[S167D]. The numbers shown under the 
blots (A and B) indicate the levels of PrP in each cell line through comparison to 
RKM. Molecular markers indicate 53, 36, 28 and 19 kDa from top to bottom. 
Cropped images are from the same exposure of the same blot.   
  
 
 
 
1        2       3     4      5      6     7      8      9     10    11     12    13   
A 
B 
 1       1.2    1.7    3.5     1.8    1.9    2.2     1.9     2.5    1.8     1.6      1.8 ( X ) 
 1       0.8      1.2      2       1.4    1.5     1.4    1.5     1.6    1.5     1.5     1.4 ( X ) 
 
C 
 
 RKV RKM RKM with altered β2-α2 loop 
 
 
97 
 
 
A 
B 
C 
D 
 
 PK -    +   -   +   -    +   -   +   -    +   -   +   -   +    -    +    
 
 Uninfected  Infected  
RKV  RKM RKV  RKM 
RKM 
S169N, 
N173T 
RML/ 
FVB 
RML/ 
RKM 
RKM 
S169N, 
N173T 
 
 
 
 PK -    +   -   +   -    +   -   +   -    +   -   +   -   +    -    +    
 
 Uninfected  Infected  
RKV  RKM RKV  RKM 
RKM 
S169N 
RKM 
S169N 
RML/ 
FVB 
RML/ 
RKM 
 PK -    +   -   +   -    +   -   +   -    +   -   +   -   +    -    +    
 
 Uninfected  Infected  
RKV  RKM RKV  RKM 
RKM 
N173T 
RKM 
N173T 
RML/ 
FVB 
RML/ 
RKM 
 PK -   +    -   +   -   +    -   +   -    +   -   +   -   +    -    +    
 
 Uninfected  Infected  
RKV  RKM RKV  RKM 
RKM 
S169N 
RKM 
S169N 
RML
/ FVB 
RML/ 
RKM 
 
 
98 
Figure 3.3. Altering the structure of the β2-α2 loop in mouse PrP changed 
the susceptibility to RML. All western blots were probed with anti-PrP 6H4 
antibody. A. The western blot showed that PrPSc did not accumulate in RML-
infected RKM[S169N, N173T], the flexible β2-α2 loop of mouse PrP was 
changed to the rigid loop, suggesting that RKM[S169N, N173T] cells lost 
susceptibility to RML prions at passage 3. B. RML-infected RKM[S169N] cells 
also did not show accumulation of PrPSc at passage 3. C. RML-infected 
RKM[S169N] cells were maintained for up to five passages after infection to see 
if delayed propagation of PrPSc occurred. However, PrPSc was absent in the 
RML-infected cells at passage 5 on western blot, suggesting that RKM[S169N] 
cells were resistant to RML. D. RML failed to produce PrPSc in RKM[N173T] 
cells, even though this single substitution was sufficient to maintain a flexible β2-
α2. RML/FVB indicates brain homogenates from RML-infected wild-type FVB 
mice. RKM is RK13 cells expressing a wild-type mouse PrP. RML/RKM are RML-
infected RKM. Samples treated with proteinase K (PK) indicate (+). Samples 
without PK digestion indicate (-). Molecular markers indicate 53, 36, 28 and 19 
kDa from top to bottom. 
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Figure 3.4. Introducing the rigid loop in mouse PrP was not sufficient to 
gain susceptibility to CWD. CWD infected mutant cells were examined for the 
conversion of PrPSc at passage 3. All western blots were probed with anti-PrP 
6H4 antibody. A. CWD-infected RKM[S169N, N173T] cells failed to produce 
PrPSc. B. CWD-infected RKM[S169N] also did not accumulate PrPSc. The lack of 
PrPSc in CWD-infected RKM[S169N, N173T] and RKM[S169N] cells showed that 
introducing the rigid loop in mouse PrP was not sufficient to confer susceptibility 
to CWD. C. PrPSc was not identified in CWD-infected RKM[N173T] cells at 
passage 3, showing that the substitution were not sufficient to confer 
susceptibility to an otherwise mouse PrP primary structure to CWD prions. 
CWD/Tg(ElkPrP) indicates brain homogenates from CWD (Bala05)-infected 
Tg(ElkPrP) mice. RKE is RK13 cells expressing elk PrP. CWD/RKE is RKE cells 
were chronically infected with CWD. RKM is RK13 cells expressing a wild-type 
mouse PrP. Samples treated with proteinase K (PK) indicate (+). Samples 
without PK digestion indicate (-). Molecular markers indicate 53, 36, 28 and 19 
kDa from top to bottom.  
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Figure 3.5. Interrupting the interaction between the β2-α2 loop and C-
terminal of mouse PrP changed susceptibility to RML prions. Infected and 
uninfected samples were determined for the propagation of PrPSc followed by the 
infection of RML prions at passage 3. All western blots were probed with anti-PrP 
mAb PRC5. Introducing substitution Y165A in the β2-α2 loop of mouse PrP 
changes the interaction between the β2-α2 loop and C-terminal region, and the 
substitution resulted in loss of susceptibility to RML (A). Additionally, the point or 
double substitutions at Y224A and/or Y225A at the C-terminal of mouse PrP were 
introduced. PrPSc did not accumulate in RK13 cells expressing RKM[Y224A, 
Y225A] (A). Further, both RML prions failed to accumulate PrPSc in RKM[Y224A] 
and RKM[Y225A] cells. Interrupting the interaction between the β2-α2 loop and 
C-terminal of mouse PrP was sufficient to lose susceptibility to RML prions. RKV 
is RK13 cells with an empty vector. RKM is RK13 cells expressing a wild-type 
mouse PrP. Samples treated with proteinase K (PK) indicate (+). Undigested 
samples indicate (-). Molecular markers indicate 53, 36, 28 and 19 kDa from top 
to bottom.  
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Figure 3.6. Horse-specific substitutions within the β2-α2 loop and its 
interaction site of mouse PrP resulted in loss of susceptibility to RML. In 
order to study unique amino acid residues in the β2-α2 loop and C-terminal 
regions of horse PrP, horse specific substitutions at residues 166, 167, 172, 224 
and 225 were introduced into the mouse PrP primary structure. RK13 cells 
expressing those mutant mouse PrP constructs were tested for susceptibility to 
RML prions. Infected and uninfected samples were determined for the 
conversion of PrPSc followed by the infection of RML prions at passage 3. All 
western blots were probed with mAb PRC5. A. The western blot showed that a 
weak signal of proteinase K (PK)-resistant PrPSc around 19 and 27-25 kDa in 
RML-infected RKM[D166S] cells. However, accumulation of PrPSc was not 
detected in RML-infected RK13 cells expressing horse PrP with a substitution of 
S to D at codon 167 (HorsePrP[S167D]). B. Although the apparent signal in the 
PK-digested sample from RML-infected RKM[Q167E] cells was present, the 
signal was most likely due to the undigested PrP or leaked sample from the 
neighboring lanes. RML-infected RKM[Q166S, Q167E] cells did not accumulate 
PrPSc. C. RKM[N172K] and RKM[D166S, N172K] cells failed to accumulate PrPSc 
upon RML infection. D. The western blot failed to detect PrPSc in RML-infected 
RKM[Y224A] and RKM[Y225A] cells. RKV is RK13 cells with an empty vector. 
RKM is RK13 cells expressing a wild-type mouse PrP. Samples treated with 
proteinase K (PK) indicate (+). Samples without PK digestion indicate (-). 
Molecular markers indicate 53, 36, 28 and 19 kDa from top to bottom.  
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Figure 3.7. Absence of PrPSc in RML or horse prion infected RK13 cells 
expressing mutant mouse PrP on cell blotting analysis at passage 5. Prion 
infected and uninfected samples were determined for the accumulation of PrPSc 
using a cell blotting technique, and the analyses confirmed the absence of PrPSc 
in the mutant RK13 cells followed by the infection of RML or horse prions. 
Selected variant mouse PrP including the hore-specific substitutions at residues 
166, 167, 172, 224 and/or 225 (mouse numbers), were tested for susceptibility of 
horse prion. Additionally, the variant horse PrP (HorsePrP[S167D]) was also 
tested for susceptibility to horse prion. However, horse prion-infected 
RK13HorsePrP[S167D] cells failed to convert PrPSc. As positive controls, RK13 
cells expressing elk PrP, which were chronically infected with sheep scrapie 
48x35 (C1) or SSBP/1 (C2) were used for the presence of PrPSc signals. RKV is 
RK13 cells with an empty vector. RKM is RK13 cells expressing a wild-type 
mouse PrP. 1. RKM[V165A]; 2. RKM[Y224A]; 3. RKM[Y225A]; 4. RKM[Y224A, 
Y225A]; 5. RKM[D166S]; 6. RKM[Q167E]; 7.RKM[N172K]; 8. RKM[D166S, 
Q167E]; 9. RKM[D166S, N172K]; 10. RKM[Y224F]; 11. RKM[Y225Q] 12. RK13 
HorsePrP[S167D].  
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Chapter 4 
A ‘dominant’ OvPrPSc-V136 conformation leads to forced templating of 
OvPrPC-A136 
 
Introduction 
Classical scrapie, long documented as a lethal infectious neurological disease in 
sheep, goat and moufflon, is by now classified as a transmissible spongiform 
encephalopathy (TSE)- a prion disease (Dickinson, 1976; Wood et al., 1992). 
Though its causative agent is now known, scrapie remains a serious problem 
with growing numbers of cases reported from many countries, necessitating 
vigilant monitoring and surveillance worldwide in sheep industries. As one result, 
the European Union and the United States have begun selective breeding of 
scrapie resistant sheep to increase the frequency of scrapie resistant genotypes 
(Commission, 2003; U.S. Department of Agriculture, 2012). There is, however, 
some debate as to whether the reduction of genetic variability in sheep results in 
loss of some of rare breeds (Alvarez et al., 2007; Windig et al., 2007; Windig et 
al., 2004). A further concern is that such selective breeding might make possible 
the emergence or adaptation of new strains of scrapie in the selected genotypes. 
In order to optimize the selective breeds most effectively and to prevent the worst 
scenario from happening, we require better understanding of how ovine 
polymorphisms affect both susceptibility and resistance of scrapie.        
The ovine PrP (OvPrP) gene is known to be highly polymorphic; however, 
three major polymorphisms at codon 136 (alanine [A] or valine [V]), 154 (arginine 
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[R] or histidine [H]), and 171 (glutamine [Q], R or H) have been identified to have 
the most impact on susceptibility to classical scrapie (Goldmann et al., 1991; 
Goldmann et al., 1994). The common haplotype is A at codon 136, R at codon 
154 and Q at codon 171 (ARQ), which is a less susceptible genotype to classical 
scrapie isolate SSBP/1 (sheep-passaged scrapie isolate 1); on the other hand, it 
is also the haplotype most susceptible to another scrapie isolate CH1641 (Baylis 
& Goldmann, 2004; Dickinson & Outram, 1988; Foster & Dickinson, 1988b; 
Goldmann et al., 1994). Genetic susceptibility to SSBP/1 and CH1641 isolates 
has been characterized experimentally by passaging through different breeds of 
sheep (Goldmann et al., 1994; Westaway et al., 1994a) and transgenic (Tg) mice 
expressing OvPrP encoding either ARQ (Baron et al., 2004) or VRQ (Tamguney 
et al., 2009a). Studies with sheep revealed that five combinations of the above 
polymorphisms appeared with any degree of frequency, and they are ARR, ARQ, 
AHQ, ARH and VRQ (Belt et al., 1995; Ikeda et al., 1995). In addition, sheep 
homozygous for ARR and VRQ are most resistant and susceptible to scrapie, 
respectively (Goldmann et al., 1994). In contrast, A136 and V136 are most 
susceptible and resistant to CH1641, respectively (Goldmann et al., 1994). 
Taken together, numerous studies of scrapie isolates have continuously shown 
that scrapie susceptibility is strongly linked to polymorphisms (Hunter, 2007); 
however, the molecular mechanisms that link the PrP genotype to scrapie 
susceptibility and incubation period continued to be poorly understood.   
Immunological tools that are able to distinguish polymorphic alleles 
especially at codon 136 and 171 are extremely useful in studying the effects of 
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polymorphisms on scrapie propagation. The previous studies have shown 
monoclonal antibodies (mAbs) to be capable of distinguishing OvPrP between 
Q171 and R171 alleles (Bilheude et al., 2007; Jacobs et al., 2011; Moudjou et al., 
2004), and four antibodies are available to differentiate the OvPrP 171 
polymorphism. Moudjou et al. produced two mAb antibodies; mAb V5 identifies 
R171, mAb V61 identifies Q171. Another mAb, 2A11, was produced by a French 
group and had reactivities with Q and H but not R at codon 171 (Bilheude et al., 
2007). The Langeveld group used mAb SAF84, which recognizes Q at codon 
171, to demonstrate that substantially reduced level of OvPrPSc with R171 was 
converted under conditions of co-expression of Q171 and R171 (Jacobs et al., 
2011). However, the mAb known as PRC5 is the first antibody to differentiate 
OvPrP alleles expressing A and V at codon 136 (Kang et al., 2012), and, we 
show here, was additionally able to provide insight into polymorphic effects on 
scrapie conversion.  
In the present study, we employ transgenic and immunological tools to 
assess the mechanisms by which the OvPrP 136 polymorphism controls scrapie 
susceptibility. The use of mouse mAb PRC5 enabled differentiation of OvPrP-
A136 from OvPrP-V136 in Tg(OvPrP) mice co-expressing A136 and V136. With 
those tools, we could pursue the following three questions regarding the effects 
of co-expressing A136 and V136 alleles on the replication of scrapie.  
(1) Are OvPrP-A136 and OvPrP-V136 independently converted to PrPSc, and 
their properties also independently maintained?  
(2) Does conversion of OvPrPC-V136 dominate that of OvPrPC-A136?  
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(3) Does expression of either allele inhibit conversion of the other?  
In light of the study on the Q171R polymorphism (Jacobs et al., 2011) and of 
above questions, we hypothesized that OvPrPC-V136 was preferentially 
converted to PrPSc under co-expressions of OvPrPC-A136 and OvPrPC-V136, 
and that the survival time of SSBP/1 in Tg(OvPrP-A/V136) would be relatively 
longer than SSBP/1-inoculated Tg(OvPrP-V136) mice. 
First, heterozygous Tg(OvPrP) mice expressing the A and V at codon 136 
(Tg(OvPrP-A/V136)) were generated and intracerebrally inoculated with SSBP/1 
scrapie prions. When SSBP/1-inoculated animals developed disease, the 
properties of OvPrPSc-A136 and OvPrPSc-V136 were examined by western 
blotting and histoblotting analyses using mAb anti-PrP PRC5 and 6H4. Next, the 
kinetics of PrPSc conversion were studied in relation to the interactions of multiple 
allelic forms of PrPC to different allelic forms of PrPSc using protein misfolding 
cyclic amplification (PMCA). We demonstrated for the first time that the 
templating characteristics including the kinetics of conversion and properties of 
PrPSc (deposition patterns) are independently unique to each allele. Moreover, 
the present study showed that the templating characteristics of OvPrPSc-V136 
are dominant over OvPrPSc-A136 when both of the alleles are present.  
 
Materials and Methods 
Generation of ovine transgenic mice. Hemizygous Tg mice expressing ovine 
PrP encoding either A or V at residue 136 were previously generated and are 
referred to as Tg(OvPrP-A136)3533+/- and Tg(OvPrP-V136)4166+/-, respectively 
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(Green, 2007). Briefly, ovine PrP (OvPrP) ARQ and VRQ open reading frame 
cassettes containing the mouse signal peptide instead of an ovine signal peptide 
were obtained from Dr. Nora Hunter. The OvPrP-ARQ and OvPrP-VRQ 
sequences were cloned into the cosSHa.Tet cosmid expression vector for 
transgene expression as described previously (Scott et al., 1992). The purified 
OvPrP-ARQ and OvPrP-VRQ DNA were then microinjected into the pronuclei of 
fertilized FVB/Prnp0/0 and wild-type FVB oocytes, respectively. Positive 
transgenic founders were identified by polymerase chain reaction (PCR) 
screening of the genomic DNA. Tg(OvPrP) mice were backcrossed to a Prnp 
knockout (Prnp0/0) background to maintain hemizygous transgenic lines. To 
produce Tg(OvPrP-A/V136) heterozygous mice, homozygous lines of Tg(OvPrP-
A136) and Tg(OvPrP-V136) were produced, and Tg(OvPrP-A136)+/+ and 
Tg(OvPrP-V136)+/+ homozygous mice were mated to generate a heterozygous 
line of Tg(OvPrP-A/V136) mice expressing OvPrP with A/V at residue 136. The 
relative expression levels of PrP in the brains of each Tg mouse line were 
determined by comparison with PrP expressed in the brains of wild-type FVB 
mice on western blots using anti-PrP mAb 6H4 (Prionics).   
 
Analysis of sheep polymorphism at codon 136. Genomic DNA was extracted 
from brain homogenates of healthy Tg(OvPrP-A136)3533+/- and Tg(OvPrP-
V136)4166+/- mice. The sense primer (5’-GGACAGGGCAGTCCTGGA-3‘) and 
antisense primer (5’-GATGAGGAGGATCACAGGAGG-3') were used to amplify 
the Prnp encoding sequence using PCR. The Prnp codon 136 polymorphism was 
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assessed by digestion of the amplicons with endonucleases BspHI (New 
England Biolabs. Inc.), and the digested products were analyzed on 1% agarose 
gels.     
 
Transmission studies and scrapie isolates. Three natural sheep scrapie 
isolates SSBP/1, CH1641 and 48x35 and two goat scrapie isolates 76/12/14 and 
76/12/22 were used for the transmission experiments to Tg mice. Classical 
sheep scrapie isolate SSBP/1 is a pool of six to eight natural sheep scrapie 
brains that were subsequently passaged through Cheviot sheep at the 
Neuropathogenesis Unit (NPU), Edinburgh UK. The polymorphisms of the 
original pooled sheep inoculum included VRQ, ARQ and possibly others 
(Dickinson, 1976), but the genetic makeup of sheep propagating the 
subsequently passaged SSBP/1 is unclear. The 48x35 sheep scrapie isolate was 
recovered from a natural scrapie case in a heterozygous VRQ/ARQ Cheviot 
sheep with L at codon 141 in the ARQ allele the NPU. CH1641 is also the result 
of a naturally infected Cheviot sheep from the NPU flock. SSBP/1, 48x35, and 
CH1641 were obtained from Dr. Nora Hunter, NPU. The US goat scrapie 
76/12/14, and 76/12/14 isolates were obtained from Dr. Jason Bartz (Creighton 
University, Omaha NE) and were the results of experimental studies at Creighton 
University. In addition, two isolates of cervid adapted SSBP/1 were used. These 
cervid adapted SSBP/1 isolates were generated by inoculating natural sheep 
scrapie SSBP/1 into Tg(CerPrP)1536+/- and Tg(CerPrP-L132)1973+/-, which 
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express wild-type deer PrP, and deer PrP genetically modified to express leucine 
at residue 132, respectively, at the University of Kentucky (Green et al., 2008). 
 Natural isolates of US sheep scrapie positive and negative sheep brain 
samples were collected from the scrapie flock in Idaho, and sheep were exposed 
to scrapie either during young or adult ages. Those sheep brain samples were 
obtained from Dr. Jürgen Richt (Kansas State University, Manhattan KS). The 
genotyping of sheep PrP was performed by the laboratory at Idaho State 
University. 
Ten-percent brain homogenates of scrapie-positive brains were prepared 
at 10% (w/v) in sterile phosphate buffered saline (PBS) lacking Ca2+ and Mg2+ 
ions by repeated extrusions through a series of needles of decreasing diameter 
from 18- to 22- gauge. Ten-percent brain homogenates were further diluted to 
1% (w/v) in PBS and thoroughly homogenized using a 26-gauge needle syringe. 
Groups of 5-week-old Tg(OvPrP-A136)3533+/-, Tg(OvPrP-V136)4166+/- and 
Tg(OvPrP-A/V136) mice were anesthetized with halothane and injected with 30 
µl of 1% (w/v) brain homogenate intracerebrally into the right parietal lobe using a 
26- gauge needle syringe. Hemizygous Tg(OvPrP-A136)3533+/- and Tg(OvPrP-
V136)4166+/- mice were inoculated with SSBP/1, CH1641, 48x35, 76/12/22, or 
76/12/14, and cervid adapted SSBP/1. Tg(OvPrP-A/V136) mice heterozygous for 
A/V codon 136 were inoculated with SSBP/1.  
 
Determination of incubation time. The general health of the mice was 
monitored on a daily basis. The onset of prion diseases was diagnosed by 
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observation of the progressive development of at least three of the following 
clinical signs: truncal ataxia, loss of extensor reflex, difficulty righting from a 
supine position, plastic tail, head bobbing or tilting, kyphotic posture, circling and 
paresis/paralysis. Animals were diagnosed when at least two investigators 
agreed with the clinical manifestation of disease. In addition, selected animals 
were recorded on video at the time of diagnosis and/or right before termination. 
The incubation time of prion diseases is defined as a period of time from the day 
of inoculation to the first day of the diagnosis. Therefore, the incubation time was 
indicated in days post inoculation (dpi).     
 
Western blot analysis. The right hemisphere of each brain was collected for 
western blot analysis. Ten-percent brain homogenates, prepared as described 
previously, were digested with 40 µg/ml of proteinase K (PK) (Roche) in the 
presence of 2% sarkosyl for 1 hour at 37°C. The concentration of total protein in 
each sample was determined by bicinchoninic acid assay. Undigested brain 
samples were also examined. For the study of mAb PRC5, total protein 
concentrations were standardized for each lane (40 µg per lane in Figure 4.1.). 
Natural sheep and goat scrapie isolates were standardized for 20 µg 
(undigested) and 150 µg (digested) of total protein per lane (Figure 4.5.). US 
sheep scrapie isolates were standardized for 20 µg (undigested) and 80 µg 
(digested) of total protein per lane (Figure 4.6.). In the transmission studies of 
SSBP/1 into Tg mice, undigested and digested samples were standardized for 25 
and 100 µg of total protein per lane, respectively (Figure 4.8.). Unless otherwise 
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indicated, undigested samples were prepared by mixing 20 µl of 10% brain 
homogenate with 40 µl of PBS and 20 µl of 4X sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) sample loading buffer (200 mM 
Tris-HCl pH 6.8, 8% SDS, 40% glycerol, 50mM ethylenediaminetetraacetic acid 
(EDTA), and 0.08% bromophenol blue), and 30 µl of the mixture was loaded in 
each lane. For digested samples, 50 µl of 10% brain homogenate was prepared 
in 200 µl of PBS in the presence of 2% sarkosyl and digested with PK. The 
digested sample was mixed with 90 µl of 4X SDS-PAGE sample loading buffer. 
Each lane contained with 100 µl of the sample mixture.  
Proteins were resolved by discontinuous SDS-PAGE and 
electrophoretically transferred to Immobilon-FL polyvinylidene difluoride (PVDF) 
membranes (Millipore). The transferred membrane was blocked with 5% non-fat 
milk in Tris-buffered saline containing 0.5% Tween-20 (TBST) and 
immunoprobed with anti-PrP mAbs 6H4, PRC1 or PRC5 followed by horseradish 
peroxidase-conjugated anti-mouse IgG secondary antibody. Proteins were 
visualized using enhanced chemiluminescence (ECL Plus, GE Healthcare) using 
an FLA-5000 scanner (Fujifilm Life Science). The expression levels of PrPC in 
Tg(OvPrP) mice were determined by densitometric analysis of PrPC signals on 
the western blot using MultiGauge (Fujifilm Life Science).  
 
Histoblots. Histoblots were performed according to the protocol previously 
described (Taraboulos et al., 1992). Briefly, 10 µm thick coronal brain sections 
were prepared on uncoated glass slides and transferred to nitrocellulose 
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membrane. The membranes were either treated or untreated with 1.8 mg/ml of 
PK and probed with mAb 6H4 and PRC5 followed by alkaline phosphatase-
conjugated goat anti-mouse secondary antibody (Southern Biotech). Images 
were documented with a NikonDMX 1200F digital camera in conjunction with 
Metamorph software (Molecular Devices). 
 
Protein Misfolding Cyclic Amplification (PMCA) Assay. Brains from healthy 
Tg(OvPrP-A136)3533+/-, Tg(OvPrP-V136)4166+/- and FVB/Prnp0/0 mice were 
perfused with 5 mM EDTA in PBS. Ten-percent brain homogenates of the 
perfused brains were prepared in conversion buffer (150 mmol/L NaCl, 1.0% 
Triton X-100 and Roche’s Complete Protease Inhibitor Cocktail in PBS) and 
briefly centrifuged (60 seconds at 500 rpm) to spin down debris. The PrP 
expression level in Tg(OvPrP-A136)3533+/- is twice as high as in Tg(OvPrP-
V136)4166+/- (Figure 4.7.C.). Therefore, the substrate of OvPrP-A/V136 was 
prepared by mixing 10% brain homogenates of Tg(OvPrP-A136)3533+/- and 
Tg(OvPrP-V136)4166+/- mice at 1:2 dilution. OvPrP-A136 substrate alone was 
prepared by mixing 10% brain homogenates of Tg(OvPrP-A136)3533+/- mice with 
an equal volume of 10% brain homogenate of FVB/Prnp0/0 mice. Undiluted 10 % 
brain homogenate of Tg(OvPrP-V136)4166+/- mice was used for OvPrP-V136 
substrate alone.  
Ten-percent brain homogenates of SSBP/1-infected Tg(OvPrP-
A136)3533+/- and Tg(OvPrP-V136)4166+/- diseased mice were used as SSBP/1-
A136 and SSBP/1-V136 seeds, respectively. The PMCA with SSBP/1-A136 seed 
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was performed by serial dilutions of seed in substrate at 1:30, 1:90, 1:270 and 
1:810 dilutions for a total of 48 cycles. The PMCA with SSBP/1-V136 seed was 
performed with a fixed ratio of seed in substrate at 1:180 dilution, and samples 
were collected every 2 hours during a total of 12 hours’ reaction (24 cycles). 
Undiluted 10% brain homogenates of CH1641-infected Tg(OvPrP-A136)3533+/- 
diseased mice were used as CH1641-A136 seed. The PMCA with CH1641-A136 
seed was performed with a fixed ratio of seed to substrate at 1:60 dilution, and 
samples were collected every 12 hours over the course of 48 hours (96 cycles). 
One cycle is 20 seconds sonication followed by 30 minutes incubation at 37°C. 
Controls were also prepared by incubating samples at 37°C for the duration 
indicated above. The SSBP/1-V136 PMCA experiments were repeated three 
times using three different seeds and substrates, and the CH1642-A136 PMCA 
experiments were performed twice with two different seeds and substrates. 
Amplified and control samples were digested with PK at a final concentration of 
0.33 µg/µl and analyzed on western blots using mAb 6H4 and PRC5. Amplified 
PrPSc was quantified by densitometric analysis of PrPC signals on the western 
blot using MultiGauge (Fujifilm Life Science), and PrPSc signals were normalized 
to signals of 37°C incubated controls at the same time points. The normalized 
PrPSc values and standard errors of the mean were prepared in graphs using 
GraphPad Prism 5 (GraphPad Software, Inc.).  
 
Statistical analysis. Survival curves of SSBP/1-inoculated Tg(OvPrP-
V136)4166+/- and Tg(OvPrP-A/V136) mice were statistically analyzed using a 
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Log-rank test. Statistical analysis of western blot data from the SSBP/1-V136 
PMCA and CH1641-A136 PMCA was performed using a one-way analysis of 
variant (ANOVA) at the fixed time points separately. When appropriate, 
differences between groups were probed using a Newman-Keuls post hoc test. 
All data were analyzed with GraphPad Prism 5. Differences with P < 0.05 was 
considered to be a significant and indicated with asterisks.  
 
Comparative computational modeling of ovine PrP. Structural differences in 
the A136 and V136 variants of ovine PrP (residues 114-228) were visualized in 
VMD (the NAMD molecular dynamics visualizer, available at 
http://www.ks.uiuc.edu/Research/vmd/). Each of the two structures was 
compared based on the 2.5-Å-resolution crystal structures of the corresponding 
antibody-bound PrP variant (Eghiaian et al., 2004). The computational modeling 
was performed in corroboration with Dr. Michel Sheetz (Center for Computational 
Science, University of Kentucky). 
 
Results 
Distinguishing the OvPrP polymorphism between A136 and V136 using 
mAb PRC5. Western blot analyses show that mAb PRC5 is able to recognize 
PrP from a wide range of species including mouse, deer, elk, bovine, equine, and 
human with methionine (M) or valine (V) 129 polymorphism (Figure 4.1.B.). 
However, the reactivity of mAb PRC5 is limited to OvPrP-A136, and OvPrP-V136 
is not recognized (Figure 4.1.B.). The expression of PrP in all species including 
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OvPrP-V136 was confirmed in western blots probed with mAb 6H4 (Figure 
4.1.A.). The absence of signals in FVB/Prnp0/0 (KO) samples show the 
recognition of the antibodies is specific to PrP (Figure 4.1.). The ability to 
distinguish OvPrP 136 polymorphism was further tested with increased numbers 
of Tg(OvPrP) samples, and mAb PRC5 recognized only OvPrP-A136 samples 
(Figure 4.2.B.). The PrP expression of Tg(OvPrP-V136)4166+/- and Tg(OvPrP-
A136)3533+/- was verified by mAb 6H4 (Figure 4.2.A.).  
 Next, brain homogenates from multiple diseased Tg(OvPrP-A136)3533+/- 
and Tg(OvPrP-V136)4166+/- mice were assessed for the accumulation of PK-
resistant PrPSc using mAb PRC5. Consistent with previous data (Figure 4.1. and 
4.2.), mAb PRC5 recognized PrPC-A136 as well as PrPSc-A136 in diseased 
Tg(OvPrP-A136)3533+/- mice (Figure 4.3.B.).  
The genotype of the Tg(OvPrP) mouse brain samples used to study the 
characteristics of mAb PRC5 was verified by RFLP using endonuclease BspHI, 
which recognizes the DNA sequence at V136 in ovine PrP and digests into two 
fragments of 279 and 251 base pairs (bp). All of the OvPrP-V136 samples (V0-7) 
showed two digested fragments of 279 and 251 bp, indicating that the genotype 
of the samples matched with the expressed 136 polymorphism of PrP (Figure 
4.4.). All of the OvPrP-A136 samples (A1-5) showed only undigested bands at 
530 bp, confirming correspondence of PrP 136 polymorphism with the genotype. 
Together, all the above data demonstrated that mAb PRC5 is a uniquely 
appropriate tool for distinguishing the A or V OvPrP polymorphism at codon 136.      
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 Furthermore, sheep and goat scrapie samples including three classical 
sheep isolates SSBP/1, CH1641 and 48x35 and two goat isolates 76/12/14, and 
76/22/15 isolates were characterized using mAb 6H4 and PRC5. The western 
blot probed with PRC5 showed that SSBP/1 and 48x35 isolates contained a 
lesser amount of OvPrPSc-A136 (Figure 4.5.). CH1641 sheep and two goat 
scrapie isolates were recognized by both 6H4 and PRC5 (Figure 4.5.). The 
presence of PrPC and absence of PrPSc in non-diseased sheep sample as well 
as the absence of PrP signals in KO samples demonstrated that the ability to 
detect disease-associated PrPSc in this assay. 
 Brain samples from the US sheep scrapie affected flock were examined 
on western blots using mAb 6H4 and PRC5. The US sheep scrapie positive 
samples showed PK resistant PrPSc (Figure 4.6.). However, low levels of PrPSc 
were detected in one out of four samples homozygous for V at codon 136 and Q 
at codon 171 and one sample heterozygous for A/V at codon 136, homozygous 
for R at codon 154 and Q at codon 171 (Figure 4.6.A.). PK-resistant PrPSc was 
absent in the scrapie negative samples (Figure 4.6.). The presence of OvPrPSc-
A136 was identified in the samples heterozygous for A/V at codon 136 using 
mAb PRC5 (Figure 4.6.B.). Three out of four samples of heterozygous A136V 
polymorphism showed significantly low levels of OvPrPSc-A136, and only one 
sample presented relatively higher levels of OvPrPSc-A136 (Figure 4.6.B.). 
Interestingly, the expression of OvPrP-A136 was not identified by mAb PRC5 in 
one scrapie negative sample heterozygous for A136V polymorphism (Figure 
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4.6.B.); thus, the genotype of the sample should be validated by DNA 
sequencing. 
 
Susceptibility to multiple scrapie isolates is strongly dependent on OvPrP 
A136V polymorphism. Transmission studies of scrapie isolates into Tg(OvPrP-
A136)3533+/- and Tg(OvPrP-V136)4166+/- mice, which were previously performed 
in our group, are summarized in Table 4.1., and pertinent information includes 
the origin of scrapie inocula, mean incubation time, attack rates and number of 
animals inoculated with scrapie (Green, 2007). The transmission studies of 
multiple scrapie isolates demonstrated that Tg(OvPrP-A136)3533+/- and 
Tg(OvPrP-V136)4166+/- mice were vulnerable to prion infection, and the 
susceptibility of the scrapie isolates was tightly regulated by OvPrP A136V 
polymorphism. For instance, the attack rates in SSBP/1-inoculated Tg(OvPrP-
A136)3533+/- and Tg(OvPrP-V136)4166+/- mice were 100%; however, the 
incubation times were significantly different between the Tg(OvPrP) mice (Table 
4.1. and Figure 4.7.A.). SSBP/1-inoculated Tg(OvPrP-V136)4166+/- mice 
developed disease at 132 ± 2 dpi, while SSBP/1-inoculated Tg(OvPrP-
A136)3533+/- mice required much longer times to develop disease, e.g. 412 ± 49 
dpi (Table 4.1. and Figure 4.7.A.). On the other hand, CH1641 could produce 
disease in Tg(OvPrP-A136)3533+/- mice at 310 ± 21 dpi, whereas not in 
Tg(OvPrP-V136)4166+/- at >450 dpi (Table 4.1. and Figure 4.7.B.). The results of 
the transmission studies in Tg(OvPrP) mice are consistent with previously 
published sheep studies about the effects of polymorphisms on scrapie 
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susceptibility, and it has been reported that OvPrP-V136 is more susceptible to 
SSBP/1 and less susceptible to CH1641 (Goldmann et al., 1994). In addition, the 
OvPrP-A136 is most resistant genotype for SSBP/1 but most susceptible for 
CH1641 (Goldmann et al., 1994). Moreover, another UK sheep scrapie isolate 
48x35 produced disease only in Tg(OvPrP-V136)4166+/- mice at 365 ± 21 dpi but 
not in Tg(OvPrP-A136)3533+/- at >575 dpi, and the genetic susceptibility or 
resistance of 48x35 isolate was similar to SSBP/1 (Table 4.1.). Two US goat 
scrapie isolates 76/12/22 and 76/12/14 could produce disease in Tg(OvPrP-
A136)3533+/- at 313 ± 15 and 270 ± 3 dpi, respectively.  
Interspecies transmission studies of SSBP/1 were previously performed 
by inoculating SSBP/1 into Tg(CerPrP-M132) and Tg(CerPrP-L132) mice, and 
both animals manifested clinical signs at 241 ± 16 and 290 ± 6 days, respectively 
(Green et al., 2008). These cervid-adapted SSBP/1 prions were transmitted back 
to Tg(OvPrP-A136)3533+/- and Tg(OvPrP-V136)4166+/- mice. As a result, 
Tg(CerPrP-M132) mouse passaged SSBP/1 produced disease in Tg(OvPrP-
V136)4166+/- mice at 150 ± 5 dpi and Tg(OvPrP-A136)3533+/- mice at 231 ± 14 
dpi (Table 4.1.), and the incubation times were extended in Tg(OvPrP-
V136)4166+/- mice and substantially shortened in Tg(OvPrP-A136)3533+/- mice, 
when compared to the transmission date with original SSBP/1 in those Tg mice. 
Tg(CerPrP-L132) passaged SSBP/1 produced disease in Tg(OvPrP-
V136)4166+/- mice at 335 ± 14 dpi and Tg(OvPrP-A136)3533+/- mice at 248 ± 14 
dpi (Table 4.1.), and the genetic susceptibility was inverted compared to the 
transmission data of original SSBP/1 in Tg(OvPrP) mice. Thus, modification of 
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the transmission properties of SSBP/1 occurred during the propagation of these 
prions in the Tg(CerPrP) mice.  
 The above Tg mouse studies confirmed that the susceptibility and 
resistance of SSBP/1 and CH1641 scrapie isolates were tightly regulated by the 
OvPrP A136V polymorphism. Moreover, it was demonstrated that Tg(OvPrP-
A136)3533+/- and Tg(OvPrP-V136)4166+/- are ideal animal models to investigate 
the underlying mechanisms of how the OvPrP genotype acts upon scrapie 
susceptibility and incubation time. In addition, the use of mAb PRC5 makes it 
possible to distinguish the A136V polymorphism and further to study the 
conditions of co-expressing OvPrP-A136 and OvPrP-V136. To study the PrPSc 
conversion in the heterozygous state, Tg(OvPrP-A/V136) mice was generated by 
crossing homozygous Tg(OvPrP-A136)3533+/+ and Tg(OvPrP-V136)4166+/+. 
The expression levels of PrPC in Tg(OvPrP-A136)3533+/-, Tg(OvPrP-
V136)4166+/- and Tg(OvPrP-A/V136) mouse brains were determined through 
comparison with wild-type FVB mouse brains on western blots using mAb 6H4 
and PRC5. Tg(OvPrP-A136)3533+/- mice express 30% higher levels of PrP, and 
Tg(OvPrP-V136)4166+/- mice express 35% lower levels of PrP (Figure 4.7.C.). 
The levels of PrP were 23% higher in heterozygous Tg(OvPrP-A/V136) mice 
compared to FVB mice (Figure 4.7.C.). The levels of PrP in all three Tg(OvPrP) 
mouse lines are fairly close to those of wild-type FVB mice. It is interesting to 
note that Tg(OvPrP-V136)4166+/- mice express less PrP than Tg(OvPrP-
A136)3533+/- mice. However, SSBP/1-inoculated-Tg(OvPrP-V136)4166+/- mice 
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developed disease with much shorter incubation times than do Tg(OvPrP-
A136)3533+/- mice (Table 4.1. and Figure 4.7.A.).    
 
Ample replication of PrPSc-A136 was identified in SSBP/1-inoculated 
Tg(OvPrP-A/V136) heterozygous mice. SSBP/1-inoculated Tg(OvPrP-A/V136) 
mice manifested clinical signs at 105 ± 5 dpi and developed disease even faster 
than Tg(OvPrP-V136)4166+/- mice (p<0.0001, Figure 4.7.A.). The accumulation 
of PK-resistant PrPSc in the brains of SSBP/1-inoculated Tg(OvPrP-A/V136) mice 
was examined by western blotting using mAb 6H4 and PRC5 along with the 
control brain samples of SSBP/1-inoculatd Tg(OvPrP-A136)3533+/- and 
Tg(OvPrP-V136)4166+/- mice (Figure 4.8.). All diseased Tg(OvPrP) mouse brains 
contained PK-resistant PrPSc which could be detected on western blots with 6H4 
(Figure 4.8.A.). The western blot probed with PRC5, only detects OvPrP-A136, 
revealed that OvPrPC-A136 was already converted to PrPSc in Tg(OvPrP-A/V136) 
mice at 105 ± 5 dpi (Figure 4.8.B.). Considering that SSBP/1-inoculated 
Tg(OvPrP-A136)3533+/- developed disease at 412 ± 49 dpi (Table 4.1. and 
Figure 4.8.), the conversion of OvPrPSc-A136 in SSBP/1-inoculated Tg(OvPrP-
A/V136) mice at around 110 days dpi was unexpected. Signals in brain 
homogenates from SSBP/1-inoculated Tg(OvPrP-V136)4166+/- mice were absent 
in the western blot with mAb PRC5, confirming PRC5 is capable to distinguish 
OvPrP-A136 from OvPrP-V136 (Figure 4.8.B.). 
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OvPrPSc-A136 acquired properties of OvPrPSc-V136 in SSBP/1-inoculated 
Tg(OvPrP-A/V136) mice. To determine the global deposition patterns of PrPSc in 
the CNS of diseased Tg mice, we analyzed coronal brain sections including the 
following regions: septum to hippocampus, hippocampus to thalamus, mid-brain 
to pons and oblongata from SSBP/1-infected Tg(OvPrP-A136)3533+/-, Tg(OvPrP-
V136)4166+/- and Tg(OvPrP-A/V136) mice and examined them by histoblots 
using either mAb 6H4 or PRC5 in the presence or absence of PK (Figure 4.9.). 
The use of mAb PRC5 made it possible to identify the presence of OvPrPSc-
A136. Consequently, the punctate deposition pattern of OvPrPSc-A136 was 
revealed in SSBP/1-inoculated Tg(OvPrP-A136)3533+/- by mAb PRC5 (left 
images in Figure 4.9.) and 6H4 (data not shown). On the other hand, a diffuse 
deposition pattern of OvPrPSc-V136 was observed in SSBP/1-inoculated 
Tg(OvPrP-V136)4166+/- using mAb 6H4 (2nd image from right in Figure 4.8,); 
however, the PrPSc-V136 signals were not identified by mAb PRC5 (2nd image 
from left in Figure 4.8.), confirming that mAb PRC5 only identified OvPrP-A136. 
Interestingly, SSBP/1-inoculated Tg(OvPrP-A/V136) mice presented an 
accumulation of OvPrPSc-A136, and the deposition pattern was diffuse, which 
was indistinguishable from that of Tg(OvPrP-V136)4166+/- (right in Figure 4.8.), 
suggesting that OvPrPSc-A136 acquires the properties of OvPrPSc-V136 in 
SSBP/1-inoculated Tg(OvPrP-A/V136) mice. Additionally, the expression of PrPC 
in the brains of diseased animals was confirmed by histoblotting in the absence 
of PK (data not shown), and brain samples of uninfected animals showed only 
PrPC but not PrPSc (data not shown). The absence of PrPC and PrPSc was 
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confirmed in brain samples from KO mice, indicating the ability to detect disease-
associated PrPSc.  
  
Propagation of OvPrPSc-A136 with SSBP/1-V136 seed was promoted by the 
presence of OvPrPSc-V136. The above immunoblotting data suggest that 
OvPrPC-A136 used OvPrPSc-V136 as a template to convert itself to PrPSc. As a 
result, OvPrPSc-A136 would appear to have acquired the property of OvPrPSc-
V136 in SSBP/1-inoculated Tg(OvPrP-A/V136) mice. To further investigate the 
interactions between PrPC and PrPSc under conditions of co-existence of 
OvPrPC-A136 and OvPrPC-V136, we used PMCA to quantify the amplification of 
PrPSc at subsequent multiple time points or serial dilutions of seed to substrate. 
In addition, we examined whether either OvPrPC-A136 or OvPrPC-V136 was 
preferentially converted to PrPSc with the homogenous genotype of SSBP/1-A136 
or SSBP/1-V136 seeds, and whether the presence of either inhibited conversion 
of the other. 
In order to study the rates of PrPSc conversion, we collected samples 
every 2 hours for a total of 12 hours of PMCA. As predicted, the amplification of 
SSBP/1-V136 seed with the genotype matched substrate OvPrPC-V136 resulted 
in the efficient propagation of OvPrPSc-V136 (Figure 4.10.B.). On the other hand, 
SSBP/1-V136 was not able to convert OvPrPC-A136 to PrPSc by PMCA (Figure 
4.10.A. and D.), suggesting that the interaction of OvPrPSc-V136 and OvPrPC-
A136 was not sufficient to produce OvPrPSc-A136. Interestingly, the propagation 
of OvPrPSc-A136 was identified when both of OvPrPC-V136 and OvPrPC-A136 
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substrates were mixed together (Figure 4.10.F.). The quantification of amplified 
PrPSc signals showed that the conversion of OvPrPSc-V136 was first identified 
after 6 hours of amplification, and the conversion of OvPrPSc-A136 was 
recognized after 8 hours of amplification under the co-existence of both alleles 
(Figure 4.11.), indicating that the preferential conversion of PrPSc-V136 was 
followed by the propagation of OvPrPSc-A136. Moreover, the different rates of 
conversion of PrPSc between OvPrP-A136 and OvPrP-V136 in the presence of 
both alleles suggest that OvPrPSc-V136 helps the propagation of OvPrPSc-A136.  
Statistical analyses were performed at fixed time points (2, 4, 6, 8, 10 or 
12 hours separately) using a one-way ANOVA, and significant difference was 
reported at 10 hours (p<0.0016) and 12 hours (p<0.01). A Newman-Keuls 
multiple comparison post-hoc test showed the following groups are statistically 
significant at 10 hours: A/V136-PRC5 vs. A/V136-6H4. Moreover, the Newman-
Keuls reported that the following groups are also statistically significant at 12 
hours: A/V136-PRC5 vs. V136-6H4. 
 
SSBP/1-A136 produced successful conversion of PrPSc only with OvPrPC-
A136 substrate. PMCA of SSBP/1-A136 was performed in serial dilutions of 
seed to substrate to see whether PrPSc could be amplified for 98 cycles (48 
hours). The amplification of SSBP/1-A136 seed to OvPrPC-A136 substrate at 
1:30, 1:90, 1:270 and 1:810 dilutions was able to produce PrPSc (Figure 4.12.A. 
and D.). However, inefficient amplification of PrPSc-V136 was observed at 1:90 
and 1:270 dilutions. PrPSc signals at 1:30 dilution in Figure 4.12.B. and E were 
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most likely coming from the seed SSBP/1-A136. Since OvPrPSc-V136 would not 
be recognized by mAb PRC5, the amplified signal on the western blot probed 
with mAb PRC5 indicated that PrPSc signals at 1:30 dilution were from the seed. 
Under the co-presence of OvPrP-A136 and OvPrP-V136 alleles, the PrPSc 
conversion was not as efficient as the amplification with OvPrPC-A136 alone. 
Some amplification of PrPSc was observed at 1:30 and 1:90 dilutions, but no 
amplification of PrPSc was detected at 1:270 and 1:810 dilutions (Figure 4.12.C. 
and F.). These data indicated that PMCA of SSBP/1-A136 was able to amplify 
PrPSc with OvPrPC-A136 compared to OvPrPC-V136 or the mixture of both.    
 
Reduced amount of PrPSc-A136 was amplified with CH1641-A136 seed in 
PMCA when the both A136 and V136 alleles existed. PMCA of CH1641-A136 
seed with OvPrP-A136, OvPrP-V136 and the mixture of both was performed 
independently, twice, to examine the compatibility of the seed and substrates for 
the conversion of PrPSc. In addition, the amplified samples were collected every 
12 hours in a total of 48 hours amplification to study the rate of PrPSc conversion. 
As predicted on the basis of the animal studies, the genotyped matched reaction 
of CH1641-A136 seed and OvPrPC-A136 substrate produced OvPrPSc-A136 
efficiently (Figure 4.14.A. and D.). However, inefficient amplification of OvPrPSc-
V136 was observed with PMCA of CH1641-A136 (Figure 4.14.B.). When two 
substrates were mixed, reduced amplification of OvPrPSc in PMCA of CH1641-
A136 was observed (Figure 4.14.C. and F.). Interestingly, the western blot probe 
with mAb PRC5 showing only OvPrPSc-A136 allele displayed that the efficiency 
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of OvPrPSc-A136 conversion was reduced remarkably (Figure 4.14.F.). Statistical 
analyses were performed at fixed time points (12, 24, 36 or 48 hours separately) 
using a one-way ANOVA, and statistical significance was reported at 24 hours 
(**p<0.013). A Newman-Keuls multiple comparison post-hoc test showed the 
following groups are statistically significant at 24 hours: A/V136-PRC5 vs. A136-
PRC5 and A/v136-6H4 vs. A136-PRC5. The quantification of PMCA amplified 
signals from each group revealed that the amplification of OvPrPSc-A136 was 
inhibited when two substrates were mixed (Figure 4.15.). 
CH1641-A136 was compatible with OvPrPC-A136 but not OvPrPC-V136 
for the conversion of PrPSc. Unlike SSBP/1-V136, the presence of another allele, 
in this case OvPrP-A136, did not promote the conversion of incompatible allele 
OvPrP-V136 in PMCA of CH1641-A136 under the co-presence of two alleles. 
Instead, the presence of OvPrP-V136 obstructed conversion of OvPrPSc-A136.   
These data suggest that the rates of PrPSc conversion were efficient when 
the genotype of seed and substrate were identical. If the seed and substrate 
carry different genotypes, the amplification of PrPSc becomes inefficient. In 
addition, the rates of PrPSc conversion were also different among three scrapie 
isolates. Even though the different effects of the A136V polymorphism on the 
propagation of PrPSc were demonstrated by the animal and PMCA studies, it is 
still not clear what are the differences between OvPrP-A136 and OvPrP-V136 
besides in the primary structures.  
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Computational modeling of structures of OvPrP-A136 and OvPrP-V136 
predicted local structural differences in the α-helices and the long-range 
interaction between the β2-α2 loop and tyrosine at codon 228. To gain more 
insight into possible conformational differences, we visualized the structures of 
OvPrP-A136 and OvPrP-V136 corresponding to amino acid residues 114-228 in 
VMD (Figure 4.17.). Each of the structures includes the disordered N-terminal 
structure and three α-helices (H1-3) shown in red ribbons (Figure 4.17.). When 
the structures of OvPrPA-136 and OvPrP-V136 were superimposed, the 
composed image showed that the two structures were not aligned exactly the 
same (Figure 4.18.). The most apparent difference between two OvPrP 
structures was the orientation of Y at codon 228 in the C-terminal region 
(indicated in a yellow circle in Figure 4.18.). In OvPrP-V136, the ring structure of 
Y228 at the C-terminal region faced down and was positioned in close proximity 
to the loop between the β2-sheet and α2-helix, suggesting the long-range 
interaction of the Y at codon 228 and β2-α2 loop. On the other hand, the ring 
structure of Y228 flipped away from the β2-α2 loop in OvPrP-A136. The NMR 
structural study of tammar wallaby PrP reported a long-range interaction between 
the β2-α2 loop and C-terminal region, which appeared to work together to control 
the susceptibility to prions (Christen et al., 2009). Additionally, a series of the cell 
culture studies in Chapter 3 above demonstrated that the interference of the 
long-range interaction by the substitutions of amino acids in the β2-α2 loop and 
C-terminal region altered susceptibility to prions (Figure 3.5 to 3.7.). Based on 
those findings, we surmised that the difference in the orientation of Y228 is a 
 
 
129 
possible explanation of differences in the susceptibility or resistance to classical 
scrapie isolates. 
 Furthermore, the subtle differences between OvPrP-A136 and OvPrP-
V136 were found in the structures of three α-helices (H-1, H-2 and H-3), and 
most conformational changes were concentrated in H-1. The N-terminal of H-1 
was relaxed and C-terminal of H-1 opened up in OvPrP-A136; therefore, the 
diameter of H-1 in OvPrP-V136 was relatively smaller than OvPrP-A136 (Figure 
4.19.C.). In addition, the N-terminal of H-1 had less twist in OvPrP-A136. The 
difference in H-2 was that the C-terminus had an additional twist in OvPrP-V136 
but not OvPrP-A136 (Figure 4.19.A and B.). In more detail, the conformational 
differences were found in the orientation of the following amino acid residues: 
asparagine at codon 147 and glutamic acid at codon 155 in H-1, asparagine at 
codon 176 and lysine at codon 188 in H-2, and glutamic acid at codon 203 in H-3 
and Y at codon 228. 
 
Discussion 
Our transmission studies of classical sheep scrapie isolates in Tg(OvPrP-
A136)3533+/- and Tg(OvPrP-V136)4166+/- mice demonstrated that the 
susceptibility and resistance to the scrapie isolates were consistent with the 
previously reported sheep study (Goldmann et al., 1994). In contrast to the 
findings reported in previous sheep transmission studies that the incubation time 
of SSBP/1-affected sheep heterozygous for the A136V genotype rise between 
those of sheep homozygous for A136 and V136 (Goldmann et al., 1994), 
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SSBP/1-inoculated Tg(OvPrP-A/V136) heterozygous mice developed disease 
even faster than did Tg(OvPrP-V136)4166+/- mice. This relatively rapid incubation 
time might be associated with the propagation of both PrPSc-A136 and PrPSc-
V136. Western blots and histoblots demonstrated that the conversion of 
OvPrPSc-A136 occurred at around 100 dpi in SSBP/1-infected Tg(OvPrP-A/V136) 
mice, and the deposition patterns of OvPrPSc-A136 were indistinguishable from 
OvPrPSc-V136 under co-expressions of OvPrP-A136 and OvPrP-V136, 
suggesting that the dominant conformational selection occurred during the 
propagation of SSBP/1. PMCA of SSBP/1-A136, SSBP/1-V136 and CH1641-
A136 demonstrated that the rates of PrPSc conversion were different between 
A136 and V136 polymorphisms. Furthermore, the comparative structural studies 
revealed differences in the orientation of amino acid molecules located in three α-
helices, resulting in the conformational differences between OvPrP-A136 and 
OvPrP-V136. Taken together, the above data provide new models for explaining 
how the polymorphism participates in the propagation of PrPSc as described 
details in the section below. 
The levels of PrP in Tg(OvPrP-A136)3533+/-, Tg(OvPrP-V136)4166+/- and 
Tg(OvPrP-A/V136) mice are close to those found in wild-type FVB mice (Figure 
4.7.). In this regard, those Tg mouse lines are unique compared to other 
overexpressing Tg(OvPrP) mice, such as: TgOvPrP4 (3-fold to sheep), 
TgOvPRC59 (3-fold to sheep), TgShp XI (4-8 fold), Tg338 (8-10 fold to sheep), 
and Tg301 (8-fold to sheep) (Cordier et al., 2006; Kupfer et al., 2007; Le Dur et 
al., 2005; Vilotte et al., 2001). Even though the levels of PrP in Tg(OvPrP-
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V136)4166+/- mice is half of the levels expressed in Tg(OvPrP-A136)3533+/- mice, 
SSBP/1-inoculated Tg(OvPrP-V136)4166+/- mice developed disease much faster 
than Tg(OvPrP-A136)3533+/- mice. Therefore, we feel justified in concluding that 
susceptibility was primarily controlled by the A136V polymorphism instead of the 
expression levels of PrP.  
The unique immunological tool, mAb PRC5 distinguishing OvPrP-A136 
from OvPrP-V136 allowed us to study the mechanism of conversion of SSBP/1 
scrapie in Tg(OvPrP) mice. Western blots probed with mAb PRC5 presented 
evidence that a significant amount of PrPSc-A136 was already converted in 
SSBP/1-inoculated Tg(OvPrP-A/V136) heterozygous mice around 110 dpi. Even 
though it is not certain whether the propagation of PrPSc-A136 occurred as early 
as 110 dpi in SSBP/1-inoculated Tg(OvPrP-A136)3533+/- mice, which required 
around 400 dpi, we unexpectedly found the ample conversion of PrPSc-A136 in 
SSBP/1-inoculated Tg(OvPrP-A/V136) mice. The Langeveld group reported that 
low levels of PK-resistant OvPrPSc-R171 in classical scrapie inoculated 
Tg(OvPrP-A/V136, R/R154, R/Q171) heterozygous mice were detected using 
mAb SAF84 which identifies OvPrP-Q171 (Jacobs et al., 2011). These studies 
suggest that two polymorphisms at codon 136 and 171 within OvPrP serve 
different functions in the propagation of PrPSc. 
The deposition patterns of PrPSc have been well-characterized for prion 
strain-typing in classical scrapie-affected sheep brains (Beck et al., 2010; Jeffrey 
& Gonzalez, 2007; Spiropoulos et al., 2007) since the development of spongiosis 
is not always the hallmark of prion pathogenesis in classical scrapie. This is 
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especially true with regard to SSBP/1 (Begara-McGorum et al., 2002; Houston et 
al., 2002) and to CH1641 (Foster & Dickinson, 1988a). In addition, the PrPSc 
profiling on western blotting appears to be homogenous and does not provide 
much information about differences in scrapie-affected brain samples (Jeffrey & 
Gonzalez, 2007). It was also true in the present study that the western blot 
profiles did not distinguish among A136, V136 and A/V136 samples (Figure 4.8.). 
The deposition patterns of PrPSc in brains of scrapie-affected sheep homozygous 
for ARQ/ARQ were described in terms of predominant “granular deposits” or 
“highly distinctive deposits” (Beck et al., 2010; Jeffrey & Gonzalez, 2007; 
Spiropoulos et al., 2007), all of which indicates punctate deposition patterns of a 
sort also shown in SSBP/1-inoculated Tg(OvPrP-A136)3533+/- mice in the 
present study (left images in Figure 4.9.). In contrast, the PrPSc profiling in 
scrapie-affected sheep homozygous for VRQ/VRQ was illustrated as consisting 
of “mild diffused” or “coalescing plaques” (Beck et al., 2010; Jeffrey & Gonzalez, 
2007; Spiropoulos et al., 2007), consistent with the diffuse deposition pattern in 
SSBP/1-inoculated Tg(OvPrP-V136)4166+/- mice (the 2nd image from right in 
Figure 4.9.). The distinctive PrPSc profiling differences found between OvPrP-
A136 and OvPrP-V136 do correspond to the pathology of scrapie-diseased 
sheep brains. Moreover, scrapie-affected sheep heterozygous for ARQ/VRQ 
showed “coalescing plaques” or “widespread general neutrophil deposition” 
(Beck et al., 2010; Spiropoulos et al., 2007), and these observations were also in 
line with diffuse PrPSc deposition in SSBP/1-inoculated Tg(OvPrP-A/V136) mice 
(right images in Figure 4.9.). Even though the previously reported studies used 
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immunohistochemistry to profile the PrPSc deposition patterns, we consider that 
the histoblotting technique used in the present study was sensitive enough to 
represent the distinctive patterns of PrPSc in SSBP/1-inoculated Tg(OvPrP) mice. 
In addition to the previously reported findings, the use of mAb PRC5 provided the 
information exclusive to the OvPrPSc-A136 profiling, and the present study 
showed that OvPrPSc-A136 could attain the properties of OvPrPSc-V136 upon co-
expression of both alleles.  
Furthermore, PMCA of SSBP/1-V136 demonstrated that the conversion of 
OvPrPSc-A136 was assisted by the presence of OvPrP-V136 in the presence of 
both alleles. Accordingly, it is hypothesized that a ‘dominant’ OvPrPSc-V136 
conformation leads to forced templating of OvPrPC-A136. However, the 
‘dominant’ conformational selection was not observed in PMCA of CH1641-A136. 
This suggests that the templating mechanism of OvPrPSc-V136 might be unique 
to the SSBP/1 isolate. Bossers group reported that the OvPrP Q171R 
polymorphism had a dominant-negative inhibition on the conversion of PrPC-
R171 to PrPSc, and that the inhibition was not due to the lack of binding or 
interaction of PrPC-R171 to PrPSc (Rigter & Bossers, 2005). Hence, OvPrP-V136 
has a dominant-positive templating effect, while OvPrP-R171 has a dominant-
negative inhibition. Thus, the ‘dominant’ templating mechanism of OvPrPSc-V136 
might be unique to the 136 polymorphism. Together, the above data indicate that 
the scrapie susceptibility-linked polymorphisms affect the conversion of PrPSc by 
modulating the properties of both PrPC and PrPSc.   
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 Based on the animal and PMCA studies, I propose the potential 
mechanisms of propagation of SSBP/1 as illustrated in Figure 4.13. The following 
proposed models are based on the heterodimer template-associated model 
(Cohen et al., 1994). Thus, PrPC is in equilibrium with an intermediate form of 
PrP*, and the formation of PrP* is thought to be facilitated by a hypothetical 
protein X (Kaneko et al., 1997; Telling et al., 1995; Telling et al., 1994). The 
conversion of PrP* to PrPSc is a catalytic step, and the operative catalyst might 
be protein X or other molecules. It is important to note that although natural 
sheep scrapie isolate SSBP/1 consists of mainly a VRQ genotype, it is a pool of 
multiple combinations of genotypes, suggesting that different conformations of 
PrPSc are available in the isolate (a box on the top right corner in Figure 4.13.). 
The first model in Figure 4.13. indicates that the conversion of OvPrPSc-V136 is 
efficient with the genotype matched SSBP/1-V136, therefore, the survival time of 
SSBP/1-inoculated Tg(OvPrP-V136) mice is relatively shorter than Tg(OvPrP-
A136) mice. On the other hand, the propagation of SSBP/1-A136 with OvPrPC-
A136 is not as efficient a process as the propagation of SSBP/1-V136 with 
OvPrPC-V136 even though the genotypes between PrPSc and PrPC are identical. 
Therefore, the survival time of SSBP/1-inoculated Tg(OvPrP-A136) mice is much 
longer due to the slow conversion rate of OvPrPSc-A136 (2nd model in Figure 
4.13.). In those proposed models, the conformations of PrPSc differ between 
OvPrPSc-V136 (pentagon) and OvPrPSc-A136 (triangle), inasmuch as the 
histoblotting data showed diffuse vs. punctate deposition patterns of PrPSc in 
SSBP/1-inoculated Tg(OvPrP-V136)4166+/- and Tg(OvPrP-A136)3533+/- mice, 
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respectively (Figure 4.9.). The last model in Figure 4.13. indicates that OvPrPC-
A136 and OvPrPC-V136 are co-expressed, the conversion of OvPrPSc-V136 
occurs followed by the conversion of OvPrPSc-A136. The intermediate forms of 
OvPrP*-V136 and OvPrP*-A136 interact to transform the conformation of 
OvPrP*-A136 into the conformation of OvPrP*-V136, and the adaptation of 
OvPrP*-V136 conformation in PrP*-A136 allows SSBP/1-V136 to become a 
template for the conversion to PrPSc. Therefore, the conformation of OvPrPSc-
A136 is identical to OvPrPSc-V136. The histoblots probed with mAb PRC5, which 
identifies only OvPrP-A136, indicated that the diffuse deposition patterns of 
OvPrPSc-A136 in SSBP/1-inoculated Tg(OvPrP-A/V136) mice were 
indistinguishable from the pattern in SSBP/1-inoculated Tg(OvPrP-V136) mice 
(Figure 4.9.). In the final proposed model, the conversion of OvPrPSc-A136 is 
promoted by the presence of the other allele, V136, and the conversion of both 
alleles can promote quicker development of disease in SSBP/1-inoculated 
Tg(OvPrP-A/V136) mice compared to Tg(OvPrP-V136) mice.  
 In the final proposed model (Figure 4.13.), the intermediate form PrP* may 
play an important role in the conversion of SSBP/1-V136 with the co-expression 
of OvPrPC-A136 and OvPrPC-V136. PrPC has been proposed to undergo a 
dramatic unfolding of α-helices to generate the β-sheet rich structure of PrPSc 
(Cobb et al., 2007; Lu et al., 2007). The presence of unfolded intermediates of 
PrP has been detected (Chen et al., 2011), and these intermediate forms are 
proposed as a more proximal precursor of PrPSc than PrPC (Roder & Colon, 
1997). The kinetic unfolding study of OvPrP ARQ and ARR identified a 
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population of intermediates formed during unfolding and refolding candidates. 
ARQ resulted in a larger population of unfolded intermediates compared to ARR, 
suggesting that differences in the population of intermediates can govern the 
susceptibility to scrapie isolates (Chen et al., 2011). In general, ARR is a more 
resistant allele for classical sheep scrapie isolates (Goldmann et al., 1994). 
These previously published studies support the involvement of unfolded 
intermediate isoforms of PrPC in the structural conversion of PrPSc  as well as the 
susceptibility to scrapie. 
The propagation mechanisms of SSBP/1-A136 and CH1641-A136 exhibit 
similarities in the effects of the A136V polymorphism with co-expressions of 
OvPrPC-A136 and OvPrPC-V136. When only OvPrPC-A136 is available, does 
propagation of OvPrPSc-A136 occur. However, the propagation of OvPrPSc-A136 
is interfered with when OvPrPC-V136 is also available for the conversion of PrPSc 
(Figure 4.16.). Even though the inhibitory effect of OvPrP-V136 was observed in 
PMCA of CH1641-A136 and SSBP/1-A136, it is not clear which isoforms of PrPC, 
PrP* or PrPSc inhibit the conversion of OvPrPSc-A136 in the presence of both 
alleles. The question arises as to whether the SSBP/1-A136 isolate becomes 
more similar to CH1641-A136 or whether CH1641-A136 is originated from a 
SSBP/1-A136 isolate.  
To answer these questions, we consider that the deposition patterns of 
PrPSc and neuropathological examinations in either CH1641-A136 or SSBP/1-
A136-inouclated animals would be informative. Serial passage of SSBP/1-A136 
into Tg(OvPrP-A136) mice might answer whether SSBP/1-A136 can adapt 
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different strain properties, such as those of CH1641. For example, an incubation 
time might become similar to CH1641-inoculated mice, and/or OvPrP-V136 might 
become no longer susceptible to SSBP/1-A136.  
Our interspecies transmission studies of cervid adapted SSBP/1 isolates 
in Tg(OvPrP-A136)3533+/- and Tg(OvPrP-V136)4166+/- mice demonstrated that 
the properties of original SSBP/1 were altered during the incubation of SSBP/1 in 
Tg(CerPrP-L132)1973+/- and Tg(OvPrP-M132) mice. The genetic susceptibility of 
cervid adapted SSBP/1 isolates in Tg(OvPrP-A136)3533+/- and Tg(OvPrP-
V136)4166+/- mice turned out to be completely different from original SSBP/1. 
These studies indicated that new prion strains could arise from an existing strain, 
for example, SSBP/1 during the adaptation of PrPSc in new host species.    
Biophysical structural studies demonstrated that the action of structural 
change of PrPC required the unfolding of H1 to open up the globular domain 
between the S1-H1-S2 and H2-H3 (Adrover et al., 2010; Eghiaian et al., 2007). 
When PrPC undergoes unfolding, the S1-H1-S2 and H2-H3 domains were 
separated while linked by the S2-H2 loop (Prigent & Rezaei, 2011). Therefore, 
the conformation of the S2-H2 loop plays a role in oligomerization. The unfolding 
process was initiated by binding hypothetical protein X to the S2-H2 loop 
(Kaneko et al., 1997). The present computational studies comparing the 
structures between OvPrP-A136 and OvPrP-V136 revealed that the majority of 
differences were found in the H1, and the orientation of Y at codon 228 was 
located in closer proximity to the S2-H2 loop in OvPrP-V136 but not in OvPrP-
A136. These findings suggest that the structural differences between the 
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polymorphic variants are associated with the susceptibility to scrapie. It might be 
that either protein X or PrPSc favors one conformation over the other to trigger the 
unfolding events of PrPC to obtain the β-sheet rich structure of PrPSc, ultimately 
leading to oligomerization of PrPSc.  
In conclusion, the templating characteristics including the kinetics of 
conversion and properties of PrPSc found in the propagation of SSBP/1 appeared 
to be unique to the scrapie isolate. Under conditions of co-expression, OvPrPC-
V136 facilitates the conversion of OvPrPSc-A136, and the templating 
characteristics of OvPrPSc-V136 are dominant over OvPrPSc-A136. On the other 
hand, CH1641 does not have the same templating characteristics, and the 
scrapie susceptibility-linked polymorphisms could control the conversion of PrPSc 
by modulating both PrPC and PrPSc. 
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Table 4.1. Transgenic modeling of the OvPrP 136 polymorphism on scrapie 
susceptibility. Incubation times indicate days post inoculation (dpi) in mean ± 
SEM (standard error of the mean). ND indicates that transmission studies of the 
goat scrapie isolates into Tg(OvPrP-V136)4166+/- were not performed. 
 
  
Mean incubation time (±  SEM) days,  
(n/n0)  
Scrapie 
Isolate Origin 
Tg(OvPrP-
V136)4166
+/- 
Tg(OvPrP-
A136)3533
+/- 
SSBP/1 UK Sheep 132 ± 2 (8/8) 412 ± 49 (6/6) 
48x35 UK Sheep 365 ± 21 (7/7) >575 (0/5) 
CH1641 UK Sheep > 450 (0/5) 310 ± 21 (6/6) 
76/12/22 US Goat ND 313 ± 15 (7/7) 
76/12/14 US Goat ND 270 ± 3 (4/4) 
Cer-SSBP/1 Tg(CerPrP)1536+/- 150 ± 5 (7/7) 231 ± 14 (7/7) 
Cer-SSBP/1 Tg(CerPrP-L132)1973+/- 335 ± 14 (8/8) 248 ± 14 (4/4) 
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Figure 4.1. Anti-PrP mAb PRC5 is capable of distinguishing the ovine PrP 
polymorphism alanine from valine at codon 136. Western blot analyses of 
brain homogenates from Tg mice expressing multiple species of PrP shows mAb 
PRC5 has reactivities with a wide-range of PrP species but not OvPrP-V136. A. 
Western blot probed with anti-PrP mAb PRC1 shows the presence of PrP in both 
OvPrP-A136 and OvPrP-V136 samples. B. The western blot including the same 
PrP samples determined in the western blot with mAb PRC1 (A) was probed with 
mAb PRC5 shows that the absence of PrP signals in OvPrP-V136 but the 
presence of the signals in OvPrP-A136, indicating that PRC5 is an OvPrP-A136 
specific antibody. FVB is a wild-type mouse. A Prnp0/0 knockout (KO) is used as 
a negative control. Molecular markers indicate 50, 40, 30 and 20 kDa from top to 
bottom. 
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Figure 4.2. Further testing the specificity of mAb PRC5 against OvPrP-A136 
polymorphism with a larger number of Tg(OvPrP) samples. Lane 1, 2 and 5 
to 9 include brain homogenates from Tg(Ovine PrP-V136)4166+/-. Lane 3, 4 and 
10 to 12 contain brain homogenates from Tg(Ovine PrP-A136)3533+/-. Animal 
identifications (ID) are indicated above lane numbers. A. Western blot probed 
with mAb 6H4 shows that all brain samples include PrP. B. Western blot including 
the same samples presented in A was examined with mAb PRC5. Consistent 
with the previous data (Figure 4.1.), PRC5 distinguishes OvPrP-A136 from 
OvPrP-V136. Molecular markers indicate 50, 40, 30 and 20 kDa from top to 
bottom. 
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Figure 4.3. Anti-PrP mAb PRC5 can recognize both PrPC and PrPSc on 
western blotting. Representative samples from the previous experiment (Figure 
4.2.) was either digested or undigested with proteinase K (PK) and tested 
whether mAb PRC5 is able to recognize PrPSc. Lane 3 to 6 include brain 
homogenates from diseased Tg(OvPrP-V136)4166+/- mice. The animal with an ID 
number V1 was inoculated with sheep scrapie CH1641, which could not produce 
disease in Tg(OvPrP-V136)4166+/-. Thus, the signal of PrPSc should be absent as 
shown in lane 2. Lane 7 to 14 contains brain homogenates from diseased 
Tg(OvPrP-A136)3533+/- mice. PK digested (+) and undigested (-) samples are 
examined in the both blots. A. The presence of PrPC in all of the samples was 
confirmed by the western blot with mAb 6H4. B. The same samples examined in 
the above western blot (A) were also determined on another western blot with 
mAb PRC5. The western blot with PRC5 was able to recognize both PrPC and 
PrPSc of Tg(OvPrP-A136)3533+/- samples. Molecular markers indicate 50, 40, 30 
and 20 kDa from top to bottom. 
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Figure 4.4. Restriction Fragmented Length Polymorphism (RFLP) validated 
that the genotype was corresponding to the expressed 136 polymorphism 
of PrP. The genotypes of the previously analyzed mouse samples including both 
Tg(OvPrP-A136)3533+/- and Tg(OvPrP-V136)4166+/- were validated by RFLP 
analysis. Restriction endonuclease enzyme BspHI recognizes the DNA sequence 
at V136 in OvPrP and digests into two fragments of 279 and 251 bp, whereas, 
OvPrP-A136 remains undigested (530 bp). All of eight Tg(OvPrP-V136)4166+/- 
mouse samples (ID numbers V0-V7) show digested fragments at 279 and 251 
bp. Five samples from Tg(OvPrP-A136)3533+/- mice (ID numbers A1-A5) show 
only undigested bands at 530 bp. The above RFLP data confirmed that the 
genotype of the samples matched with the expressed 136 polymorphism of PrP 
(Figure 4.2. and 4.3.). Molecular markers indicate 1000, 850, 650, 500, 400 and 
300 bp from top to bottom. 
 
 
 
  
!""""+""""""""!"""""+"""""""!""""+"""""""!""""+"""""""!"""""+""""""!""""+"""""""!""""+"""""""!"""""+""""""!"""""+""""""!"""""+""""""!""""+"""""""!""""+""""""!"""""+ 
 
 ID V2        V1      V0       V4      V5      V6       V3       V7      A1       A2      A5      A3      A4 
 Tg(OvPrP-V136)4166+/- Tg(OvPrP-A136)3533
+/-
 
BspHI 
 
 
144 
 
 
Figure 4.5. Natural sheep and goat scrapie prions were recognized by mAb 
PRC5. Brain homogenates of sheep brains with SSBP/1, CH1641 or 48x35 
sheep scrapie prions and of goat brains with 76/12/14 or 76/12/22 goat prions 
were examined whether mAb PRC5 was able to recognize those sheep and goat 
samples on western blots. Prnp knockout FVB mouse brains (KO) were used as 
a negative control. Non-diseased indicates a brain homogenate of healthy sheep, 
and it was used as a non-diseased control for the absence of PrPSc. OvPrP-A136 
and OvPrP-V136 includes brain homogenates from SSBP/1-inoculated 
Tg(OvPrP-ARQ)3533+/- and Tg(OvPrP-VRQ)4166+/- mice, respectively. 
Proteinase K (PK) digested (+) samples were examined along with undigested (-) 
samples. A. Western blot probed with mAb 6H4 presents that all brain samples 
contain PrP. B. The same samples presented in the above western blot (A) were 
also examined on another western blot probed with mAb PRC5. Molecular 
markers indicate 50, 40, 30 and 20 kDa from top to bottom. 
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Figure 4.6. Anti-PrP mAb PRC5 was able to recognize an A136 allele in 
sheep brain samples with or without US sheep scrapie. Different genotypes 
of sheep samples from a US sheep scrapie affected flock were examined on 
western blots with mAb PRC5. Proteinase K (PK) digested (+) and undigested 
samples (-) are determined on the bots. A. The western blot probed with mAb 
6H4 presents all brain samples contain PrP. B. The western blot including the 
same samples examined on the above blot (A) was analyzed with mAb PRC5. 
The blot with PRC5 recognized only an A136 allele in homozygous or 
heterozygous samples, corresponding to the genotype indicated above. Three 
OvPrP polymorphisms at codons 136, 154 and 171 are indicated, and a blank 
box indicates a genotype at the position was not reported. Molecular markers 
indicate 40, 30 and 20 kDa from top to bottom. 
  
 
 
 
 PK - + 
KO 
QR 
AA VV 
154 RR 
136 
171 
AV AA AV AA AV AA VV VV VV VV AV AV AV AV 
RR RR 
QQ QQ 
RR 
RR RR 
QQ QQ QQ QQ QQ QQ QQ QQ QR QQ QQ QQ QQ 
Negative Positive Positive Negative 
A 
B 
Sheep 
US sheep  
scrapie  
 
 
146 
 
  
Natural sheep scrapie SSBP/1 inoculated Ovine mice
0 200 400 600
0
25
50
75
100
Pe
rc
en
t H
ea
lth
y 
M
ic
e
Days Post Inoculation
A/VRQ mice
ARQ mice
VRQ mice
Natural sheep scrapie CH1641 inoculated Ovine mice
0 100 200 300 400
0
25
50
75
100
Pe
rc
en
t H
ea
lth
y 
M
ic
e
Days Post Inoculation
ARQ mice
VRQ mice
Natural sheep scrapie SSBP/1 inoculated Ovine mice
0 200 400 600
0
25
50
75
100
Pe
rc
en
t H
ea
lth
y 
M
ic
e
Days Post Inoculation
A/VRQ mice
ARQ mice
VRQ mice
Natural sheep scrapie CH1641 inoculated Ovine mice
0 100 200 300 400
0
25
50
75
100
Pe
rc
en
t H
ea
lth
y 
M
ic
e
Days Post Inoculation
ARQ mice
VRQ mice
A B 
 
(µg)  60    60   30   15        60  30  15       60   30   15      60   30  15 
KO FVB A136 A/V136 V136 C 
(%)         100                   130                   65                    123 
Natural sheep scrapie SSBP/1 inoculated Ovine mice
0 200 400 600
0
25
50
75
100
Pe
rc
en
t H
ea
lth
y 
M
ic
e
Days Post Inoculation
A/VRQ mice
ARQ mice
VRQ mice
Natural sheep scrapie CH1641 inoculated Ovine mice
0 100 200 300 400
0
25
50
75
100
Pe
rc
en
t H
ea
lth
y 
M
ic
e
Days Post Inoculation
ARQ mice
VRQ mice
Natural sheep scrapie SSBP/1 inoculated Ovine mice
0 200 400 600
0
25
50
75
100
Pe
rc
en
t H
ea
lth
y 
M
ic
e
Days Post Inoculation
A/VRQ mice
ARQ mice
VRQ mice
Natural sheep scrapie CH1641 inoculated Ovine mice
0 100 200 300 400
0
25
50
75
100
Pe
rc
en
t H
ea
lth
y 
M
ic
e
Days Post Inoculation
ARQ mice
VRQ mice
SSBP/1 CH1641 
Tg(OvPrP-A136)3533
+/- 
Tg(OvPrP-V136)4166
+/- 
Tg(OvPrP-A/V136) 
 
 
147 
Figure 4.7. Tg(OvPrP) mice expressing A136, V136 or A and V136 showed 
different susceptibilities to SSBP/1 and CH1641. A. Survival curves of 
SSBP/1-inoculated Tg(OvPrP-A136)3533+/-, Tg(OvPrP-V136)4166+/- and 
Tg(OvPrP-A/V136) mice were shown. The mean incubation time for Tg(OvPrP-
A136)3533+/- and Tg(OvPrP-V136) 4166+/- are 412 ± 49 days post inoculation 
(dpi) (attack rate, 6/6) and 132 ± 2 dpi (attack rate, 8/8), respectively. SSBP/1-
inoculated Tg(OvPrP-A/V136) mice heterozygous for A and V at codon 136 
developed disease with a shorter incubation time at 105 ± 5 dpi (attack rate, 7/7). 
The Log-rank test analysis showed that each incubation time was statistically 
different (p<0.0001).  B. Survival curves of CH1641-inoculated Tg(OvPrP-
A136)3533+/-and Tg(OvPrP-V136)4166+/- mice are presented. Unlike SSBP/1, 
CH1641-inoculated Tg(OvPrP-V136)4166+/- mice (n = 5) failed to develop 
disease at > 450 dpi. CH1641-inoculated Tg(OvPrP-A136)3533+/- mice 
developed disease at 310  21 dpi (attack rate, 6/6). The above data shows the 
susceptibility of SSBP/1 and CH1641 to Tg(OvPrP) mice is associated with the 
136 polymorphism. C. The expression levels of PrP in Tg(OvPrP-A136)3533+/-, 
Tg(OvPrP-V136)4166+/- and Tg(OvPrP-A/V136) mouse brains were examined 
through comparison with wild-type FVB mice on western blotting using mAb 6H4. 
Tg(OvPrP-A136)3533+/- mice express 30% higher levels of PrP, and Tg(OvPrP-
V136)4166+/- mice express 35% lower levels of PrP. The levels of PrP were 23% 
higher in heterozygous Tg(OvPrP-A/V136) mice compared to FVB mice. The 
concentrations of total protein were standardized to 60, 30 and 15 µg per lane. A 
FVB Prnp0/0 (KO) was used as a negative control. Molecular markers indicate 36, 
28 and 19 kDa from top to bottom. 
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Figure 4.8. Ample signals of PrPSc-A136 were observed in SSBP/1-
inoculated Tg(OvPrP-A/V136) heterozygous mouse brains. Western blotting 
analyses show that protease-resistant OvPrPSc was accumulated in the SSBP/1-
inoculated brains from Tg(OvPrP-A136)3533+/-, Tg(OvPrP-V136)4166+/- and 
Tg(OvPrP-A/V136) mice. A. Both OvPrP-A136 and OvPrP-V136 alleles were 
shown on the blot with mAb 6H4. Three samples from each group are shown and 
all included PrPSc in the brains. B. OvPrP-A136 but not OvPrP-V136 alleles was 
shown on the blot with mAb PRC5. Interestingly, OvPrPSc-A136 was 
accumulated in SSBP/1-inoculated Tg(OvPrP-A/V136) mouse brains (lane 10-
12), indicating that OvPrP-A136 was already converted to PrPSc at 105 ± 5 dpi. It 
is important to note that SSBP/1-inoculated Tg(OvPrP-A136)3533+/- mice 
required much longer incubation time to develop disease at 412 ± 49 dpi (Figure 
4.7.A.). Proteinase K (PK) digested (+) and undigested (-) samples were 
analyzed. Lane1, PK(-) Prnp knockout FVB (KO); lane 2, PK(-) Tg(OvPrP-
A136)3533+/-; lane 3, PK(-) Tg(OvPrP-V136)4166+/-; lane 4-6, PK(+) Tg(OvPrP-
A136)3533+/-; lane 7-9, PK(+) Tg(OvPrP-V136)4166+/-; lane 10-12, PK(+) 
Tg(OvPrP-AV136). Molecular marker indicates 53, 36, 28 and 19 kDa from top to 
bottom.    
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Figure 4.9. OvPrPSc-A136 acquires properties of OvPrPSc-V136 in SSBP/1 
diseased Tg(OvPrP-A/V136) mice. Histoblots were treated with proteinase K 
(PK) and determined with either mAb 6H4 or PRC5. Punctate deposition of 
OvPrPSc-A136 was observed in SSBP/1-inoculated Tg(OvPrP-A136)3533+/- 
mouse brains at the levels of the mid-brain, pons and oblongata (left images). On 
the other hand, diffused deposition patterns were observed in SSBP/1-inoculated 
Tg(OvPrP-V136)4166+/- mouse brains (second from right images). As shown in 
the previous western blots (Figure 4.8.), the conversion of OvPrPSc-A136 allele in 
SSBP/1-inoculated Tg(OvPrP-A/V136) heterozygous mouse brains was 
observed in histoblots as well. The histoblot data revealed that deposition 
patterns of OvPrPSc-A136 were diffused and identical to OvPrPSc-V136 under the 
state of co-expression of A136 and V136 (right images), indicating the 
recruitment of PrPC-A136 by PrPSc-V136.  
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Figure 4.10. OvPrP-A136 allele was converted to PrPSc only in the presence 
of OvPrP-V136 allele by PMCA with SSBP/1-V136 seed. SSBP/1 diseased 
Tg(OvPrP-V136)4166+/- mouse brains were used as SSBP/1-V136 seed. Brain 
homogenates from healthy Tg(OvPrP-A136)3533+/- (A, D) and Tg(OvPrP-
V136)4166+/- (B, E) mice were mixed with the SSBP/1-V136 seed. A mixture of 
brain homogenates from Tg(OvPrP-A136)3533+/- and Tg(OvPrP-V136)4166+/- 
mice at the ratio corresponding to equal PrP expression levels was prepared and 
mixed with the SSBP/1-V136 seed (C, F). Amplified (A) and 37°C incubated 
control (C) samples were collected every 2 hours in the total of 12 hours of 
PMCA (48 cycles). The samples were digested with PK and analyzed for PrPSc 
conversion on western blots along with controls including undigested (-) 
substrates (lane 1), digested (+, lane 2) and undigested (lane 3) seed. In addition 
to those controls, PMCA reactions without seed were also prepared, and those 
samples were digested with PK (lanes 4, 5). Western blots A, B and C were 
probed with mAb 6H4 showing a total PrPSc, and blots D, E and F were probed 
with mAb PRC5 presenting only OvPrPSc-A136. Unsuccessful amplification of 
OvPrPSc-A136 was observed in OvPrP-A136 substrate alone (A, D). On the other 
hand, OvPrP-V136 allele was efficiently converted to PrPSc (B). The mixture of 
OvPrP-A136 and OvPrP-V136 showed amplification of PrPSc (C, F). Those data 
showed that amplification of OvPrPSc-A136 was observed only in the presence of 
OvPrP-V136 alleles with SSBP/1-V136 (F), indicating that the recruitment of 
OvPrPC-A136 by OvPrPSc-V136 promotes the OvPrPSc-A136 conversion. 
Molecular marker indicates 53, 36, 28 and 19 kDa from top to bottom.    
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Figure 4.11. Conversion of OvPrPSc-V136 appears to take place followed by 
conversion of OvPrPSc-A136 in PMCA with SSBP/1-V136 seed. Three 
independent experiments of PMCA with SSBP/1-V136 were performed, and 
three experimental data were plotted in the graph. Amplified PrPSc signals were 
normalized to signals of 37°C incubated controls at the same time points. 
Normalized PrPSc signals on western blots with mAb 6H4 presenting a total PrPSc 
 
were shown in solid lines. Normalized PrPSc signals on western blots with PRC5 
presenting only OvPrP-A136 are plotted in dashed lines. The gradual increase of 
amplified OvPrPSc-V136 is evidenced in PMCA reactions with OvPrP-V136 
substrate alone (blue solid line). Unsuccessful amplification of OvPrPSc-A136 is 
observed in reactions with OvPrP-A136 substrate alone (pink solid and dashed 
lines). However, amplification of OvPrPSc-A136 was observed only when 
OvPrPSc-V136 was co-existed in PMCA reactions, indicating that the recruitment 
of OvPrPC-A136 by OvPrPSc-V136 promotes the OvPrPSc-A136 conversion. Error 
bars indicate standard errors of the mean. Statistical analyses were performed at 
fixed time points (2, 4, 6, 8, 10 or 12 hours separately) using a one-way ANOVA, 
and asterisks at 10 hours (**p<0.0016) and 12 hours (*p<0.01) indicate 
significant difference. A Newman-Keuls multiple comparison post-hoc test 
showed the following groups are statistically significant at 10 hours: A/V136-
PRC5 vs. A/V136-6H4. Moreover, the Newman-Keuls reported that the following 
groups are also statistically significant at 12 hours: A/V136-PRC5 vs. V136-6H4.  
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Figure 4.12. PMCA of SSBP/1-A136 produced successful conversion of 
PrPSc only with OvPrPC-A136 substrate. PMCA of SSBP/1-A136 was 
performed in serial dilutions of seed to substrate to see whether PrPSc could be 
amplified after 98 cycles (48 hours). The amplification of SSBP/1-A136 seed to 
OvPrPC-A136 substrate at 1:30, 1:90, 1:270 and 1:810 dilutions was able to 
produce PrPSc (A. and D). However, inefficient amplification of PrPSc-V136 was 
observed at 1:90 and 1:270 dilutions (B). PrPSc signals at 1:30 dilution (B and E) 
were most likely coming from the seed SSBP/1-A136. Since OvPrPSc-V136 
would not be recognized by mAb PRC5, the amplified signal on the western blot 
probed with mAb PRC5 indicated that PrPSc signals at 1:30 dilution were from the 
seed. Under the co-presence of OvPrP-A136 and OvPrP-V136 alleles, the PrPSc 
conversion was not as efficient as the amplification with OvPrPC-A136 alone. 
Some amplification of PrPSc was observed at 1:30 and 1:90 dilutions, but no 
amplification of PrPSc was detected at 1:270 and 1:810 dilutions (C and F). These 
data indicated that PMCA of SSBP/1-A136 was able to amplify PrPSc with 
OvPrPC-A136 compared to OvPrPC-V136 or the mixture of both. Lanes 1: 
undigested substrate, 2: undigested seed, 3: PK-digested seed, 4: PMCA 
reaction without seed (No seed) incubated at 37°C without sonication, 5: No seed 
incubated at 37°C with sonication, 6-13: PMCA samples at multiple dilutions. 
PMCA samples (lanes 4 to 13) were digested with PK. Molecular marker 
indicates 53, 36, 28 and 19 KDa from top to bottom. 
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Figure 4.13. PrPSc conversion models of SSBP/1 in Tg(OvPrP) expressing 
both A and V 136 polymorphism: a dominant OvPrPSc-V136 conformation 
leading to forced templating of OvPrPC-A136. The above-proposed models 
are based on the heterodimer template-associated model. In the models, PrPC is 
in equilibrium with an intermediate form of PrP*, and the formation of PrP* is 
thought to be facilitated by a hypothetical protein X. The conversion of PrP* to 
PrPSc is a catalytic step, and the operative catalyst might be protein X or other 
molecules. It is important to note that natural sheep scrapie isolate SSBP/1 
consists of mainly a VRQ genotype, however, it is a pool of multiple combinations 
of genotypes, suggesting that different conformations of PrPSc are available in 
the isolate (a box on the top right corner). The first model indicates that the 
conversion of OvPrPSc-V136 is efficient with the genotype matched SSBP/1-
V136, therefore, the survival time of SSBP/1-inoculated Tg(OvPrP-V136) mice is 
relatively shorter than Tg(OvPrP-A136) mice. The second model describes that 
the propagation of SSBP/1-A136 with OvPrPC-A136 is not as efficient a process 
as the propagation of SSBP/1-V136 with OvPrPC-V136 even though the 
genotypes between PrPSc and PrPC are identical. Therefore, the survival time of 
SSBP/1-inoculated Tg(OvPrP-A136) mice is much longer due to the slow 
conversion rate of OvPrPSc-A136. In those proposed models, the conformations 
of PrPSc are different between OvPrPSc-V136 (pentagon) and OvPrPSc-A136 
(triangle), inasmuch as the histoblotting data showed diffused vs. punctate 
deposition patterns of PrPSc in SSBP/1-inoculated Tg(OvPrP-V136)4166+/- and 
Tg(OvPrP-A136)3533+/- mice, respectively (Figure 4.9.). The last model explains 
when OvPrPC-A136 and OvPrPC-V136 are co-expressed, the conversion of 
OvPrPSc-V136 occurs followed by the conversion of OvPrPSc-A136. The 
intermediate forms of OvPrP*-V136 and OvPrP*-A136 interact together to 
transform the conformation of OvPrP*-A136 into the conformation of OvPrP*-
V136, and the adaptation of OvPrP*-V136 conformation in PrP*-A136 allows 
SSBP/1-V136 to become a template for the conversion to PrPSc. Therefore, the 
conformation of OvPrPSc-A136 is identical to OvPrPSc-V136. In the last proposed 
model, the conversion of OvPrPSc-A136 is promoted by the presence of other 
allele V136, and the conversion of both alleles can promote quicker development 
of disease in SSBP/1-inoculated Tg(OvPrP-A/V136) mice as compared to 
Tg(OvPrP-V136) mice. 
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Figure 4.14. Presence of OvPrPC-V136 inhibits the amplification of OvPrPSc-
A136 in PMCA with CH1641-A136 seed. PMCA of CH1641-A136 seed with 
OvPrP-A136, OvPrP-V136 and the mixture of both was performed. Brain 
homogenates from CH1641-inoculated Tg(OvPrP-A136)3533+/- mice was used 
as CH1641-A136 seed and mixed with brain homogenates from healthy 
Tg(OvPrP-A136)3533+/- (A, D) and Tg(OvPrP-V136)4166+/- (B, E) mice. A mixture 
of brain homogenates from Tg(OvPrP-A136)3533+/- and Tg(OvPrP-V136)4166+/- 
mice at the ratio corresponding to equal PrP expression levels was prepared and 
amplified with CH1641-A136 (C, F). The amplified samples were collected every 
12 hours in a total of 48 hours amplification to study the rate of PrPSc conversion. 
The genotyped matched reaction of CH1641-A136 seed and OvPrPC-A136 
substrate produced OvPrPSc-A136 efficiently (A and D). However, inefficient 
amplification of OvPrPSc-V136 was observed with PMCA of CH1641-A136 (B). 
When two substrates were mixed, reduced amplification of OvPrPSc in PMCA of 
CH1641-A136 was observed (C and F). The western blot with mAb PRC5 
showing only OvPrPSc-A136 allele displayed that the efficiency of OvPrPSc-A136 
conversion was reduced remarkably (F). Samples incubated at 37°C without 
sonication was used as control (C), and letter A indicates PMCA amplified 
samples at 37°C with sonication. Lane 1, PK undigested (-) substrate OvPrP-
A136 (A, D), OvPrP-V136 (B, E) and mixture of OvPrP-A136 and OvPrP-V136 at 
1:2 dilution (C, F); lane 2 and 3, PK (-) and digested (+) CH1641-A136 seed, 
respectively; lane 4 and 5, digested PMCA reaction sample without seed (No 
seed); lane 6-13, PK(-) and PK(+) PMCA samples. Molecular marker indicates 
53, 36, 28 and 19 KDa from top to bottom.  
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Figure 4.15. The OvPrPC-V136 allele suppressed the conversion of PrPSc-
A136 in the presence of the both alleles in PMCA with CH1641 seed. PMCA 
of CH1641-A136 seed with OvPrP-A136, OvPrP-V136 and the mixture of both 
was performed independently, twice, to examine the compatibility of the seed and 
substrates for the conversion of PrPSc. Two independent experiments were 
plotted in the graph. The signals of amplified PrPSc was normalized to the signals 
of 37°C incubated control in the same time points. The X-axis indicated a 
duration of PMCA cycles in a total of 48 hours. Samples were collected every 12 
hours. The Y-axis indicates the value of normalized PrPSc signals. Solid lines are 
normalized PrPSc signals from western blots with mAb 6H4 showing a total signal 
of PrPSc. Dashed lines are normalized PrPSc signals from western blots with mAb 
PRC5 showing only OvPrPSc-A136. The efficient amplification of OvPrPSc-A136 
(pink solid and dashed lines) and inefficient amplification of OvPrPSc-V136 (blue 
solid line) were observed. The green dashed line shows inefficient amplification 
of PrPSc-A136 in the presence of OvPrP-V136. Statistical analyses were 
performed at fixed time points (12, 24, 36 or 48 hours separately) using a one-
way ANOVA and showed significant difference indicating with an asterisk at 24 
hours (*p<0.013). A Newman-Keuls multiple comparison post-hoc test showed 
the following groups are statistically significant at 24 hours: A/V136-PRC5 vs. 
A136-PRC5 and A/V136-6H4 vs. A136-PRC5. 
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Figure 4.16. PrPSc conversion models of CH1641 in Tg(OvPrP) expressing 
A136V polymorphism: an inhibitory effect of OvPrPC-V136 on the 
propagation of OvPrPSc-A136. The above-proposed models are based on the 
heterodimer template-associated model. In the models, PrPC is in equilibrium 
with an intermediate form of PrP*, and the formation of PrP* is thought to be 
facilitated by a hypothetical protein X. The conversion of PrP* to PrPSc is a 
catalytic step, and the operative catalyst might be protein X or other molecules. It 
is important to note that natural sheep scrapie isolate CH1641 consists of mainly 
a A136 genotype, however, it is a pool of multiple combinations of genotypes, 
suggesting that different conformations of PrPSc are available in the isolate (a box 
on the right bottom corner). The first model describes that CH1641-A136 is able 
to propagate OvPrPSc-A136 from OvPrP*-A136. The second model shows that 
the conversion of OvPrPSc-V136 can happen but the process is inefficient. 
OvPrPSc-V136 might be cleared by a cellular mechanism as soon as PrPSc is 
produced. In addition, the rate of PrPSc conversion is slow enough that the 
cellular mechanism is able to remove PrPSc before produce more PrPSc or 
aggregates. Thus, CH1641-inoculated Tg(OvPrP-V136) mice did not develop 
disease, and the accumulation of PK-resistant OvPrPSc was not observed in their 
brains. The conformation of OvPrPSc is unknown. The last model explains the 
propagation of CH1641-A136 under co-expressions of OvPrPC-A136 and 
OvPrPC-V136. The presence of OvPrPC-V136 prevents the conversion of 
OvPrPSc-A136; however, what isoforms of OvPrP-V136 among PrPC, PrP* or 
PrPSc play a role in an inhibitory effect on the conversion of PrPSc is not clear. 
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Figure 4.17. 3D structures of ovine PrP expressing either A or V 136 
polymorphism. The structures of OvPrPA-136 and OvPrP-V136 corresponding 
to amino acid residues 114-228 were visualized in VMD. Each of the structures 
includes the disordered N-terminal structure and three α-helices (H1-3) 
shown in red ribbons. The top molecule is ovine PrP (residues 114-228) 
expressing alanine at codon 136. The bottom molecule is ovine PrP (residues 
114-228) expressing valine at codon 136. OvPrP 136 polymorphism either 
alanine (top) or valine (bottom) are shown in green. 
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Figure 4.18. Composed 3D structures of ovine PrP expressing 136 
polymorphism either alanine or valine. When the structures of OvPrPA-136 
and OvPrP-V136 (residues 114-228) were superimposed, the composed image 
showed that the two structures were not aligned exactly the same. The most 
apparent difference between two OvPrP structures was the orientation of Y at 
codon 228 in the C-terminal region (indicated in a yellow circle). Tyrosine at 
codon 228 in the C-terminal region is facing down to locate in close proximity to 
the β2-α2 loop in OvPrP-V136 but not OvPrP-A136. In OvPrP-V136, the ring 
structure of Y228 at the C-terminal region faced down and was positioned in 
close proximity to the loop between the β2-sheet and α2-helix, suggesting the 
long-range interaction of the Y at codon 228 and β2-α2 loop. On the other hand, 
the ring structure of Y228 flipped away from the β2-α2 loop in OvPrP-A136. 
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Figure 4.19. Ribbon diagrams of the C-terminal domain of OvPrP (residues 
114-228). A green circle indicates the location of codon 136. Blue dashed lines 
indicate intramolecular hydrogen bonds. A. OvPrP-A136. B. OvPrP-V136. C. 
Superimposed images of OvPrP-A136 and OvPrP-V136 are enlarged at the α-
helix 1 (H-1). The subtle differences between OvPrP-A136 and OvPrP-V136 
were found in the structures of three α-helices (H-1, H-2 and H-3), and most 
conformational changes were concentrated in H-1. The N-terminal of H-1 was 
relaxed and C-terminal of H-1 opened up in OvPrP-A136; therefore, the diameter 
of H-1 in OvPrP-V136 was relatively smaller than OvPrP-A136. In addition, the 
N-terminal of H-1 had less twist in OvPrP-A136. The difference in H-2 was that 
the C-terminus had an additional twist in OvPrP-V136 but not OvPrP-A136 
(Figure 4.19.A and B.). In more detail, the conformational differences were found 
in the orientation of the following amino acid residues: asparagine at codon 147 
and glutamic acid at codon 155 in H-1, asparagine at codon 176 and lysine at 
codon 188 in H-2, glutamic acid at codon 203 in H-3 and Y at codon 228. 
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Figure 4.20. Comparison of intramolecular hydrogen bonding in ovine PrP 
(residues 114-228) with 136 polymorphism either alanine or valine. Blue 
dashed lines indicate intramolecular hydrogen bonding. A. OvPrP-A136. B. 
OvPrP-V136. Differences are found especially in the N- or C-terminal of three α-
helices. The diagram was generated using VMD.   
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Chapter 5 
Unaltered prion protein expression in Alzheimer disease patients 
Published in Prion, 5:2, 109-116; April/May/June 2011 
 
Introduction 
For many years, the overlapping clinical, pathological and biochemical 
characteristics of Alzheimer’s and prion diseases suggested a shared pathogenic 
mechanism. The prion protein (PrP) and the amyloid β (Aβ) peptide, derived from 
the amyloid precursor protein (APP), both undergo structural transitions 
associated with a gain of toxic function leading to neurodegeneration (Prusiner, 
1998). APP and PrP are directly or indirectly associated on the cell surface 
(Schmitt-Ulms et al., 2004), and there are similarities in the post-translational 
processing of both proteins. Analogous to the α-secretase cleavage of APP, PrPC 
undergoes proteolytic cleavage at amino acids 110/111 to produce a 17-kDa 
carboxyl-terminal fragment referred to as C1 (Chen et al., 1995) by the possible 
action of TNFα-converting enzyme (TACE) or members of the ADAM (α 
disintegrin and metalloprotease) family. PrP cleavage following residue 89 results 
in the formation of an approximately 21 kDa carboxy-terminal C2 fragment, 
which, in infected brains, is resistant to protease digestion and appears to be 
facilitated by calpain (Yadavalli et al., 2004). These two cleavage sites flank the 
amino acid charge cluster in the central domain where oligomeric Aβ has been 
proposed to bind PrPC (Lauren et al., 2009). Both proteins contain conserved 
histidine metal-binding domains, GxxxG transmembrane recognition motifs and 
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histidine-based high-affinity metal-binding sites, which favor the binding of 
transition metals. Related to this, oxidative stress has been implicated in AD 
(Martins et al., 1986) and prion disease (Brazier et al., 2006).  
There is now convincing evidence that amplification of Aβ aggregates 
occurs by a prion-like mechanism (Eisele et al., 2010; Eisele et al., 2009; Meyer-
Luehmann et al., 2006). Moreover, prion infection is associated and formic acid-
extractable Aβ1-42 peptide levels are higher, in transgenic mice expressing 
mutant APP (Tg2576 mice) compared to non-transgenic controls (Baier et al., 
2008), suggesting that cross-seeding of the two abnormally conformed proteins 
may occur. In line which this observation, the brains of diseased scrapie-infected 
wild-type mice also contain increase levels of the Aβ1-41 peptide (Parkin et al., 
2007). Conformational templating also appears to occur in other protein 
misfolding diseases (Brundin et al., 2010) involving tau (Frost et al., 2009), α-
synuclein (Desplats et al., 2009) and polyglutamine proteins (Ren et al., 2009). 
Although soluble oligomeric forms of the Aβ peptide, derived from APP, 
are proposed as key mediators of synaptic and cognitive dysfunction in AD, the 
mechanisms by which these events occur remain unclear. Several recent studies 
suggest a direct mechanistic link between PrP and the Aβ peptide in AD 
pathogenesis. The studies of Strittmatter and co-workers implicated PrPC as a 
major receptor for synthetic soluble Aβ1-42 oligomers, and indicated that PrPC 
mediates the deleterious effects of oligomeric Aβ1-42 on synaptic function 
(Lauren et al., 2009). Soluble Aβ1-42 oligomer binding was shown to occur at 
amino-acid residues 95–110 of PrP, a region close to the PRNP 
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methionine/valine codon 129 polymorphism, which has numerous important 
influences on human prion diseases, and is also implicated as a risk factor for 
early-onset AD (Del Bo et al., 2006; Riemenschneider et al., 2004). In 
subsequent studies, this group demonstrated a requirement for PrP expression 
for axonal degeneration, loss of synaptic markers, early death, and learning and 
memory deficits in AD transgenic mice (Gimbel et al., 2010).  
While the foregoing findings implicate PrP as a potential therapeutic target 
in AD, other studies have been less supportive of this concept. In independent 
transgenic mouse studies, ablation or overexpression of PrPC had no effect on 
impairment of hippocampal synaptic plasticity (Calella et al., 2010). Moreover, 
while the interaction of Aβ1–42 oligomers with PrPC was confirmed in separate 
studies, both PrP-expressing and PrP knockout mice were equally impaired in 
hippocampal dependent behavioral tests following intracerebroventricular 
injections of synthetic Aβ1–42 oligomers (Balducci et al.). Finally, other studies in 
which overexpression of PrP in vitro was shown to negatively regulate β-
secretase (Parkin et al., 2007) would appear to be consistent with a model in 
which high levels of PrP result in low levels of Aβ1-42 oligomers. 
Here we performed an extensive analysis of PrP levels in AD and pre-AD 
patients to address the hypothesis that variable PrPC expression is involved in 
AD pathogenesis.  
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Materials and Methods 
Patients. Frozen samples of hippocampus, superior frontal cortex (BA9) and 
superior-middle temporal cortex (BA21-22) were obtained from the University of 
Kentucky Rapid Autopsy Program of the Alzheimer's Disease Clinical Center 
(UKADC). Tissue was examined from 37 individuals with a mean age of 86.7 ± 
7.6 years (Table 5.1.) were examined. These individuals were part of a 
longitudinal clinical-pathologic study of aging and AD at the UKADC (Davis et al., 
1999; Schmitt et al., 2000). The Human Investigations Committee at the 
University of Kentucky College of Medicine approved the studies. Individuals 
included in these studies agreed to annual clinical evaluation and brain donation 
at the time of death. For all subjects, cognitive test scores were available within 
the last year of life; the average interval from last evaluation to time of death was 
7.0 ±3.6 months, with no differences among the three diagnostic groups (p < 
0.1). Subjects were categorized as no cognitive impairment (NCI; n = 13), 
amnestic mild cognitive impairment (aMCI; n = 7), mild Alzheimer disease (mAD; 
n=6), or AD (n = 11) (Petersen, 2004), based on cognitive testing prior to death. 
The NCI subjects were without a history of dementia or other neurological 
disorders. Standard criteria for exclusion were the presence of (1) significant 
cerebral stroke regardless of antemortem date, (2) large cortical infarcts 
identified in the postmortem neuropathologic evaluation, (3) significant trauma 
within 12 months before autopsy, (4) individuals on a respirator longer than 12 
hours before death, (5) individuals in coma longer than 12 hours immediately 
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before death, (6) individuals currently undergoing radiation therapy for CNS 
tumor, or (7) individuals with Lewy bodies.  
Details of the UKADC have been published elsewhere in reference 
(Schmitt et al., 2000). All subjects have detailed mental status testing annually, 
and have neurologic and physical examinations annually. Subjects had been 
followed for 1-14 years (median 8.2 years). Once a subject transitioned to having 
aMCI or mAD, they received the mental status test battery and neurologic 
evaluation every 6-9 months. The 7 subjects with aMCI, 6 with mAD, and 11 with 
AD were initially normal on enrollment into the longitudinal study and later 
developed aMCI and AD during follow-up. All aMCI subjects were amnestic 
without multi domain involvement. The diagnosis of aMCI, mAD, AD and NCI 
were defined by consensus conference. Histological examination of NCI subjects 
showed only age-related changes and Braak stage score of 0-II, meeting the 
NIA-RI low-likelihood criteria for the histopathologic diagnosis of AD. The clinical 
criteria for diagnosis of aMCI included (1) memory complaints, (2) intact activities 
of daily living, (3) objective memory impairment for age and education, (4) failure 
to meet criteria for dementia, and (5) a clinical dementia rating (CDR) scale score 
of 0.5. The Braak stage scores had a range of I-V. Clinical progression to AD 
was diagnostically characterized by (1) a decline in cognitive functions from a 
previous higher level, (2) decline in one or more areas of cognition in addition to 
memory, (3) impaired activities of daily living, (4) a CDR score between 0.5-1, 
and (5) a clinical evaluation that excludes other causes of dementia. The criteria 
for mAD subjects included the above clinical progression plus a histopathologic 
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diagnosis that included a Braak stage score of II-VI. For an AD categorization, 
subjects demonstrated a more progressive intellectual decline as described 
above, a MMSE less than that of the mAD cohort, and Braak scores of II-VI. 
None of the mAD subjects were considered to be at the end-stage of the disease 
progression.  
 
Transgenic mice. Tg(HuPrP-M129)6812+/- mice and Tg(HuPrP-V129)7823+/- 
mice express human PrP encoding either M or V at codon 129, referred as 
HuPrP-M129 and HuPrP-V129, respectively (Kurt et al., 2009). Transgenic lines 
were maintained by breeding with Prnp0/0 mice maintained on an FVB 
background (FVB/Prnp0/0) and transgenic offspring were identified by tail biopsy 
and extraction of genomic DNA using a Beckman Biomek FX robotic station 
followed by PCR screening for the presence of the transgene. Approximately, 1 
cm of tail tissue was digested overnight at 55°C with proteinase K (0.5 mg/ml 
final concentration) in 50 mM Tris pH 8.0, 100 mM EDTA, 0.5% SDS, the DNA 
extracted with phenol and chloroform and concentrated by ethanol precipitation. 
 
Analysis of the PRNP codon 129 polymorphism. Genomic DNA was extracted 
from brain homogenates of the 37 individuals. The sense primer (5’-
ATGGCGAACCTTGGCTGCTGGATGC-3‘) and antisense primer (5’-
GTGGTTGTGGTGACCGTGTGCTGCTTGAT-3') were used to amplify the PRNP 
cording sequence using PCR. The PRNP codon 129 polymorphism was 
assessed by digestion of the amplicons with endonucleases NspI (New England 
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Biolabs. Inc.) and MaeII (HpyCH4IV, New England Biolabs. Inc.), and the 
digested products were analyzed on 1.2% agarose gels.     
  
Western Blotting. 10% brain homogenates were prepared in sterile phosphate 
buffered saline (PBS) lacking Ca2+ and Mg2+ ions. The concentration of a total 
protein in each sample was determined by bicinchoninic acid assay and 
standardized for each lane (5 µg per lane).  Proteins were resolved by sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to 
polyvinylidene difluoride Immobilon-FL membranes (Millipore). The transferred 
membrane was blocked with 5% non-fat milk in 0.5% Tween-20 in Tris-buffered 
saline (TBST) and immunoprobed with mouse monoclonal antibody anti-PrP 6H4 
(Prionics) and 3F4 (Covance) followed by horseradish peroxidase–conjugated 
anti-mouse secondary antibody. Proteins were visualized using ECL Plus (GE 
Healthcare) in an FLA-5000 scanner (Fujifilm Life Science). Anti-actin (Pan) Ab-5 
monoclonal antibody (NeoMarkers) was used as an internal control. 
 
Statistical analysis. Statistical analysis of western blot data from the frontal and 
temporal cortices and hippocampus of NCI, aMCI, mAD and AD was performed 
using a one-way ANOVA for each region separately. When appropriate, 
differences between groups were probed using a Newman-Keuls post hoc test. 
Each histogram of PrPC in western blots was read by MultiGauge (Fujifilm Life 
Science) and the values were standardized against the histogram value of actin. 
All data were analyzed with GraphPad Prism 4 and values were expressed as 
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mean standard deviation. Differences with P < 0.05 was considered to be a 
significant and indicated with asterisks.  
 
Results and Discussion 
Table 5.1. summarizes patient characteristics by diagnostic group. Included in 
our studies were 13 individuals with NCI, 7 patients with aMCI, 6 with mAD, and 
11 with AD. Braak and CERAD scores were determined for all samples (Tables 
5.2. and Table 5.3.). Age, post-mortem interval (PMI), and brain weight were 
similar among the various groups (Table 5.1.). Differences in mini-mental state 
examination (MMSE) scores were highly significant between groups [F(3,33) = 
88.853, p < 0.0001]. Post hoc comparisons using the student Newman-Keuls test 
showed statistically significant differences between NCI and aMCI (p < 0.05), 
between aMCI and mAD (p < 0.05), and between mAD and AD groups (p < 
0.05). All dementia groups showed lower MMSE scores than NCI. Both AD 
groups showed lower scores than aMCI patients, while the AD group showed 
lower scores than mAD (Table 5.1.).  
In addition to its important influence on human prion diseases (Wadsworth 
et al., 2004), the methionine (M)/valine (V) polymorphism at codon 129 of the 
human PrP gene (PRNP) has also been implicated as a risk factor for early-onset 
AD (Del Bo et al., 2006; Riemenschneider et al., 2004), although its influence as 
a risk factor for AD has been challenged (Li et al., 2005). Analysis of this 
polymorphism is also important given its close proximity to the proposed region 
of Aβ1-42 oligomer binding (Lauren et al., 2009). We analyzed codon 129 
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genotypes by treating PCR amplified patient genomic DNA samples with NspI or 
MaeII restriction endonucleases (Figure 5.1.A and B) to distinguish PRNP coding 
sequence restriction fragment length polymorphisms (RFLPs) produced by the M 
and V codons. The PRNP M129 and V129 allele frequencies were approximately 
77% and 23% respectively in the NCI group compared to 71% and 29% in the 
cognitively impaired groups. Valine homozygosity was not observed in the NCI 
group (Table 5.4.). A previous association of 129V homozygosity and increased 
risk of early-onset AD was reported in a Dutch population (Dermaut et al., 2003). 
The mean age in each AD group in the current study is over 80 (Table 5.1.). The 
period of follow up for patients was up to 14 years with a mean of 8 years 
approximately, raising the possibility that some case may have been younger 
onset. Nonetheless, patient numbers in our study are too small to draw definitive 
conclusions.  
To examine a possible relationship between cognitive decline and PrPC 
expression, brain homogenates were prepared from frozen samples of 
hippocampus, superior frontal cortex (BA9) and superior-middle temporal cortex 
(BA21-22) of NCI, aMCI, mAD and AD patients, and immunoblots of samples 
containing equivalent total protein levels were probed with either anti-PrP 
monoclonal antibodies (mAb) 6H4 or 3F4. Levels of PrP in these preparations 
were determined by densitometric analysis of western blots using actin levels as 
an internal control in each sample. While we observed a tendency of diminished 
PrP levels in rostral compared to caudal areas when immunoblots were probed 
with mAb 6H4, regional differences were not significant, and rostrocaudal 
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decreases in PrPC were not confirmed when the experiment was repeated using 
mAb 3F4 (Figure 5. 2.).  
Western blot analysis using both mAb 6H4 and 3F4 showed that 
expression of PrPC was not significantly altered among NCI compared to aMCI, 
mAD or AD in either the frontal and temporal cortices or hippocampus (Figure 5. 
3.). Levels of unglycosylated PrP were not higher in AD compared to control 
cases, although there was a tendency for higher levels of aglycosyl PrPC levels in 
the temporal cortex of aMCI patients compared to other study groups, and when 
measured with mAb 3F4 levels were significantly higher in temporal cortex of 
aMCI compared to NCI and AD patients (Figure 5.4.). PrPC expression levels 
were also independent of PRNP codon 129 genotype (Figure 5.5.). 
Our results appeared to be in general disagreement with the central topic 
of recently published studies by Velayos and coworkers (Velayos et al., 2009) 
which indicated a tendency for lower steady state PrPC levels in the brains of AD 
patents compared to controls (Velayos et al., 2009), especially in the 
hippocampus, an outcome apparently inconsistent with previous reports of 
increased PrPC immunereactivity in the temporal cortex, hippocampus (CA2) and 
subiculum in AD patients compared to controls (Voigtlander et al., 2001). 
Although not discussed in the context of their data, the report of Valayos and 
coworkers was significant in light of recent studies implicating PrPC as a major 
receptor that mediates the deleterious effects of oligomeric Aβ1-42 on synaptic 
function (Lauren et al., 2009). Here we observed no differences in total PrPC 
levels in AD compared to NCI controls, nor did we observe a graded decrease in 
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PrP levels with increasing cognitive impairment. The minor observed differences 
between PrPC levels probed with mAb 6H4 and mAb 3F4 could be related to the 
site of the binding of these mAbs to PrP. The epitope mAb 6H4 has been 
mapped to the sequence DYEDRYYRE, corresponding to PrP residues 144-152 
(Korth et al., 1997), while the epitope for 3F4 is located in the KTNMKHM, 
corresponding to residues 106-112 (Lund et al., 2007; Rubenstein et al., 1999; 
Zou et al., 2010a). Thus, while mAb 6H4 can detect the proteolytically processed 
sub-fragment of PrPC, referred to as C1 (Chen et al., 1995), mAb 3F4 cannot. 
Because diglycosylated C1 fragments overlap with mono- and non-glycosylated 
forms of full-length PrPC, this could potentially affect quantification of PrPC levels 
and explain the discrepancy between the two mAbs.  
What could explain the discrepancies between our studies and previous 
report? Velayos and coworkers studied three patients with AD. No clinical 
information was provided, except that one AD patients also had Down syndrome. 
Western blotting of PrPC was recorded in three control human cases and two AD 
patients. In the present study, we analyzed PrPC expression in a larger cohort 
comprised of 37 individuals including 11 AD cases, 6 mAD, 7 aMCI patients and 
13 non-demented controls. All patients were well characterized by diagnostic 
group, and all samples had short post-mortem intervals (Table 5.1-3.). Our 
analysis also included actin as an internal loading control for all samples. In 
addition to mAb 6H4, which was also used in the previous study, we used a 
second thoroughly characterized mAb (3F4) with reactivity against human PrPC. 
The high numbers of well-characterized patients, and the rigorous analysis of 
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regional PrPC expression allows for meaningful associations (or lack of 
association in this case) to be made between levels of PrP and the presence of 
AD.  
Velayos and coworkers also reported a shift in the profile of PrP 
glycosylation, with the unglycosylated form predominating in AD patients 
compared to controls. While we were also unable to confirm the finding of 
increased levels of aglycosyl PrPC in AD or mAD patients, we did observe 
significantly higher levels of unglycosylated PrP in the temporal cortex of aMCI 
patients compared to NCI and AD (but not mAD) patients. Whether this change 
corresponding to a specific role for PrP expressing cells in this critical brain 
region at early stages of the development of AD, prior to the onset of significant 
neurodegeneration and neuronal loss, remains to be determined. 
In summary, we conclude that, if PrPC is involved in mediating the toxic 
effects of oligomeric Aβ, then this occurs by a mechanism that does not involve 
modulation of steady state levels of PrP. This would appear to be an important 
insight given recent associations of PrP in AD pathogenesis that implicate PrP as 
a potential therapeutic target. 
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Table 5.1. General demographics of subjects. ap < 0.05 compared to NCI. bp < 
0.05 compared to aMCI. cp <0.05 compared to mAD. Published in Prion, 5:2, 
109-116; April/May/June 2011. 
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Table 5.2. Braak scores by clinical diagnosis.  
Published in Prion, 5:2, 109-116; April/May/June 2011. 
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 Table 5.3. CERAD classification by clinical diagnosis. 
Published in Prion, 5:2, 109-116; April/May/June 2011. 
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Table 5.4. Codon 129 PRNP allele frequency and genotype of subjects. 
Published in Prion, 5:2, 109-116; April/May/June 2011. 
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Figure 5.1. Representative restriction fragment length polymorphism 
(RFLP) analyses. Lanes 1 and 2, brain extracts from Tg(HuPrP-M129)6816+/-
mice expressing human PrP-M129; lanes 3 and 4, brain extracts from Tg(HuPrP-
V129)7826+/- mice expressing human PrP-V129; lanes 5 and 6, equal mixture of 
brain extracts from transgenic mice expressing human PrP-M129 and transgenic 
mice expressing human PrP-V129; lanes 7 – 16, five representative human 
samples. Odd numbers, undigested PCR samples; even numbers, digested PCR 
samples. (A) PCR amplified samples treated with restriction enzyme NspI, which 
cleaves PRNP encoding methionine at codon 129. Methionine carriers produce a 
363 bp fragment; valine carriers produce a 438 bp fragment. (B) PCR samples 
treated with MaeII, which cleaves PRNP encoding valine at codon 129. Valine 
carriers produce a 359 bp fragment. Published in Prion, 5:2, 109-116; 
April/May/June 2011. 
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Figure 5.2. Rostrocaudal analysis of PrPC levels in NCI and AD patients. For 
all sample, levels of total PrPC and actin were measured by densitometric 
scanning of western blots. Each PrP value was normalized to its actin value. 
Normalized PrP
 
 values were compared among the frontal (F) and temporal (T) 
cortices and hippocampus (H) in NCI and AD groups. Error bars represent 
standard deviations from the mean. Published in Prion, 5:2, 109-116; 
April/May/June 2011. 
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Figure 5.3. Levels of PrPC in different brain regions of patients with 
differing levels of cognitive impairment. Representative western blot analyses 
of brain homogenates from NCI, aMCI, mAD and AD patients are shown. Anti-
PrP 6H4 (A-C) and 3F4 (D-F) antibodies were used to compare the levels of 
PrPC among the groups. Actin controls are shown below the 6H4 or 3F4 
immunoblots. NCI: lanes 1-4. aMCI: 5-8. mAD: 9-12. AD: 13-16. Three brain 
regions including the frontal (A, D, G and J), temporal (B, E, H and K) cortices 
and hippocampus (C, F, I and L) were analyzed. Molecular markers indicated are 
53, 36, 28 and 19 kDa. Graphs in (G – L) include analyses of all samples from 
each group. For each sample, levels of total PrPC were measured by 
densitometry. For each sample, levels of actin were also assessed. Each PrP 
value was normalized to its actin value. Means and standard deviations were 
calculated for each patient group and expressed as the percent value relative to 
the NCI group. Published in Prion, 5:2, 109-116; April/May/June 2011. 
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Figure 5.4. Unaltered levels of unglycosylated PrPC in AD patients 
compared to NCI individuals. Levels of unglycosylated PrPC (~ molecular 
weight 25-30 kDa) were measured by densitometric analysis of western blots. 
Means and standard deviations were calculated for samples from each patient 
group. y-axis values are arbitrary densitometric units. * indicates p< 0.05. 
Published in Prion, 5:2, 109-116; April/May/June 2011. 
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Figure 5.5. Levels of PrPC do not correlate with human PrP 129 
polymorphism in AD patients. Levels of PrPC were measured by densitometry. 
For each sample, levels of actin were also assessed. Each PrP value was 
normalized to its actin value. These values were compared among individuals 
with various PRNP genotypes (M/M, M/V, V/V). (A – C) represent the data 
analyzed with 6H4; (D – F) represent the data analyzed with 3F4. Three brain 
regions including the frontal (A and D) and temporal (B and E) cortices and 
hippocampus (C and F) were analyzed. Published in Prion, 5:2, 109-116; 
April/May/June 2011. 
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Chapter 6 
Discussion and future directions 
 
Prion diseases are caused by misfolding of a normal PrPC isoform into a 
pathogenic PrPSc isoform, and PrPSc is believed to serve as a template for PrPC 
to undergo a profound conformational structural change to become a pathogenic 
PrPSc isoform (Prusiner, 1998). Moreover, numerous studies show that the 
conversion of PrPC to PrPSc is constrained by transmission or species barriers 
between host PrPC and donor PrPSc. In Chapter 2, the species barrier between 
CWD (cervid PrPSc) and human PrPC was directly determined by inoculating 
CWD prions into Tg mice expressing human PrP encoding either M or V at codon 
129. The results showed that the species barrier between human and cervid was 
considerably high in CWD prions. To understand the species barrier of prion 
disease, the conformational selection model has been hypothesized to explain 
how the species barrier in prion disease restricts transmission of prions (Collinge, 
1999, 2010). For example, CWD1, CWD2 and CWD mix prions used in Chapter 
2, according to the conformational selection model, contain multiple PrPSc 
conformations, and each CWD prion includes the same PrPSc conformation as 
well as completely different PrPSc conformations (Figure 6.1.). Those different 
PrPSc conformations, which are unique to each CWD prion, reflect to different 
properties of CWD prions, referred to as ‘strains’. In the conformation selection 
model, host PrPC interact donor PrPSc in preference to selected sets of PrPSc 
conformations, and each species prefers different sets of PrPSc conformations. 
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For instance, HuPrPC-M129, HuPrPC-V129 and cervid PrPC prefer completely 
different sets of PrPSc conformations to facilitate conversion of PrPC to PrPSc 
(Figure 6.1.). CWD contains the PrPSc conformations, which are preferred by 
cervid PrPC, therefore, donor CWD PrPSc could convert cervid PrPC into PrPSc 
resulting in accumulation of proteinase-resistant PrPSc and development of 
disease. On the other hand, CWD prions do not contain the PrPSc conformations, 
which are preferred by HuPrP-M129 or HuPrP-V129 (Figure 6.1.). Thus, no 
accumulation of proteinase-resistant PrPSc is detected, and no disease 
development is confirmed. If HuPrPC preferred PrPSc conformations present in 
CWD prions, concentrations of the preferred PrPSc were too low to facilitate PrPSc 
conversion to reach a detectable level. Thus, the rate of PrPSc conversion by 
CWD in Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice was not be 
efficient to accumulate proteinase-resistant PrPSc in the brain. Since some of 
CWD-inoculated Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice 
presented clinical signs without accumulation of proteinase-resistant PrPSc in 
their brains, this suggest the great possibility of presence of PrPSc conformations 
preferred by HuPrP-M129 and HuPrP-V129 in CWD. This question would be 
possible to test by inoculating the brain materials from CWD-inoculated 
Tg(HuPrP-M129)6816+/- and Tg(HuPrP-V129)7826+/- mice with clinical signs into 
genotype matched Tg(HuPrP) mice. If any animals develop disease during the 
secondary passage of CWD, it suggests the presence of human PrPC preferred 
PrPSc conformations in CWD. 
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The conformational selection model proposes that PrPC preferentially 
interacts with preferred PrPSc conformations to convert itself into PrPSc, 
suggesting that interactions between host PrPC and donor PrPSc at the level of 
the tertiary structures play important roles in PrPSc conversion. The tertiary 
structure of proteins is, in general, predominantly assessed by the primary 
structure of proteins. The series of cell culture studies in Chapter 3 tested 
whether modifying the primary structure of mouse PrPC led to alter susceptibility 
to mouse-adapted RML scrapie prion. I particularly asked that introducing 
substitutions of amino acids in specific regions of PrP where majority of 
differences among mammalian PrPs were clustered, involve in the transmission 
barrier of RML and CWD prions by identifying accumulation of proteinase-
resistant PrPSc post infection. The present in vitro data suggest that the primary 
structure of PrP encodes crucial information to fold itself into a defined tertiary 
structure to facilitate conversion of PrPSc.  
 Most cellular proteins need to be folded into correct conformations to gain 
own functions, and numerous studies have reported that molecular chaperones 
play an important role in maintaining functional protein conformations (Hartl & 
Hayer-Hartl, 2009). There has been increasing numbers of molecular 
chaperones reported to serve different functions in protein folding (Hartl & Hayer-
Hartl, 2009). Nonetheless, an essential function of molecular chaperones is to 
catalyze or mediate a proper folding process of proteins or to recognize 
misfolded proteins for degradation. Moreover, chaperons could provide an 
adequate space for proteins to be able to unfold and refold into a proper 
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conformation in a dynamic and busy cellular environment. It is important to note 
that molecular chaperones are defined by any molecules that interact with any 
proteins to assist and/or stabilize functional protein folding, and structures of 
molecular chaperones are not clearly defined all the time (Hartl, 1996; Hartl & 
Hayer-Hartl, 2009). 
 Protein misfolding in neurodegenerative diseases has been associated 
with molecular chaperones, and elevated levels of molecular chaperones, such 
as, heat shock proteins (HSPs) have been reported in Alzheimer’s disease, 
Parkinson’s disease and prion disease (reviewed in (Brownell et al., 2012)). For 
example, increased levels of small heat shock proteins (sHSPs) were reported in 
scrapie-affected sheep (Vidal et al., 2009), BSE-inoculated Tg mice (Tortosa et 
al., 2008), and CJD-diseased human brains, especially in neurons and glial cells 
(Renkawek et al., 1992). sHSPs are distinguished from large heat shock proteins 
by molecular weights. sHSPs bind misfolded proteins to prevent from forming 
aggregations until large heat shock proteins come to accommodate refolding 
process. Increased levels of HSPs in those neurodegenerative diseased brains 
suggest cells attempt to clear misfolded proteins or aggregates; however, the 
cellular clearance mechanism mediated by HSPs might slowly compromised over 
a long period of time, resulting in accumulation of aggregated proteins. 
 On the contrary, other group of molecular chaperones might mediate a 
misfolding process of proteins, such as PrPSc. Unidentified molecular chaperons, 
we denote ‘protein X’, might play a role in conversion of PrPSc from PrPC in 
neurons. In PrPSc conversion models including the heterodimer template-
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associated and nucleated-polymerization models (Figure 1.2.), PrPSc is 
thermodynamically stable compared to PrPC. Thus, it will be necessary to 
overcome the energy barrier for PrPSc conversion to take place (Figure 6.2.). 
Moreover, protein X might assist in unfolding, refolding and/or stabilizing proper 
conformation of PrPSc (Figure 6.2.). In addition to overcoming the energy barrier 
using a catalyst, the spontaneous conversion of PrPC to PrPSc could be induced 
by increasing concentration of PrPSc. 
The conformational selection model was introduced earlier to explain the 
species barrier, which is determined by compatible conformations between host 
PrPC and donor PrPSc. In addition to the conformational selection model, an 
unidentified catalyst or molecular chaperone, we denote hypothetical ‘protein X’ 
might paly an important role in the species barrier of prion diseases. ‘Protein X’ 
could be a species-specific molecular chaperone to facilitate PrPSc conversion. 
As a matter of fact, the Tg mouse study using a human-mouse chimera PrP 
demonstrated that Tg mice expressing human-mouse chimera PrP were 
susceptible to human prions, whereas Tg mice expressing human PrP were 
resistant to the same human prions (Telling et al., 1995). Both host PrPC and 
donor PrPSc are from humans; however, cellular factors are from mice. This Tg 
mouse study suggests that a species-specific molecular interaction is required to 
facilitate PrPSc conversion, which might be mediated by ‘protein X’. Therefore, 
the susceptibility or resistance to prions might also be determined by ‘protein X’. 
Further, ‘protein X’ could be a group of chaperones to mediate in 
unfolding, refolding and stabilizing newly synthesized PrPSc. Another possibilities 
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are that ‘protein X’ could be co-chaperone to assist a chaperone or could be one 
subunit in a functional chaperone. This one piece of subunits in chaperone might 
alter a normal function of existing chaperones to facilitate PrPSc conversion. If a 
group of molecular chaperones involves in PrPSc conversion, not all molecular 
chaperones determine the species barrier of prion diseases. Some of subunits in 
molecular chaperones might be well conserved among mammalian species, 
whereas other subunits are unique to species. Those species-specific molecular 
chaperones might play a key role in the species barrier of prion diseases. 
 The PrPSc conversion models in Figure 6.3. explain how a species-specific 
protein X determines transmission of CWD and RML prions in cervid and CWD 
and CJD prions in humans. According to the conformation selection model, host 
PrPC selects preferred PrPSc conformations to facilitate substantial 
conformational change using donor PrPSc as a template. Even though host PrPC 
finds preferred PrPSc conformation, the conversion of PrPC into PrPSc does not 
occur spontaneously without any catalysts because of the high energy barrier 
(Figure 6.2.). In order for PrPC to become PrPSc resulting in disease development 
within a host lifespan or within a certain period of time, a catalyst or molecular 
chaperone becomes essential to facilitate PrPSc conversion by lowering the 
energy barrier. An unidentified catalyst or molecular chaperone ‘protein X’ is a 
species-specific in the proposed conversion models (Figure 6.3.). For example, 
cervid carries a cervid-specific chaperone, and the cervid-specific chaperone 
might be completely different from a chaperone found in humans. A cervid-
specific chaperone could facilitate the conversion of cervid PrPC with cervid 
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preferred PrPSc and stabilize newly synthesized PrPSc (Figure 6.3.A). On the 
other hand, mouse adapted RML scrapie prion dose not contain cervid PrPC 
preferred PrPSc conformations, and the cervid-specific chaperone could not 
mediate PrPSc conversion (Figure 6.3.B). As a result, RML prion could not 
produce PrPSc and disease in cervid. CWD prions do not contain human PrPC 
(HuPrPC) preferred PrPSc conformations, further, a human-specific protein X 
could not facilitate PrPSc conversion (Figure 6.3.C). Thus, CWD prions failed to 
develop disease in humans. When HuPrPC find preferred PrPSc conformations, 
such as, CJD prions, HuPrPSc conversion occurs (Figure 6.3.D). A human-
specific protein X could facilitate PrPSc conversion, as a result, humans develop 
CJD. 
 The rabbit epithelial kidney (RK13) cell culture system was used to test 
whether altering amino acids in specific regions of mouse PrP altered 
susceptibility to species matched prion (mouse adapted RML scrapie prion) in 
Chapter 3. RK13 cells expressing a wild-type mouse PrPC (RKM cells) are highly 
susceptible to mouse adapted scrapie RML prion (Figure 6.4.A). However, RKM 
cells are not susceptible to CWD because PrPSc conformations in CWD are not 
mouse PrPC preferred PrPSc conformations (Figure 6.4.B). The series of cell 
culture studies in Chapter 3 suggest that altering even one amino acid in specific 
regions of mouse PrP, where majority of differences among mammalian species 
are clustered, could result in loss of susceptibility to RML prion (Figure 6.4.C). 
Since wild-type and variant mouse PrP are expressed in rabbit epithelial kidney 
(RK13) cells, ‘protein X’ is a rabbit-specific. Therefore, the present in vitro data 
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shows the primary structure of host PrPC primarily determines susceptibility to 
RML prion. These results also suggest that properties of mouse-specific and 
rabbit-specific chaperones might be functionally identical. To test whether a 
rabbit-specific and mouse-specific ‘protein X’ is functionally identical in RML 
transmission, Tg mice expressing the same variant mouse PrP used in the cell 
culture studies could be inoculated with RML to see whether develop disease. If 
results turn out to be consistent with the in vitro data, mice and rabbits have 
functionally identical molecular chaperones to facilitate PrPSc conversion. If those 
Tg mice expressing variant mouse PrP develop disease with RML, a mouse-
specific chaperone has more capacity to facilitate PrPSc conversion of variant 
mouse PrPC with RML prion. Thus, molecular chaperones in mouse and rabbit 
are functionally different in respect to PrPSc conversion.  
 The intraspecies transmission barrier of prion disease could be explained 
by the conformational selection model. In sheep, susceptibility and resistance to 
sheep scrapie prions are strongly controlled by ovine PrP polymorphisms 
especially at codon 136 encoding either A or V (Goldmann et al., 1991; 
Goldmann et al., 1994). According to the conformational selection model, 
SSBP/1 sheep scrapie prion include multiple PrPSc conformations, which can be 
classified into at least two groups based on the results in Chapter 4 (Figure 6.5.). 
One group contains PrPSc conformations with the OvPrPSc-V136 properties (a 
blue box in SSBP/1 in Figure 6.5.), while another group consists of completely 
different sets of PrPSc conformations, which have the identical properties to 
OvPrPSc-A136 (a pink box in SSBBP/1 in Figure 6.5.). CH1641 sheep scrapie 
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prion also has multiple PrPSc conformations; however, a further classification of 
PrPSc conformations is unclear (Figure 6.5.). OvPrPC-V136 prefers a specific set 
of PrPSc conformations (blue boxes in Figure 6.5.), on the other hand, OvPrPC-
A136 prefers a different sets of PrPSc conformations (pink boxes in Figure 6.6.). 
SSBP/1 prion contains OvPrPC-V136 preferred PrPSc conformations, and 
CH1641 does not. Thus, OvPrP-V136 is only susceptible to SSBP/1. Both 
SSBP/1 and CH1641 prions include OvPrPC-A136 preferred PrPSc conformations, 
therefore, OvPrP-A136 is susceptible to both SSBP/1 and CH1641. However, 
OvPrPC-A136 preferred PrPSc conformations are not the major conformations in 
SSBP/1. Lower concentration of OvPrPC-A136 preferred PrPSc conformations in 
SSBP/1 prion are available for OvPrPSc-A136 conversion. The probability of 
OvPrPSc-A136 conversion is considerably low, therefore, OvPrPC-A136 requires 
a longer period of time to accumulate OvPrPSc-A136 and to develop disease with 
SSBP/1.   
A hypothetical chaperone ‘protein X’ might involve in the conversion of 
OvPrPSc-A136 and OvPrPSc-V136 (Figure 6.6.). In the following OvPrPSc-V136 
and OvPrPSc-A136 conversion models, an unidentified molecular chaperone 
‘protein X’ might be linked to an ovine PrP 136 polymorphism. An OvPrP-V136-
specific protein X facilitates the conversion of OvPrPC-V136 into PrPSc using 
OvPrPSc-V136 in SSBP/1 as a template and stabilizes newly synthesized 
OvPrPSc-V136 (Figure 6.6.A-1). However, the OvPrP-V136-specific protein X is 
not most efficient chaperone for OvPrPSc-V136 conversion with OvPrPSc-A136 in 
SSBP/1 prion (Figure 6.6.A-2). Therefore, OvPrPSc-V136 conversion requires a 
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longer time with SSBP/1-A136 prion. In addition, newly synthesized OvPrPSc-
V136 might never accumulate in cells because a cellular clearance mechanism 
could promptly remove OvPrPSc-V136 as slowly synthesized.  
Although an OvPrP-A136-specific protein X might facilitate the conversion 
of OvPrPC-A136 into PrPSc with SSBP/1-V136 prion, the OvPrP-A136-specific 
protein X might not be most efficient chaperone to facilitate OvPrPSc-A136 
conversion with SSBP/1-V136 prion (Figure 6.6.B-1). Thus, the rate of PrPSc 
conversion will not be fast enough to accumulate PrPSc in the brain and to 
develop disease. On the other hand, the OvPrP-A136-specific protein X could 
facilitate the conversion of OvPrPC-A136 into PrPSc using OvPrPSc-A136 in 
SSBP/1 as a template (Figure 6.6.B-2). Newly synthesized OvPrPSc-A136 could 
be stabilized by the OvPrP-A136-specific protein X.  
There is also another possibility that ‘protein X’ might not be linked to the 
ovine PrP polymorphism at codon 136, rather universal in ovine, referred to as 
ovine-specific ‘protein X’. An ovine-specific protein X facilitates PrPSc conversion 
in both OvPrP-A136 and OvPrP-V136 sheep (Figure 6.6. C and D).  
In a heterozygous state, an unidentified molecular chaperone ‘protein X’ 
could be an ovine-specific or OvPrP-A136-specific and OvPrP-V136-specific. If 
‘protein X’ is linked to the ovine PrP polymorphism at codon 136, both OvPrP-
A136-specific and OvPrP-V136-specific ‘protein X’ will be available to facilitate 
PrPSc conversion in heterozygous for A/V 136. Conversions of both OvPrPC-
V136 and OvPrPC-A136 into PrPSc are taken place in the heterozygous state, 
even though rates of PrPSc conversion differ between OvPrPSc-V136 and 
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OvPrPSc-A136 (Figure 6.7.). Either ovine-specific or OvPrP-V136-specific ‘protein 
X’ could facilitate OvPrPSc-V136 conversion and stabilize newly synthesized 
OvPrPSc-V136 (Figure 6.7.A.). The conversion rate of OvPrPSc-V136 is higher 
than OvPrPSc-A136. The conversion of OvPrPC-A136 into PrPSc will be facilitated 
by either ovine-specific or OvPrP-A136-specific ‘protein X’, and the ovine-specific 
or OvPrP-A136-specific ‘protein X’ could stabilize newly synthesized OvPrPSc-
A136 (Figure 6.7.C). In addition to the above conversion mechanisms of 
OvPrPSc-V136 (Figure 6.7.B) or OvPrPSc-A136 (Figure 6.7.C), a ‘dominant’ 
templating mechanism of OvPrPSc-V136 conformation, which leads to forced 
templating of OvPrPC-A136, is also occurring in the heterozygous state. In the 
‘dominant’ templating mechanism, OvPrPSc-V136 helps to convert OvPrPC-A136 
to PrPSc using an ovine-specific or OvPrP-V136-specific protein X. Therefore, this 
newly synthesized OvPrPSc-A136 obtains the identical properties with a template 
OvPrPSc-V136.  
CH1641 sheep scrapie prion is most susceptible to OvPrP-A136 and most 
resistant to OvPrP-V136 (Goldmann et al., 1994). CH1641 sheep scrapie prion 
does not include OvPrPC-V136 preferred PrPSc conformations based on the 
conformational selection model (Figure 6.5.). OvPrP-V136-specific or ovine-
specific ‘protein X’ is available to facilitate PrPSc conversion. Either ovine-specific 
or OvPrP-V136-specific ‘protein X’ could not accommodate the OvPrPC-V136-
CH1641 PrPSc complex to facilitate PrPSc conversion (Figure 6.8.A-(1).). If 
‘protein X’ is linked to OvPrP-V136, PrPSc conversion does not take place due to 
the OvPrP-V136-specific protein X. Even though those ‘protein X’ could 
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accommodate the OvPrPC-V136-CH1641 PrPSc complex, inefficient ‘protein X’ 
could not mediate PrPSc conversion fast enough to accumulate PrPSc in the brain 
(Figure 6.8.A-(2)). A cellular clearance mechanism might remove newly 
synthesized PrPSc as slowly synthesized.  CH1641 sheep scrapie prion includes 
OvPrPC-A136 preferred PrPSc conformations (Figure 6.5.B). Either OvPrP-A136-
specific protein X or ovine-specific protein X facilitates OvPrPSc-A136 conversion 
and stabilizes newly synthesized OvPrPSc-A136.  
In the heterozygous state, OvPrPSc-A136 conversion is inhibited by the 
presence of OvPrPC-V136 or OvPrP-V136-specific protein X. OvPrPC-V136 
inhibits the conversion of OvPrPC-A136 by preventing interactions among OvPrP-
A136, CH1641-PrPSc and/or ‘protein X’ (Figure 6.8.C-1). Even though an 
appropriate ‘protein X’ is available, ‘protein X’ could not mediate OvPrPSc-A136 
conversion. The OvPrP-V136-specific ‘protein X’ could not facilitate OvPrPSc-
A136 conversion (Figure 6.8.C-2). In the heterozygous state, the OvPrP-V136-
specific ‘protein X’ is available and becomes an inhibitor or antagonist by 
interacting with the OvPrPC-A136-CH1641 PrPSc complex before an appropriate 
OvPrP-A136-specific protein X interact with the PrPC-PrPSc complex.  
Up to this point, I have explained the PrPSc conversion models based on 
the conformational selection model using ‘hypothetical protein X’. In order to 
identify ‘protein X’, it would be helpful to think where the conversion of PrPC into 
PrPSc happens in cells. Cell culture studies reported that PrPC was able to 
convert to PrPSc at the cholesterol-rich, detergent-soluble microdomains of the 
plasma membrane (Goold et al., 2011; Taraboulos et al., 1995) followed by 
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trimming the amino terminus of PrPSc in an acidic environment such as lysosome 
(Caughey et al., 1991). These studies suggest that PrPSc conversion happens at 
the intercellular and intracellular environments (Figure 6.9.). in order to involve in 
PrPSc conversion, catalysts or molecular chaperones, ‘protein X’, which could 
mediate PrPSc conversion, might be membrane-bound molecules and closely 
located to PrPC at the cholesterol-rich microdomains of the plasma membrane. 
Molecules in lysosome might mediate PrPSc conversion in vesicles. Therefore, 
‘protein X’ should be intracellular molecules usually available in neurons.   
During prion infection, infectious, abnormal PrPSc isoform is taken into 
lysosomes by fusing phagocytic vesicles with lysosomes or by translocating with 
chaperones and transporting through chaperones into lysosomes. Recent studies 
in tauopathy in Alzheimer’s disease revealed that unfolded tau is translocated by 
a heat-shock chaperone to lysosome and transported into lysosome through a 
transporter (reviewed in (Kaushik & Cuervo, 2012)). The chaperon-mediated 
autophagy, which degrades proteins in lysosomes, can only degrade unfolded 
tau, and aggregated tau could malfunction the transporters on lysosomes 
(reviewed in (Kaushik & Cuervo, 2012)). In prion disease, PrPSc could enter the 
intracellular space by phagocytosis for degradation or PrPSc in the cytosol could 
be transported into lysosomes using a similar mechanism to tau transportation in 
lysosome. However, degradation of PrPSc might turn into multiplying truncated 
PrPSc templates in lysosomes. Some studies reported that truncated PrPSc could 
convert host PrPC into PrPSc and a full-length of PrPSc is not necessary for PrPSc 
conversion (Fischer et al., 1996; Rogers et al., 1993).   
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Taken together, ‘protein X’ could be present on the microdomains of the 
plasma membrane, lysosomes as well as cytosol. Thus, there are increasing 
possibilities that ‘protein X’ could be multiple intracellular molecules. Moreover, 
the intracellular molecules could be diverged among mammalian species since 
the transmission/species barrier is an important factor in developing prion 
disease. 
‘Protein X’ hypothesis is not necessarily widely accepted in prion field, and 
so far ‘protein X’ is still hypothetical possibly molecular chaperone. However, 
through the course of the dissertation work, I started thinking more about true 
existence of  ‘protein X’ and actual functions in prion pathogenesis.  Although the 
identity of ‘protein X’ and how it involves in prion pathogenesis might be 
overlooked, the results of this dissertation work strongly implies the presence of 
‘protein X’ to understand the underlying mechanisms of PrPSc conversion, 
transmission/species barrier, and propagating new prion strains within the same 
species.  
In order to support the proposed models of PrPSc conversion with ‘protein 
X’, more questions need to be addressed. First, what is conformational 
compatibility? Is it only the conformations between PrPC and PrPSc? Or does the 
conformation of the PrPC-PrPSc-chaperone ‘protein X’ complex determine the 
transmission barrier? How many chaperones involve in PrPSc conversion? Does 
‘protein X’ become available only when PrPSc in neurons or all the time? It would 
be helpful to further understand the transmission/species barrier of prion disease 
if more precise conformations of PrPSc in each prion strain could be available. It 
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might be possible to study the interactions between PrPC and molecular 
chaperone ‘protein X’ by blocking the potential epitope where is the loop between 
β2-sheet and α2-helix in PrPC using antibodies against the epitope. Additionally, 
it would be helpful to identify whether known molecular chaperones are up or 
down regulated upon infection. Understanding the transmission/species barrier in 
prion disease is crucial to develop early detection assays and strain specific 
treatments for prion disease.   
The potential functions of PrP were suggested by the studies in the 
pathogenesis of AD (Gimbel et al., 2010; Lauren et al., 2009), therefore, further 
understanding roles of PrPC in the pathogenesis of AD will greatly help to identify 
the function of PrPC. In order to study a relationship between expression levels of 
PrPC and its functions in AD patient brains, the expression levels of PrP were 
determined in the brains of individuals with AD at three different stages of 
cognitive impairments. The three brain regions including the frontal and temporal 
cortices and hippocampus were examined; however, unaltered expression levels 
of PrPC in those brain regions from different stages of AD did not help to identify 
the function of PrPC in the present study. It suggests that increased or decreased 
levels of PrPC are not associated with PrPC mediated functions in the 
pathogenesis of AD. Unaltered expression levels of PrPC and increased level of 
Aβ in the brains of AD patients suggest that the interaction between PrPC and Aβ 
induces neurotoxic effects, as proposed by Strittmatter (Gimbel et al., 2010; 
Lauren et al., 2009). Therefore, the increased level of Aβ is could be driving force 
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to bind PrPC to form more Aβ+PrPC complex with neuronal toxicity causing cell 
death and ultimately developing AD. 
 In future studies, it will be useful to determine the affinity of the complex 
formation between PrPC and Aβ. In addition, it will be interesting to quantify the 
amount of the Aβ+PrPC complexes in the time course of cell death and also to 
identify the threshold levels of the Aβ+PrPC complexes or Aβ alone that cells can 
manage before inducing neuronal toxicity.  
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Figure 6.1. The species barrier between cervid and human in interspecies 
transmission of CWD. This diagram is based on the conformational selection 
model, which explains PrPC preferentially interacts with preferred PrPSc 
conformations to facilitate PrPSc conversion. Three gray boxes on the top show 
that multiple PrPSc conformations include in CWD1, CWD2 and CWD mix. 
Different shapes and colors represent different conformations. The bottom three 
boxes indicate potential host species including HuPrPC-M129 (blue box), 
HuPrPC-V129 (red box) and cervid PrPC (yellow box). Each host PrPC selectively 
interacts with preferred PrPSc conformations. Since any CWD prions do not 
include HuPrPC-M129 and HuPrPC-V129 preferred PrPSc conformations, PrPSc in 
CWD prions could not become a template to convert these HuPrPC into PrPSc. 
Therefore, HuPrPC-M129 and HuPrPC-V129 do not develop disease. On the 
other hand, CWD prions contain cervid PrPC preferred PrPSc conformations, 
showing in different shapes in red color. Thus, PrPSc in CWD converts cervid 
PrPC into PrPSc, resulting in the development of disease.  
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Figure 6.2. Hypothetical chaperone ‘protein X’ lowers the energy barrier of 
the conversion of PrPC into PrPSc and stabilizes newly synthesized PrPSc. In 
this model, PrPSc is thermodynamically stable compared to PrPC; furthermore, 
the conversion of PrPSc from PrPC does not happen spontaneously without a 
catalyst or chaperon, such as, hypothetical ‘protein X’. The conversion of PrPC 
into PrPSc without ‘protein X’ (red arrow) requires overcoming the high energy 
barrier than the reaction with ‘protein X’ (blue arrow). ‘Protein X’ could reduce the 
energy barrier to facilitate the conversion of PrPC into PrPSc. Moreover, newly 
synthesized PrPSc is stabilized by ‘protein X’.     
 
 
  
 
 
 
 
Reaction coordinate 
En
er
gy
 
Without protein X 
With  
protein 
X
PrP
C
 
PrP
Sc
 
Energy 
barrier with 
protein X 
Energy 
barrier 
without 
protein X 
PrP
Sc
 
Stabilized 
by  
protein X 
 
 
206 
  
 
  PrP
C
  PrP
C
  PrP
Sc
  PrP
Sc
 + 
 
 PrP
Sc
  PrP
S
c
  
Cervid 
Protein X 
(1) Protein X facilitates 
the conversion of PrP
Sc
 
by lowering the energy 
barrier 
(2) Protein X 
stabilizes newly 
synthesized PrP
Sc
 
A. Cervid and CWD 
Cervid CWD 
 
  PrP
C
  PrP
C
 
+ 
 
 
Cervid 
Protein X 
Cervid-specific protein X 
could not accommodate 
the PrP
C
+PrP
Sc
 complex to 
facilitate PrP
Sc
 conversion 
No PrP
Sc
 
conversion occurs 
 PrP
Sc
 
 PrP
Sc
 
 PrP
C
  PrP
Sc
 
B. Cervid and RML 
Cervid RML 
 
 PrP
C
 
 PrP
Sc
 +  PrPSc  
Human 
Protein X 
 
 PrP
S
c PrP
C
 
 PrP
C
 
 Human-specific protein X 
could not accommodate 
the PrP
C
+PrP
Sc
 complex to 
facilitate PrP
Sc
 conversion 
No PrP
Sc
 
conversion occurs 
C. Human and CWD 
Human CWD 
 
 PrP
C
 
 PrP
Sc
 +  
Human 
Protein X 
 PrP
C
 
 
D. Human and CJD 
 PrP
Sc
   PrP
Sc
 
(1) Human-specific 
protein X facilitates 
PrPSc conversion by 
lowering the energy 
barrier 
(2) Human-specific 
protein X stabilizes 
newly synthesized 
PrP
Sc
 
 PrP
Sc
  
Human CJD 
 
 
207 
Figure 6.3. Proposed models explain ‘protein X’ plays a key role in 
determining the species barrier of prion diseases in addition to the 
conformational selection model. According to the conformation selection 
model, host PrPC preferentially interacts with preferred PrPSc conformations and 
undergoes substantial conformational change using donor PrPSc as a template. 
As shown in Figure 6.2., the conversion of PrPC into PrPSc does not occur 
spontaneously without any catalysts because of the high energy barrier. In order 
for PrPC to convert into PrPSc and accumulate to cause disease within a host 
lifespan or within a certain period of time, a catalyst or molecular chaperone 
plays an important role in PrPSc conversion. An unidentified catalyst or molecular 
chaperon, we denote hypothetical ‘protein X’. In this model, ‘protein X’ is a 
species-specific. For example, cervid carries a cervid-specific chaperon, and the 
cervid-specific chaperon might be completely different from a chaperon found in 
humans. A. Cervid PrPC and cervid preferred PrPSc could interact with a cervid-
specific chaperon to mediate PrPSc conversion, and the cervid-specific ‘protein X’ 
stabilizes newly synthesized PrPSc. B. PrP conformations between cervid (host) 
and RML mouse prion (donor) are not compatible. Moreover, the cervid-specific 
chaperone could not accommodate the cervid PrPC-mouse PrPSc complex to 
facilitate PrPSc conversion, resulting in no disease development. C. PrPSc 
conformations in CWD prion are not human PrPC (HuPrPC) preferred PrPSc 
conformations, and a human-specific protein X could not facilitate PrPSc 
conversion. Thus, no disease is developed. D. When HuPrPC finds preferred 
PrPSc conformations, such as, in CJD prions, HuPrPSc conversion occurs. In 
addition, a human-specific ‘protein X’ could facilitate PrPSc conversion. As a 
result, humans develop CJD. 
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Figure 6.4. Conformational selection model is used to explain how RML 
mouse prion could not convert variant mouse PrP in RK13 cell culture 
systems. The rabbit epithelial kidney (RK13) cell culture system was used to test 
whether changing amino acids in specific regions of mouse PrP altered 
susceptibility to species matched prion (mouse adapted RML scrapie prion) in 
Chapter 3. A. RK13 cells expressing a wild-type mouse PrPC (RKM cells) is 
highly susceptible to mouse adapted scrapie RML prion. B. However, RKM cells 
are not susceptible to CWD because PrPSc conformations in CWD are not mouse 
PrPC preferred PrPSc conformations. C. The series of cell culture studies in 
Chapter 3 suggest that substituting even one amino acid in the specific regions of 
mouse PrP, where majority of differences among mammalian species are 
clustered, could result in loss of susceptibility to RML prion. Since wild-type and 
variant mouse PrP are expressed in rabbit epithelial kidney (RK13) cells, ‘protein 
X’ is a rabbit-specific. Therefore, the present in vitro data shows the primary 
structure of host PrPC is a predominant determinant in susceptibility to RML 
prion. These results also suggest that properties of mouse-specific and rabbit-
specific chaperones might be functionally identical.    
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Figure 6.5. Conformational selection model to explain the intraspecies 
transmission barrier of SSBP/1 and CH1641 prions in sheep. The 
conformational selection model explains PrPC preferentially interacts with 
preferred PrPSc conformations to facilitate PrPSc conversion. The top gray box on 
left presents multiple PrPSc conformations include in SSBP/1 sheep scrapie 
prion, and the blue and pink boxes in SSBP/1 (left gray box) indicate different 
PrPSc conformations in SSBP/1 could be classified into at least two groups based 
on the findings in histoblot data in Chapter 4. The right gray box on the top 
presents different sets of multiple PrPSc conformations are contained in CH1641 
sheep scrapie prion. Different shapes represent different conformations. The 
bottom four boxes indicate potential host species including OvPrPC-V136 (blue 
boxes) and OvPrPC-A136 (pink boxes). Each host OvPrPC selectively interacts 
with different sets of preferred PrPSc conformations. SSBP/1 prion contains 
OvPrPC-V136 preferred PrPSc conformations, and CH1641 does not. OvPrPC-
V136 is only susceptible to SSBP/1. Both SSBP/1 and CH1641 prions include 
OvPrPC-A136 preferred PrPSc conformations, therefore, OvPrPC-A136 is 
susceptible to both SSBP/1 and CH1641. However, OvPrPC-A136 preferred 
PrPSc conformations are not major PrPSc conformations in SSBP/1. Lower 
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amount of OvPrPC-A136 preferred PrPSc conformations are available for OvPrPC-
A136 to interact and utilize for PrPSc conversion. Therefore, OvPrPC-A136 
requires a longer period of time to develop disease with SSBP/1.   
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Figure 6.6. SSBP/1 conversion models of OvPrPSc-A136 and OvPrPSc-V136: 
ovine-specific ‘protein X’ catalyzes PrPSc conversion and stabilizes newly 
synthesized PrPSc. In the A and B models, an unidentified molecular chaperone 
‘protein X’ is link to the ovine PrP 136 polymorphism. A-1. An OvPrP-V136-
specific ‘protein X’ facilitates the conversion of OvPrPC-V136 into PrPSc using 
OvPrPSc-V163 in SSBP/1. Newly synthesized OvPrPSc-V136 is also stabilized 
by the OvPrP-V136-specific ‘protein X’. A-2. The OvPrP-V136-specific ‘protein X’ 
could accommodate the OvPrPC-V136-SSBP/1-A136 PrPSc complex to facilitate 
the conversion of OvPrPSc-V136 using OvPrPSc-A136 in SSBP/1; however, the 
OvPrP-V136-specific ‘protein X’ is not most efficient chaperone for the OvPrPC-
V136-SSBP/1-A136 PrPSc complex. Therefore, OvPrPSc-V136 conversion 
requires a longer time with OvPrPSc-A136 as a template. Newly synthesized 
OvPrPSc-V136 might never accumulate in neurons because a cellular clearance 
mechanism could promptly remove PrPSc as slowly synthesized. B-1. An OvPrP-
A136-specific ‘protein X’ might be able to accommodate the OvPrPC-A136-
SSBP/1-V136 PrPSc complex to facilitate the conversion of OvPrPSc-A136; 
however, the OvPrP-A136-specific ‘protein X’ is not most efficient chaperone for 
the conversion of OvPrPC-A136 into PrPSc using OvPrPSc-V136 in SSBP/1. Thus, 
OvPrPSc-V136 conversion will take a longer time. In addition, a cellular clearance 
mechanism could remove newly synthesized OvPrPSc-A136 as slowly 
synthesized. B-2. The OvPrP-A136-specific ‘protein X’ facilitates the conversion 
of OvPrPC-A136 into PrPSc using OvPrPSc-A136 in SSBP/1a1. Newly synthesized 
OvPrPSc-A136 is also stabilized by the OvPrP-A136-specific ‘protein X’. In the C 
and D models, an unidentified molecular chaperone ‘protein X’ is universal 
among ovine. An ovine-specific ‘protein X’ facilitates PrPSc conversion in both 
OvPrP-A136 and OvPrP-V136 sheep.  
 
 
215 
 
Ovine-V136 
associated 
Protein X 
(1) Ovine-V136-specific or 
ovine-specific protein X 
facilitates PrP
Sc
 
conversion by lowering the 
energy barrier 
(2) Ovine-V136-
specific or ovine-
specific protein X 
stabilizes newly 
synthesized PrP
Sc
 
Ovine-A136 
associated 
Protein X 
OvPrP-A/V136 and SSBP/1-V136 
OvPrP 
V136 
SSBP/1 
V136 
  PrP
C
 + 
 
  PrP
Sc
  PrP
C
  PrP
Sc
  PrP
Sc
  PrP
Sc
  
+  
OvPrP 
A136 
SSBP/1 
V136 
 PrP
C
 
 
 PrP
Sc
  PrP
C
  PrP
Sc
   PrP
Sc
  PrP
Sc
  
Ovine-A136-specific or 
ovine-specific protein X 
could accommodate the 
PrP
C
+PrP
Sc
 complex, but 
is not perfect fit 
Thus, PrP
Sc
 conversion 
requires a longer period 
of time and this PrP
Sc
 
conformation never 
reach a detectable level 
Ovine-V136 
associated 
Protein X 
(1) Ovine-V136-specific or 
ovine-specific protein X 
facilitates PrP
Sc
 
conversion by lowering the 
energy barrier 
(2) Ovine-V136-
specific or ovine-
specific protein X 
stabilizes newly 
synthesized PrP
Sc
 
OvPrP 
A136 
SSBP/1 
V136 
+ 
 
  PrP
Sc
  PrP
Sc
  PrP
Sc
   PrP
Sc
  PrP
C
  PrP
C
  
 
OR 
Ovine-specific 
protein X 
 
OR 
Ovine-specific 
protein X 
 
OR 
Ovine-specific 
protein X 
(C) 
(A) 
(B) 
 
 
216 
Figure 6.7. SSBP/1 conversion models of OvPrPSc-V136 and OvPrPSc-A136 
in the OvPrP 136 A/V heterozygous: OvPrP-V136-specific ‘protein X’ 
facilitates a dominant ‘templating’ of OvPrPSc-V136 to convert OvPrPC-A136 
conversion. In a heterozygous state, an identified molecular chaperone ‘protein 
X’ could be an ovine-specific universal protein X or OvPrP-A136-specific and 
OvPrP-V136-specific protein X. If ‘protein X’ is linked to the ovine 136 
polymorphism, both OvPrP-A136-specific and OvPrP-V136-specific ‘protein X’ 
will be available to facilitate PrPSc conversion. In the heterozygous state, 
conversions of both OvPrPC-V136 and OvPrPC-A136 into PrPSc are taken place 
even though rates of PrPSc conversion differ between OvPrPSc-V136 and 
OvPrPSc-A136. (A). The conversion of OvPrPC-V136 into PrPSc will be facilitated 
by either universal ovine-specific or OvPrP-V136-specific ‘protein X’, and newly 
synthesized OvPrPSc-V136 will be stabilized by ‘protein X’. (C). The conversion 
rate of OvPrPSc-V136 is higher than OvPrPSc-A136. The conversion of OvPrPC-
A136 into PrPSc will be facilitated by either ovine-specific universal ‘protein X’ or 
OvPrP-A136-specific ‘protein X’, and the ovine-specific or OvPrP-A136-specific 
‘protein X’ could stabilize newly synthesized OvPrPSc-A136. (B). In addition to the 
above conversion mechanisms of OvPrPSc-V136 or OvPrPSc-A136, a ‘dominant’ 
templating mechanism of OvPrPSc-V136 conformation, which leads to forced 
templating of OvPrPC-A136, is also occurring in the heterozygous state. In the 
‘dominant’ templating mechanism, OvPrPSc-V136 helps to convert OvPrPC-A136 
to PrPSc using an ovine-specific or OvPrP-V136-specific ‘protein X’. Therefore, 
this newly synthesized OvPrPSc-A136 obtains the same properties as a template 
OvPrPSc-V136.  
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Figure 6.8. CH1641 conversion models of OvPrPSc-V136 and OvPrPSc-A136: 
Conversion of OvPrPSc-A136 is inhibited by the presence of OvPrPC-V136 
and/or OvPrP-V136-specific ‘protein X’ in the OvPrP 136 A/V heterozygous 
state. CH1641 sheep scrapie prion is most susceptible to OvPrP-A136 and most 
resistant to OvPrP-V136. A. CH1641 sheep scrapie prion does not include 
OvPrPC-V136 preferred PrPSc conformations based on the conformational 
selection model (Figure 6.5.). OvPrP-V136-specific or ovine-specific universal 
‘protein X’ is available to facilitate PrPSc conversion. A-(1) Neither ovine-specific 
nor OvPrP-V136-specific ‘protein X’ could accommodate the OvPrPC-V136-
CH1641 PrPSc complex to facilitate PrPSc conversion. If ‘protein X’ is linked to 
OvPrP-V136, PrPSc conversion does not take place due to the OvPrP-V136-
specific ‘protein X’. A-(2) Even though those ‘protein X’ could accommodate the 
OvPrPC-V136-CH1641 PrPSc complex, inefficient ‘protein X’ could not mediate 
PrPSc conversion fast enough to accumulate PrPSc in the brain. A cellular 
clearance mechanism could promptly remove newly synthesized PrPSc as slowly 
synthesized. B. OvPrPC-A136 preferred PrPSc conformations are included in 
CH1641 sheep scrapie prion (Figure 6.5.). Either OvPrP-A136-specific ‘protein X’ 
or ovine-specific ‘protein X’, could facilitate PrPSc conversion and stabilize newly 
synthesized OvPrPSc-A136. C. In the heterozygous state, OvPrPSc-A136 
conversion is inhibited by the presence of OvPrPC-V136 or OvPrP-V136-specific 
‘protein X’. C-(1). OvPrPC-V136 inhibits the conversion of OvPrPC-A136 by 
interacting with OvPrP-A136, CH1641-PrPSc, or protein X to prevent from forming 
an OvPrPC-A136-CH1641 PrPSc complex. Even though most efficient ‘protein X’ 
is available, ‘protein X’ could not mediate PrPSc conversion. C-(2). The OvPrP-
V136-specific ‘protein X’ could not facilitate OvPrPSc-A136 conversion. In the 
heterozygous state, the OvPrP-V-specific ‘protein X’ is available and becomes an 
inhibitor or antagonist by interacting with the OvPrPC-A136-CH1641 PrPSc 
complex before most efficient OvPrP-A136-specific ‘protein X’ interact with the 
PrPC-PrPSc complex.  
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Figure 6.9. PrPSc conversion sites in neuron. A. PrPSc conversion occurs at 
the cholesterol-rich microdomains in the plasma membrane. B. PrPSc can enter 
neurons by phagocytosis. A phagocytic vesicle can fuse to lysosomes. 
Proteolytic enzymes and other molecules become available in the fused vesicles. 
PrPSc conversion occurs in lysosomes possibly utilizing molecules from 
lysosomes. New PrPC could be provided by phagocytosis to continue converting 
PrPSc in lysosomes. The vesicles eventually rupture and newly synthesized PrPSc 
will be released to the cytosol. Some PrPSc will be captured by molecular 
chaperones to translocate into lysosomes for degradation.  
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